Document:

<PAGE>
                                                                 EXHIBIT 10.1

     WHENEVER CONFIDENTIAL INFORMATION IS OMITTED HEREIN (SUCH OMISSIONS ARE
        DENOTED BY AN ASTERISK *), SUCH CONFIDENTIAL INFORMATION HAS BEEN
         SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION
                PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT.

                       LICENSE AND COLLABORATION AGREEMENT

                                     BETWEEN

                                 ALKERMES, INC.

                                       AND

                                 CEPHALON, INC.
<PAGE>
                                TABLE OF CONTENTS

<TABLE>
<S>                                                                           <C>
ARTICLE 1 DEFINITIONS......................................................    1

ARTICLE 2 MANAGEMENT OF THE COLLABORATION..................................    2

   2.1     Joint Steering Committee........................................    2
   2.2     Modifications to Agreement after Sharing of Distributable Loss
              and Distributable Profit Converts to a Royalty-Based
              Arrangement..................................................   17

ARTICLE 3 DEVELOPMENT......................................................   18

   3.1     Development Team................................................   18
   3.2     Accounting and Financial Reporting for DT and CT................   20
   3.3     Development Efforts.............................................   21
   3.4     Development Responsibilities....................................   21
   3.5     Pharmacovigilence and Adverse Event Reporting...................   24
   3.6     Development Costs...............................................   24
   3.7     Development Plan Budget.........................................   24
   3.8     Limitation on Development Team Decision Making..................   25

ARTICLE 4 COMMERCIALIZATION................................................   25

   4.1     Commercialization Efforts.......................................   25
   4.2     Commercialization Team..........................................   26
   4.3     Contents of Commercialization Plan..............................   28
   4.4     Compliance with Law.............................................   29
   4.5     Corporate Name and Logo.........................................   30
   4.6     Sales and Distribution..........................................   30
   4.7     Commercialization Costs.........................................   30
   4.8     Commercialization Plan Budget...................................   30
   4.9     Product Label and Packaging.....................................   31
   4.10    Promotional Materials...........................................   31
   4.11    Sales Force.....................................................   32
   4.12    Training Materials..............................................   34
   4.13    Samples.........................................................   35
   4.14    Medical Inquiries...............................................   35
   4.15    Limitation on Commercialization Team Decision Making............   35

ARTICLE 5 MANUFACTURE AND SUPPLY...........................................   36

   5.1     Supply Agreement................................................   36
   5.2     Supply Team.....................................................   36
   5.3     Supply Costs....................................................   36
</TABLE>

                                        i
<PAGE>
<TABLE>
<S>                                                                           <C>
ARTICLE 6 LICENSE GRANTS AND ASSIGNMENTS...................................   36

   6.1     Patent and Know-How License Grant...............................   36
   6.2     Alkermes Patents Update.........................................   37
   6.3     Trademark Assignment............................................   37
   6.4     Trademark License...............................................   37
   6.5     Corporate Name and Logo.........................................   38
   6.6     ROW Territory...................................................   38
   6.7     Termination of License to Contested Patent Rights...............   39

ARTICLE 7 INTELLECTUAL PROPERTY RIGHTS.....................................   39

   7.1     Ownership of Intellectual Property..............................   39
   7.2     Disclosure of Patentable Inventions.............................   40
   7.3     Patent Committee................................................   40
   7.4     Patent Filings..................................................   41
   7.5     Defense and Enforcement Rights..................................   43
   7.6     Infringement Defense............................................   45
   7.7     Third-Party Patent Licenses.....................................   46
   7.8     Patent Marking..................................................   46
   7.9     Trademark Maintenance...........................................   46
   7.10    Trademark Infringement..........................................   47

ARTICLE 8 CONFIDENTIALITY..................................................   47

   8.1     Confidentiality.................................................   47
   8.2     Authorized Use and Disclosure...................................   48
   8.3     Survival........................................................   49
   8.4     Publications....................................................   49

ARTICLE 9 UP-FRONT PAYMENT, MILESTONE PAYMENTS
   AND PROFIT SPLIT.....................................................      50

   9.1     Up-front Payment................................................   50
   9.2     Milestone Payments..............................................   51
   9.3     Profit Sharing..................................................   51
   9.4     Reporting Net Sales and Shared Expenses.........................   51
   9.5     Financial Reconciliation........................................   52
   9.6     Generic Product.................................................   53
   9.7     Records and Reporting; Audits...................................   54
   9.8     Manner of Payment...............................................   55
   9.9     Interest on Late Payments.......................................   55
   9.10    Taxes...........................................................   55
   9.11    [**]............................................................   56
</TABLE>

                                       ii
<PAGE>
<TABLE>
<S>                                                                           <C>
ARTICLE 10 REPRESENTATIONS AND WARRANTIES..................................   59

   10.1    Disclaimer......................................................   59
   10.2    Mutual Representations and Warranties...........................   59
   10.3    Alkermes Representations and Warranties.........................   59
   10.4    No Guaranty of Development or Commercialization Success.........   61

ARTICLE 11 LIABILITY.......................................................   61

   11.1    Limitation of Liability.........................................   61
   11.2    Cephalon Indemnification........................................   61
   11.3    Alkermes Indemnification........................................   62
   11.4    Insurance.......................................................   64

ARTICLE 12 DISPUTE RESOLUTION..............................................   65

   12.1    Disputes........................................................   65
   12.2    Reserved Disputes...............................................   66
   12.3    Arbitration.....................................................   67
   12.4    Jurisdiction....................................................   67
   12.5    Determination of Disputes Relating to Patents
              and Other Intellectual Property..............................   67

ARTICLE 13 TERM AND TERMINATION............................................   68

   13.1    Term............................................................   68
   13.2    Right to Terminate for Breach...................................   68
   13.3    Cephalon's Right to Terminate...................................   68
   13.4    Alkermes' Rights on Termination.................................   69
   13.5    Cephalon's Rights on Termination................................   70
   13.6    Cephalon's Rights on Expiration.................................   71
   13.7    Right to Terminate Upon Bankruptcy..............................   71
   13.8    Survival of Certain Provisions..................................   72

ARTICLE 14 GENERAL PROVISIONS..............................................   72

   14.1    Notices.........................................................   72
   14.2    Governing Law...................................................   73
   14.3    Entire Agreement; Amendment.....................................   73
   14.4    Binding Effect and Assignment...................................   73
   14.5    Waiver..........................................................   73
   14.6    Severability....................................................   74
   14.7    Publicity.......................................................   74
   14.8    Counterparts....................................................   74
   14.9    Force Majeure...................................................   74
   14.10   Ambiguities.....................................................   75
</TABLE>

                                       iii
<PAGE>
<TABLE>
<S>                                                                           <C>
   14.11   Headings........................................................   75
   14.12   No Partnership..................................................   75
   14.13   Use of Names, Trade Names and Trademarks........................   75
   14.14   Performance by an Affiliate.....................................   75
   14.15   Non-Solicitation of Employees...................................   75
</TABLE>

Exhibit A Alkermes Patents
Exhibit B Alkermes Manufacturing Patents
Exhibit C Vivitrex Trademark and Medisorb Trademark
Exhibit D Development Plan for Calendar Years 2005 and 2006
Exhibit E [**]
Exhibit F Press Release

                                       iv
<PAGE>
     WHENEVER CONFIDENTIAL INFORMATION IS OMITTED HEREIN (SUCH OMISSIONS ARE
   DENOTED BY AN ASTERISK *), SUCH CONFIDENTIAL INFORMATION HAS BEEN SUBMITTED
   SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST
                           FOR CONFIDENTIAL TREATMENT.

                       LICENSE AND COLLABORATION AGREEMENT

     This License and Collaboration Agreement (the "Agreement") is entered into
effective as of June 23, 2005 (the "Effective Date") by and between Alkermes,
Inc., a Pennsylvania corporation with its principal office at 88 Sidney Street,
Cambridge, Massachusetts 02139 ("Alkermes"), and Cephalon, Inc., a Delaware
corporation with its principal office at 41 Moores Road, Frazer, Pennsylvania
19355 ("Cephalon").

                                   RECITALS:

     WHEREAS, Alkermes is developing an injectable sustained-release microsphere
form of the pharmaceutical compound naltrexone for the treatment and/or
prevention of alcohol abuse/dependence or other indications approved for
development pursuant to this Agreement; and

     WHEREAS, Cephalon and Alkermes wish to collaborate in the development of
the Products (as defined herein) for use and sale in the Field (as defined
herein) in the Territory (as defined herein); and

     WHEREAS, Cephalon has experience and expertise in the commercialization of
pharmaceutical products and will promote, market and sell the Products in the
Field in the Territory; and

     WHEREAS, Alkermes will manufacture and supply to Cephalon the Medisorb
Product (as defined herein) pursuant to the terms of a Supply Agreement (as
defined herein); and

     WHEREAS, the Parties intend through these various arrangements, subject to
budget constraints and other limitations set forth herein, to maximize the
profitability of the Products in the Field in the Territory; and

     WHEREAS, Cephalon and Alkermes therefore agree to undertake the foregoing,
all under the terms and conditions set forth in this Agreement and for the
consideration set forth herein.

     NOW, THEREFORE, in consideration of the premises and the mutual covenants
and agreements set forth herein, and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties agree as
follows:

                                    ARTICLE 1
                                   DEFINITIONS

     1.1 "ACT" shall mean the United States Food, Drug and Cosmetic Act, as

** CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
amended from time to time, and the regulations promulgated thereunder including
the guidelines and guidance issued by the FDA.

     1.2 "ADDITIONAL PRODUCT TRADEMARK" shall have the meaning set forth in
Section 7.9.

     1.3 "AFFILIATE" with respect to any Party, shall mean any entity that
controls, is controlled by, or is under common control with such Party, but only
for so long as such control shall continue. For these purposes, "control" shall
refer to: (i) the possession, directly or indirectly, of the power to direct the
management or policies of an entity, whether through ownership of voting
securities, by contract or otherwise, or (ii) the ownership, directly or
indirectly, of at least fifty percent (50%) of the voting securities or other
ownership interest of an entity.

     1.4 "ALKERMES KNOW-HOW" shall mean any Know-How, including any
Collaboration Technology (other than Joint Know-How), that is Controlled by
Alkermes or its Affiliates on the Effective Date or thereafter during the Term
and that is necessary or directly related to the use, sale, offer for sale or
import of the Products in the Field in the Territory, but shall not include
Know-How covering only the Manufacture of a Product.

     1.5 "ALKERMES MANUFACTURING KNOW-HOW" shall mean any Know-How that is
Controlled by Alkermes or its Affiliates on the Effective Date or thereafter
during the Term and that is necessary or directly related to the Manufacture of
the Products in the Territory or the Manufacture of the Products in the ROW
Territory for use, sale, offer for sale or import in the Territory.

     1.6 "ALKERMES MANUFACTURING PATENTS" shall mean shall mean any Patent
Rights that are Controlled by Alkermes or its Affiliates on the Effective Date
or thereafter during the Term and that are necessary or directly related to the
Manufacture of the Products in the Territory or the Manufacture of the Products
in the ROW Territory for use, sale, offer for sale or import in the Territory,
including those patents and patent applications listed on Exhibit B.

     1.7 "ALKERMES PATENTS" shall mean (i) the Patent Rights Controlled by
Alkermes or its Affiliates on the Effective Date that are necessary or directly
related to the use, sale, offer for sale or import of the Products in the Field
in the Territory, including those patents and patent applications listed on
Exhibit A, and (ii) any Patent Rights, including any patents or patent
applications that claim Collaboration Technology (other than Joint Patents),
that are Controlled by Alkermes or its Affiliates after the Effective Date and
that are necessary or directly related to the use, sale, offer for sale or
import of the Products in the Field in the Territory, but shall not include
Patent Rights covering only the Manufacture of a Product.

** CONFIDENTIAL TREATMENT REQUESTED

                                       2
<PAGE>
     1.8 "BUSINESS DAY" shall mean a day on which banking institutions in New
York, New York are open for business.

     1.9 "CALL" shall mean a face-to-face meeting in an individual, hospital or
group setting between a Sales Representative and one or more Target Prescribers.

     1.10 "CEPHALON COMMERCIALIZATION COSTS" shall have the meaning set forth in
Section 4.1.2.

     1.11 "CEPHALON KNOW-HOW" shall mean any Know-How, including any
Collaboration Technology (other than Joint Know-How), that is Controlled by
Cephalon or its Affiliates on the Effective Date or thereafter during the Term
and that is necessary or directly related to the Manufacture, use, sale, offer
for sale or import of the Products in the Field in the Territory.

     1.12 "CEPHALON PATENTS" shall mean any Patent Rights, including any patent
or patent applications that claim Collaboration Technology (other than Joint
Patents), that are Controlled by Cephalon or its Affiliates on the Effective
Date or thereafter during the Term and that are necessary or directly related to
the Manufacture, use, sale, offer for sale or import of the Products in the
Field in the Territory.

     1.13 "CLINICAL STUDIES" means human studies designed to measure the safety
and/or efficacy of a Product. Clinical Studies include Phase I clinical trials,
Phase II clinical trials, Phase III clinical trials, and Phase IV clinical
trials other than Post Marketing Clinical Trials.

     1.14 "CLINICAL SUPPLIES" shall mean supplies of the Products, Placebo and
diluent to be used for the conduct of pre-clinical studies and/or Clinical
Studies of a Product in the Field pursuant to a Development Plan.

     1.15 "CODE" shall mean the Code on Interactions with Healthcare
Professionals promulgated by the Pharmaceutical Research and Manufacturers of
America (PhRMA) and the American Medical Association (AMA) Guidelines on Gifts
to Physicians from Industry, as either of the foregoing may be amended from time
to time.

     1.16 "COLLABORATION TECHNOLOGY" shall mean any Know-How developed, made or
conceived by or on behalf of a Party pursuant to a Development Plan or
Commercialization Plan that relates to a Product or Naltrexone or the
Manufacture or use in the Field of a Product or Naltrexone.

     1.17 "COMMERCIAL SUPPLIES" shall mean supplies of the Products (i) for
commercial sale by Cephalon and its Affiliates in the Field in the Territory
pursuant to this Agreement or (ii) for compassionate use, use in
investigator-sponsored Clinical

** CONFIDENTIAL TREATMENT REQUESTED

                                       3
<PAGE>
Studies or Post Marketing Clinical Trials in the Field in the Territory pursuant
to this Agreement.

     1.18 "COMMERCIALIZATION" (including variations such as "COMMERCIALIZE" and
the like) shall mean the performance of any and all activities directed to
promoting, marketing, importing, exporting, distributing, selling or offering to
sell (including pre-marketing), sampling, Post Marketing Clinical Trials and
post-marketing drug surveillance of the Products in the Field in the Territory.

     1.19 "COMMERCIALIZATION COSTS" shall mean direct costs incurred (i.e., paid
or accrued) after the Effective Date by or on behalf of either Party in
accordance with GAAP applied on a consistent basis to the extent attributable to
fulfilling such Party's responsibilities under the Commercialization Plan in
accordance therewith and with this Agreement, all as calculated in accordance
with Section 9.7. Commercialization Costs shall also comprise the costs of
Commercialization performed by Cephalon's or its Affiliates' or Alkermes' or its
Affiliates' FTEs at the Commercialization FTE Rate or the Treatment System
Specialist FTE Rate, as applicable, and performance of the Parties' Sales
Representative FTEs at the Sales Representative FTE Rate. Such direct costs
shall include:

          (I) costs of internal marketing, scientific, medical, technical or
managerial personnel engaged in such efforts, which costs shall be documented;

          (II) costs of Post Marketing Clinical Trials for a Product included
within the Commercialization Plan, as well as the Fully Burdened Manufacturing
Cost of Commercial Supplies for such trials, any shipping and storage costs
relating to such supplies;

          (III) costs of marketing, advertising, sampling and promoting the
Products in the Field in the Territory, including by way of example educational
expenses, speakers' programs and symposia, and marketing meetings, but solely to
the extent reasonably allocable to the Products and excluding the costs of
activities that promote a Party's business as a whole;

          (IV) costs of customer services, such as call centers, and services
related to case management, patient reimbursement, technical complaints and
medical and patient inquiries;

          (V) costs of developing sales force training materials and conducting
sales force training sessions;

          (VI) costs of primary and secondary market research for the Territory
and collection of data about sales to hospitals and other end users;

** CONFIDENTIAL TREATMENT REQUESTED

                                       4
<PAGE>
          (VII) costs of developing, producing and distributing Promotional
Materials for the Territory, including copyright registrations therefor;

          (VIII) costs of contracting with managed care organizations, hospital
systems, group purchasing organizations, physician networks, pharmacies and any
other private or government healthcare provider or reimbursement entity, in each
case solely with respect to the Products, or if not solely, as allocated among a
Party's products on a fair and equitable basis;

          (IX) costs of communications and meetings with the FDA, exchange of
information, assistance, medical inquiries, and post-market surveillance in
connection with Products sold in the Territory, following the receipt of
Regulatory Approval therefor;

          (X) costs of developing and carrying out the Medical Activity Plan for
the Products, including costs for developing, producing and distributing medical
information, developing and implementing continuing medical education programs,
field-based medical affairs personnel and safety monitoring;

          (XI) costs incurred in connection with receiving, investigating,
recording, reviewing, communicating, and exchanging adverse events and other
reportable information as provided in a safety data exchange agreement between
the Parties to the extent relating to the Commercialization of the Products;

          (XII) costs and expenses of prosecuting, maintaining and defending the
Vivitrex Trademark and the Additional Product Trademark in the Territory
pursuant to Section 7.9 and trademark enforcement costs pursuant to Section
7.10;

          (XIII) Sales Representative FTE costs;

          (XIV) Treatment System Specialist FTE costs; and

          (XV) Distribution Costs.

     1.20 "COMMERCIALIZATION FTE RATE" shall mean initially an amount equal to
[**] per FTE per year; on January 1, 2006, and annually thereafter, such amount
shall be adjusted to reflect any increase, since the prior adjustment (or the
initial rate, as applicable), in the Bureau of Labor Statistics Consumer Price
Index for Urban Wage Earners and Clerical Workers, Northeast Urban, based on the
most recent monthly index available as of the adjustment date.

     1.21 "COMMERCIALIZATION PLAN" shall mean the marketing and sales plan
intended to encourage sales of the Products in the Field in the Territory, as
prepared and updated at least annually by the CT.

     1.22 "COMMERCIALLY REASONABLE EFFORTS" shall mean [**].

** CONFIDENTIAL TREATMENT REQUESTED

                                       5
<PAGE>
     1.23 "[**]" shall have the meaning set forth in Section 9.11.

** CONFIDENTIAL TREATMENT REQUESTED

                                       6
<PAGE>
     1.24 "CONFIDENTIAL INFORMATION" shall have the meaning set forth in Section
8.1.

     1.25 "CONTROLLED" shall mean with respect to Patent Rights or Know-How that
the applicable Party or its Affiliates, in whole or in part, owns or has a
license to such patents or know-how and has the ability to grant a license or a
sublicense, as applicable, or to otherwise disclose proprietary or trade secret
information, to such other Party, without paying any consideration to any Third
Party and without either violating the terms of any agreement or other
arrangement with any Third Party existing and in effect at the time such Party
would be required hereunder to grant the other Party such license or sublicense
or misappropriating the proprietary or trade secret information of a Third
Party.

     1.26 "CT" shall mean a commercialization team established pursuant to
Section 4.2.

     1.27 "DETAIL" OR "DETAILING" shall mean, with respect to the Products, the
activity undertaken by a Sales Representative during a Call in which one or more
Product benefits are verbally presented to one or more Target Prescribers, but
shall exclude discussions at conventions, marketing meetings or seminars, and
all forms of communication not involving face-to-face contact by a Sales
Representative and a Target Prescriber. A Detail does not include a reminder or
sample drop.

     1.28 "DEVELOPMENT" (including variations such as "DEVELOP" and
"DEVELOPING") shall mean the performance of any and all activities relating to
obtaining Regulatory Approval of a Product in the Field in the Territory and to
supporting and expanding such Regulatory Approval, including activities relating
to developing the ability to Manufacture and to continue to Manufacture the
Product. Development activities include the performance by the Parties, their
Affiliates or Third Parties of pre-clinical studies, pharmacokinetic studies,
toxicology studies, formulation, test method development and stability testing,
manufacturing process development, manufacturing technical support, validation
and scale-up (including bulk compound production), manufacturing Clinical
Supplies, quality assurance and quality control for formulations of a Product,
Clinical Studies (including post-marketing Clinical Studies to obtain or support
Regulatory Approval), and regulatory affairs including regulatory legal
services.

     1.29 "DEVELOPMENT COSTS" shall mean the direct costs incurred (i.e., paid
or accrued) after the Effective Date by or on behalf of either Party in
accordance with GAAP applied on a consistent basis to the extent attributable to
fulfilling such Party's responsibilities under the Development Plan in
accordance therewith and with this Agreement, all as calculated in accordance
with Section 9.7. Development costs shall also comprise costs of Development
performed by Cephalon's or its Affiliates' or Alkermes' or its Affiliates' FTEs
at the Development FTE Rate. Such direct costs shall include:

** CONFIDENTIAL TREATMENT REQUESTED

                                       7
<PAGE>
          (I) costs of internal scientific, medical, technical or managerial
personnel engaged in such efforts, which costs shall be documented;

          (II) costs of research or development, including costs of studies on
the toxicological, pharmacokinetic, metabolic or clinical aspects of a Product
conducted internally or by individual investigators or consultants, necessary or
desirable for the purpose of obtaining Regulatory Approval and for conducting
post-marketing activities to support such Regulatory Approval;

          (III) Fully Burdened Manufacturing Costs of Clinical Supplies and any
shipping and storage costs relating to such supplies;

          (IV) costs of manufacturing process development, validations,
scale-up, quality assurance and quality control for formulations of a Product
pursued by the Parties under any Development Plan, but excluding costs relating
to the [**] Manufacturing process scale-up, validation of the [**] Manufacturing
process or the Regulatory Approval of the [**] Manufacturing process that are
required to obtain Regulatory Approval for the Medisorb Product for the Initial
Indication (which costs shall be borne solely by Alkermes);

          (V) costs of preparing and reviewing data or information for the
purpose of submitting to the FDA an NDA for a Product in the Field;

          (VI) costs of communications and meetings with the FDA, exchange of
information and assistance until Regulatory Approval for the Product has been
obtained; and

          (VII) costs incurred in connection with receiving, investigating,
recording, reviewing, communicating, and exchanging adverse events and other
reportable information as provided in a safety data exchange agreement between
the Parties to the extent relating to the Development of a Product in the Field
in the Territory.

     1.30 "DEVELOPMENT FTE RATE" shall mean initially an amount equal to [**]
per FTE per year; on January 1, 2006, and annually thereafter, such amount shall
be adjusted to reflect any increase, since the prior adjustment (or the initial
rate, as applicable), in the Bureau of Labor Statistics Consumer Price Index for
Urban Wage Earners and Clerical Workers, Northeast Urban, based on the most
recent monthly index available as of the adjustment date.

     1.31 "DEVELOPMENT PLAN" shall mean a plan for the Development of a Product
for one or more indications in the Field in the Territory, as prepared and
updated at least annually by the DT.

** CONFIDENTIAL TREATMENT REQUESTED

                                       8
<PAGE>
     1.32 "DISTRIBUTABLE LOSS" AND "DISTRIBUTABLE PROFIT" shall mean the amount
equal to Net Sales for the Products in the Field in the Territory in the
applicable reporting period less the Shared Expenses, which shall be a
Distributable Loss if negative and a Distributable Profit if zero (0) or
positive.

     1.33 "DISTRIBUTION COSTS" shall mean costs incurred (i.e., paid and
accrued) after the Effective Date by or on behalf of a Party to the extent
attributable to the distribution of Commercial Supplies, including (i)
distributor customer services, (ii) order entry, (iii) billing, (iv)
warehousing, (v) freight and transportation for delivery of the Products to the
end user and (vi) credit and collection services.

     1.34 "DT" shall mean a development team established pursuant to Section
3.1.

     1.35 "EFFECTIVE DATE" shall mean the date first written above.

     1.36 "FDA" shall mean the United States Food and Drug Administration or any
successor agency.

     1.37 "FIELD" shall mean the treatment, prevention or diagnosis of any human
disease, disorder or condition, including the treatment and/or prevention of
alcohol abuse/dependence.

     1.38 "FILING PARTY" shall have the meaning set forth in Section 7.4.

     1.39 "FINISHED PRODUCT" shall mean a finished, packaged, labeled final
dosage unit of a Product plus diluent and syringes.

     1.40 "FIRST COMMERCIAL SALE" shall mean the first commercial sale of a
Finished Product in the Field in the Territory after Regulatory Approval has
been obtained in the Territory for such Finished Product.

     1.41 "FTE" shall mean [**].

** CONFIDENTIAL TREATMENT REQUESTED

                                       9
<PAGE>
     1.42 "FULLY BURDENED MANUFACTURING COST" shall mean the costs incurred
(i.e., paid or accrued) by a Party, its Affiliates or agents in the Manufacture
of a Product, Placebo or diluent, as applicable, which shall be [**]. Fully
Burdened Manufacturing Cost shall exclude [**] that are required to obtain
Regulatory Approval for the Medisorb Product for the Initial Indication (which
costs shall be borne solely by Alkermes). In addition, for the avoidance of
doubt, any Manufacturing development costs that are included in Shared Expenses
as Development Costs shall not be included as part of the Fully Burdened
Manufacturing Cost.

     1.43 "GAAP" shall mean United States Generally Accepted Accounting
Principles.

     1.44 "GENERIC PRODUCT" shall mean [**].

     1.45 "GOVERNMENT AUTHORITY" shall mean any court, tribunal, agency,
department, legislative body, commission or other instrumentality of any
federal, state, county, city or other political subdivision in the Territory.

     1.46 "INITIAL INDICATION" shall mean the alcohol abuse/dependence
indication.

     1.47 "INITIAL INDICATION DEVELOPMENT COSTS" shall mean those Development
Costs that are necessary to obtain Regulatory Approval for the Medisorb Product
for the Initial Indication at the manufacturing scale and in the presentation
form contained in NDA number 21-897 filed with the FDA by Alkermes on March 31,
2005; provided, however, that such costs shall only include the cost of one
Phase III clinical trial (including the Fully Burdened Manufacturing Costs of
Clinical Supplies for such trial) in addition to the Phase III clinical trial
the data from which is included in such NDA and such costs shall not include any
costs incurred after the receipt of such Regulatory Approval for the Medisorb
Product, including any costs incurred to support or expand such Regulatory
Approval.

     1.48 "IND" shall mean an Investigational New Drug Application for a Product
or a [**] filed with the FDA pursuant to 21 C.F.R. Part 312.

     1.49 "[**]" shall mean [**].

     1.50 "JOINT KNOW-HOW" shall mean any Collaboration Technology developed,
made or conceived jointly by or on behalf of Cephalon or its Affiliates and by
or on behalf of Alkermes or its Affiliates.

     1.51 "JOINT PATENTS" shall mean any patent applications (including
provisional patent applications) claiming discoveries or inventions that are
conceived and reduced to practice jointly by or on behalf of Cephalon or its
Affiliates and by or on behalf of Alkermes or its Affiliates and that claim
Collaboration Technology, and all Patent Rights

** CONFIDENTIAL TREATMENT REQUESTED

                                       10
<PAGE>
related to such patent applications.

     1.52 "JSC" shall mean that joint steering committee established pursuant to
Section 2.1.

     1.53 "KNOW-HOW" shall mean all proprietary data, technical information,
know-how, inventions, discoveries, trade secrets, processes, techniques,
compositions, material, methods, formulas or improvements, whether patentable or
not.

     1.54 "LAWS" or "LAW" shall mean all applicable laws, statutes, rules,
regulations, ordinances and other pronouncements having the binding effect of
law of any applicable Government Authority, including the Act.

     1.55 "MANUFACTURING" (including variations such as "MANUFACTURE") shall
mean the performance of any and all activities directed to producing,
manufacturing, processing, filling, finishing, packaging, labeling, quality
control, quality assurance, testing and release, shipping and warehousing of the
Products, Finished Products, Placebo, or diluent as applicable.

     1.56 "MARKETING PLAN" shall mean that portion of the Commercialization Plan
described in Section 4.3.

     1.57 "MEDICAL ACTIVITY PLAN" shall mean that portion of the
Commercialization Plan described in Section 4.3.

     1.58 "MEDISORB PRODUCT" shall mean a Product utilizing Alkermes'
Medisorb(R) sustained-release technology as described in NDA number 21-897 filed
with the FDA by Alkermes on March 31, 2005.

     1.59 "MEDISORB TRADEMARK" shall mean the mark MEDISORB, and the
applications for registration of such mark listed on Exhibit C.

** CONFIDENTIAL TREATMENT REQUESTED

                                       11
<PAGE>
     1.60 "MINIMUM SALES REPRESENTATIVES" shall have the meaning set forth in
Section 4.11.1.

     1.61 "NALTREXONE" shall mean [**].

     1.62 "NET SALES" shall mean, as to each calendar month, the gross amount
invoiced by Cephalon and its Affiliates to Third Parties for the sale of
Finished Products in the Territory, less accruals estimated, credits taken, and
actual payments (to the extent not previously accrued) made for: (i) credits,
fees paid to wholesalers, retroactive price reductions, rebates (including
Medicaid, managed care and similar types of government rebates or rebates to
other health care providers and payers), refunds, charge backs, and adjustments
actually granted; (ii) trade, quantity and cash discounts actually allowed or
given; (iii) sales, excise, value-added and similar taxes assessed on the sale
of the Finished Products (other than income taxes of Cephalon and its
Affiliates), and import and customs duties; and (iv) shipping and insurance
charges, postage, and freight out (to the extent not separately paid by the
Third-Party customer). Each of such deductions shall only be applicable to the
extent it is determined in accordance with GAAP as consistently applied by
Cephalon and its Affiliates for pharmaceutical products other than a Finished
Product.

     [**].

     The sale of a Finished Product by and among Cephalon and its Affiliates
intended for subsequent resale is not a sale to a Third Party and shall be
excluded from Net Sales calculations. Cephalon and its Affiliates shall not sell
or otherwise transfer Finished Product other than in an arm's length transaction
exclusively for money except in accordance with normal industry practice: (i)
for charitable purposes; (ii) for pre-clinical studies, Clinical Studies and
Post Marketing Clinical Trials; (iii) for regulatory purposes and (iv) as
promotional samples.

     1.63 "NEW DRUG APPLICATION" or "NDA" shall mean an application for
Regulatory Approval required for commercial marketing or sale of a Product as a
pharmaceutical product in the Territory.

     1.64 "NEW INDICATION" shall mean any indication for a Product in the Field
other than the Initial Indication.

     1.65 "PARTY" shall mean Cephalon or Alkermes and, when used in the plural,
shall mean both Cephalon and Alkermes.

     1.66 "PATENT COSTS" means the (i) fees and expenses paid to outside legal
counsel and experts, or the cost of Alkermes' or its Affiliates' or Cephalon's
or its Affiliates' FTEs at the Development FTE Rate, incurred in connection with
the preparation, filing, prosecution and maintenance of Patent Rights after the
Effective

** CONFIDENTIAL TREATMENT REQUESTED

                                       12
<PAGE>
Date, including costs of patent interference, reexamination, reissue,
revocation, opposition and appeal proceedings, and (ii) cost to litigate the
enforcement and defense of such Patent Rights, in all cases as explicitly
included in Patent Costs pursuant to Article 7 hereof.

     1.67 "PATENT RIGHTS" shall mean any and all of the following: (i) patent
applications (including provisional patent applications) and patents (including
the inventor's certificates); and (ii) any substitution, extension (including
patent term extensions and supplementary protection certificates), registration,
confirmation, reissue, continuation, divisional, continuation-in-part,
reexamination, renewal, patent of addition or the like thereof or thereto.

     1.68 "PLACEBO" shall mean an inactive substitute for a Product.

     1.69 "POST MARKETING CLINICAL TRIAL" shall mean a clinical trial of a
Product in human patients (including investigator initiated trials) that is
conducted for a purpose other than to obtain or support Regulatory Approval.

     1.70 "PRC" shall have the meaning set forth in Section 4.10.2.

     1.71 "PRIMARY POSITION DETAIL" shall mean a Detail in which key Product
attributes are verbally presented in the first position, consistent with the
terms of this Agreement, where the Product is given primary emphasis (i.e., an
emphasis that is more important than the emphasis given to any other product
presented), and where no more than [**] products are presented.

     1.72 "PRODUCT" shall mean any sustained-release, time-release or other
extended-release formulation or dosage form of a pharmaceutical product
containing Naltrexone.

     1.73 "PRODUCT LIABILITY CLAIM" shall mean any claim, action or demand by a
Third Party relating to death or bodily injury caused or allegedly caused by the
use of a Product.

     1.74 "PROMOTIONAL MATERIALS" shall mean all written, printed, audio, video
or graphic advertising, promotional, educational and communication materials
(other than the Product label) for marketing, advertising and promotion of the
Products for use by the Parties' sales forces in accordance with the terms of
the applicable Commercialization Plan.

** CONFIDENTIAL TREATMENT REQUESTED

                                       13
<PAGE>
     1.75 "REGULATORY APPROVAL" shall mean any approvals of the FDA necessary
for the manufacture, marketing or sale of a Product in the Territory.

     1.76 "ROW TERRITORY" shall mean all countries in the world, other than the
Territory.

     1.77 "SALES REPRESENTATIVE" shall mean an individual whose primary
responsibility is to engage in Detailing and other promotional efforts with
respect to the Products.

     1.78 "SALES REPRESENTATIVE FTE" shall mean [**].

     1.79 "SALES REPRESENTATIVE FTE RATE" shall mean initially an amount equal
to [**] per Sales Representative FTE per year; on January 1, 2006, and annually
thereafter, such amount shall be adjusted to reflect any increase, since the
prior adjustment (or the initial rate, as applicable), in the Bureau of Labor
Statistics Consumer Price Index for Urban Wage Earners and Clerical Workers,
Northeast Urban, based on the most recent monthly index available as of the
adjustment date.

     1.80 "SECONDARY POSITION DETAIL" shall mean a Detail in which key Product
attributes are verbally presented in the second position, consistent with the
terms of this Agreement, where the Product is given significant but not primary
emphasis (i.e., an emphasis that is at least or more important than the emphasis
given to any product presented other than the product that is presented in the
Primary Position Detail), and where no more than three (3) products are
presented.

     1.81 "SHARED EXPENSES" shall mean Development Costs, but not including the
Initial Indication Development Costs; the Fully Burdened Manufacturing Cost of
Commercial Supplies (excluding such costs relating to Post Marketing Clinical
Trials that are included in Commercialization Costs); the Commercialization
Costs, but not including Cephalon Commercialization Costs; Patent Costs; all
amounts paid by Cephalon in connection with a Third Party license that are
identified as Shared Expenses pursuant to Section 7.7; and Product Liability
Claim-related costs not covered by either Party's indemnification obligations
set forth in Article 11.

     1.82 "ST" shall mean a supply team established pursuant to the Supply
Agreement.

     1.83 "STANDARDS" shall mean the Accreditation Council for Continuing
Medical Education (ACCME) Standards for Commercial Support of Continuing Medical
Education, as they may be amended from time to time.

     1.84 "SUPPLY AGREEMENT" shall mean the Supply Agreement between the Parties
for the manufacture and supply to Cephalon of the Products, Finished Products,

** CONFIDENTIAL TREATMENT REQUESTED

                                       14
<PAGE>
Placebo and/or diluent.

     1.85 "TARGET PRESCRIBER" shall mean a practitioner with authority to
prescribe the Products or issue hospital orders for the Products, or with
substantial influence over the prescription of the Products or issuance of
hospital orders for the Products, in the Field in the Territory as identified in
the Commercialization Plan.

     1.86 "TERM" shall have the meaning set forth in Section 13.1.

     1.87 "THIRD PARTY" shall mean any entity other than the Parties or their
respective Affiliates.

     1.88 "TERRITORY" shall mean the United States of America, its territories
and possessions, including the Commonwealth of Puerto Rico.

     1.89 "TREATMENT SYSTEM SPECIALISTS" shall have the meaning set forth in
Section 4.11.2.

     1.90 "TREATMENT SYSTEM SPECIALIST FTE" shall mean [**].

     1.91 "TREATMENT SYSTEM SPECIALIST FTE RATE" shall mean initially an amount
equal to [**] per Treatment System Specialist FTE per year; on January 1, 2006,
and annually thereafter, such amount shall be adjusted to reflect any increase,
since the prior adjustment (or the initial rate, as applicable), in the Bureau
of Labor Statistics Consumer Price Index for Urban Wage Earners and Clerical
Workers, Northeast Urban, based on the most recent monthly index available as of
the adjustment date.

     1.92 "[**]" shall have the meaning set forth in Section 4.1.2.

     1.93 "VALID CLAIM" shall mean a claim of an issued or granted and unexpired
patent, including an Alkermes Patent or Joint Patent, which has not lapsed, been
revoked or abandoned or held permanently unenforceable or invalid by a decision
of a court or other governmental agency of competent jurisdiction, unappealable
or unappealed within the time allowed for appeal, and which has not been
disclaimed, denied or admitted to be invalid or unenforceable through reissue,
reexamination, disclaimer or otherwise.

     1.94 "VIVITREX TRADEMARK" shall mean the mark VIVITREX, and the
applications for registration of such mark listed on Exhibit C.

     Where words and phrases are used herein in the singular, such usage is
intended to include the plural forms where appropriate to the context, and vice
versa. The words "including", "includes" and "such as" are used in their
non-limiting sense and have the same meaning as "including without limitation"
and "including but not limited

** CONFIDENTIAL TREATMENT REQUESTED

                                       15
<PAGE>
to". References to Articles, Sections, subsections, and clauses are to the same
with all their subparts as they appear in this Agreement. "Herein" means
anywhere in this Agreement. "Hereunder" and "hereto" means under or pursuant to
any provision of this Agreement.

                                    ARTICLE 2
                         MANAGEMENT OF THE COLLABORATION

     2.1 JOINT STEERING COMMITTEE.

          2.1.1 ESTABLISHMENT OF THE JSC. Within fifteen (15) days of the
Effective Date, the Parties shall establish a joint steering committee (the
"JSC"), which shall have overall responsibility for the collaboration between
the Parties, including overseeing the Development and Manufacturing of the
Products in the Field for the Territory, and the Commercialization of the
Products in the Field in the Territory, as contemplated by this Agreement. The
JSC will comprise [**] representatives of each Party, who shall be appointed
(and may be replaced at any time) by such Party on notice to the other Party in
accordance with this Agreement. Such representatives shall include individuals
within the senior management of each Party. To conduct the activities described
in Section 2.1.2 below, the JSC will meet at least [**] each calendar quarter
for the first [**] years following the Effective Date, and thereafter at least
[**] each calendar year, or more frequently if agreed by the JSC. The
representatives from each Party shall collectively have one vote in decisions,
with decisions made by unanimous vote.

          2.1.2 JSC RESPONSIBILITIES. The JSC shall perform the following
functions:

               (I) review, coordinate and, in its discretion, approve the
strategies for the Development, Commercialization and Manufacture of the
Products in the Field in the Territory, and provide direction to the DT, CT and
ST as provided herein;

               (II) approve the scope of the DT's, CT's and ST's decision-making
authority;

               (III) except as otherwise provided herein, review and, in its
discretion, approve by [**] of each calendar year the Development Plan for the
subsequent calendar year (including the Development Plan annual budget and the
division of responsibilities between the Parties under such plan);

** CONFIDENTIAL TREATMENT REQUESTED

                                       16
<PAGE>
               (IV) review and, in its discretion, approve substantive
amendments to the Development Plan (including the Development Plan annual
budget);

               (V) review and, in its discretion, approve the multiyear
long-range plan for Development of the Products in the Field in the Territory
(including the budget for Development Costs) formulated by the DT;

               (VI) review and, in its discretion, approve recommendations for
further Development of the Products, including Development of the Products for a
New Indication;

               (VII) review and, in its discretion, approve by [**] of each
calendar year the Commercialization Plan for the subsequent calendar year
(including the Commercialization Plan annual budget);

               (VIII) review and, in its discretion, approve substantive
amendments to the Commercialization Plan (including the Commercialization Plan
annual budget);

               (IX) review and, in its discretion, approve the multiyear
long-range plan for Commercialization of the Products in the Field in the
Territory (including the budget for Commercialization Costs) formulated by the
CT;

               (X) review and, in its discretion, make a commercially reasonable
determination whether the budget for Patent Costs prepared by the Patent
Committee pursuant to Section 7.3 should be approved, and if appropriate,
approve the budget in accordance with such determination;

               (XI) serve as the first forum for the settlement of disputes or
disagreements that are unresolved by the DT, CT or ST, unless otherwise
indicated in this Agreement; and

               (XII) perform such other functions as appropriate to further the
purposes of this Agreement as determined by the Parties.

          2.1.3 JSC CHAIRPERSON; PROCEDURES. For a [**]-year period commencing
on the Effective Date, an Alkermes representative to the JSC shall serve as the
chairperson of the JSC. For each subsequent [**]-year period, representatives of
the Parties shall alternate as the chairperson of the JSC. The chairperson shall
establish the timing and agenda for all JSC meetings and shall send notice of
such meetings, including the agenda therefor, to all JSC members; provided,
however, either Party may request that specific items be included in the agenda
and may request that additional meetings be scheduled as needed. The location of
regularly scheduled JSC

** CONFIDENTIAL TREATMENT REQUESTED

                                       17
<PAGE>
meetings shall alternate between the offices of the Parties, unless otherwise
agreed. Meetings may be held telephonically or by videoconference. A quorum of
at least [**] JSC members appointed by each Party shall be present at or shall
otherwise participate in each JSC meeting. The Party hosting any JSC meeting
shall appoint one person (who need not be a member of the JSC) to attend the
meeting and record the minutes of the meeting in writing. Such minutes shall be
circulated to the Parties promptly following the meeting for review, comment and
approval. Any modifications to any Development Plan or Commercialization Plan
(including the work, budget, and timeline therefor) approved at a JSC meeting
shall be considered approved and shall constitute a valid, binding amendment to
such Development Plan or Commercialization Plan, as applicable, upon JSC review
and approval of the meeting minutes related thereto.

          2.1.4 JSC DECISION MAKING. As a general principle, the JSC will
operate by consensus with each Party collectively having one vote. In the event
that the JSC members do not reach consensus with respect to a matter that is
within the purview of the JSC within [**] days after they have met and attempted
to reach such consensus, such matter shall be resolved by the Parties under the
terms of Article 12 below; provided, however, that to the extent any matters are
required by Law or by safety concerns with respect to a Product to be resolved
within a shorter period of time, the periods set forth in this Section 2.1.4 and
in Article 12 shall be shortened as appropriate to permit the resolution of such
matters within the required period.

     2.2 MODIFICATIONS TO AGREEMENT AFTER SHARING OF DISTRIBUTABLE LOSS AND
DISTRIBUTABLE PROFIT CONVERTS TO A ROYALTY-BASED ARRANGEMENT. The Parties intend
that in those instances where the sharing of Distributable Loss and
Distributable Profit hereunder is eliminated in favor of a royalty-based
arrangement, the DT and the CT will cease operations, the Parties' operational
Development and Commercialization obligations and all related collaboration
governance provisions (including the provisions of Section 12.2 relating to the
resolution of disputes outside of the arbitration provisions of Section 12.3)
shall terminate, and Cephalon shall be obligated only to use Commercially
Reasonable Efforts to Commercialize the Products in the Field in the Territory.
Notwithstanding the foregoing, the Parties' mutual obligations to cooperate with
one another to enable one another to comply with applicable Laws shall continue,
including Alkermes' right to require that Cephalon not implement decisions that
adversely affect, in any material respect, the obligation of Alkermes, as the
holder of the Regulatory Approval for a Product, to comply with applicable Law.
Cephalon shall have the right to make all decisions regarding Development and
Commercialization, subject to the preceding sentence and to Cephalon's royalty
and other surviving financial obligations and related reporting obligations to
Alkermes hereunder. Section 9.11 shall also no longer apply. In addition, each
Party shall have the right to prosecute, defend and enforce Patent Rights owned
or controlled by it, each Party shall be responsible for the payment of any
Patent Costs it incurs, each Party shall have the right to retain all associated
recovery in connection with a patent enforcement or defense action, and Cephalon
shall be responsible for the costs and expenses incurred in connection with

** CONFIDENTIAL TREATMENT REQUESTED

                                       18
<PAGE>
the prosecution, maintenance, defense and enforcement of the Vivitrex Trademark
and the Additional Product Trademark.

                                    ARTICLE 3
                                   DEVELOPMENT

     3.1 DEVELOPMENT TEAM.

          3.1.1 ESTABLISHMENT OF DEVELOPMENT TEAM. The JSC shall establish a
development team (the "DT") no later than [**] days after the Effective Date to
coordinate and implement all activities for the Development of the Products in
the Field in the Territory, within the budgets approved by the JSC. One
representative from each Party shall be designated as that Party's team leader
to act as the primary DT contact for that Party. The DT shall consist of an
equal number of representatives of each Party as are reasonably necessary to
accomplish the goals of the DT hereunder. Such representatives will include
individuals with expertise and responsibilities in the areas of pre-clinical and
clinical development, manufacturing process development, quality control,
quality assurance, regulatory affairs and product development, as applicable to
the stage of Development of a Product. Either Party may replace any or all of
its representatives at any time upon notice to the other Party.

          3.1.2 DEVELOPMENT TEAM RESPONSIBILITIES. The DT shall be responsible
for:

               (I) developing an overall strategy for the Development of the
Products in the Field in the Territory for review and approval by the JSC;

               (II) formulating the Development Plans (including the allocation
of Development activities between the Parties) and associated annual budgets and
any substantive amendments thereto for review and approval by the JSC, which
Development Plans will include the plans for Manufacture development and
associated annual budgets and any substantive amendments thereto received by the
DT from the ST;

               (III) formulating the multiyear long-range plan for Development
of the Products in the Field in the Territory (including the budget for
Development Costs) for review and approval by the JSC;

               (IV) implementing in coordination with the ST, as appropriate,
all activities pursuant to the Development Plans approved by the JSC;

               (V) making recommendations for further Development of the
Products, including Development of the Products for a New Indication;

** CONFIDENTIAL TREATMENT REQUESTED

                                       19
<PAGE>
               (VI) in consultation with intellectual property representatives
of each Party, developing a strategy, and implementing methods for compliance,
to protect trade secrets, know-how and other confidential material, data and
information developed, made or conceived by the Parties pursuant to a
Development Plan;

               (VII) in consultation with the CT, developing and co-ordinating a
communications and publication strategy for the Products in the Territory;

               (VII) generating forecasts of supply requirements for the Product
and Placebo pursuant to the Development Plans and delivering this forecast to
the CT;

               (IX) exchanging information and facilitating cooperation and
coordination between the Parties as they exercise their respective rights and
meet their respective obligations under the Development Plans and this
Agreement;

               (X) providing status updates to the JSC regarding Development
activities in the Territory; and

               (XI) performing such other functions as appropriate to further
the purposes of this Agreement as determined by the Parties.

     In addition, the DT may designate subteams as appropriate to facilitate
coordination and cooperation in key areas. The Development Plan for the Medisorb
Product for the Initial Indication for calendar years 2005 and 2006 and the
accompanying budget are attached hereto as Exhibit D. This Development Plan
shall be deemed to have been reviewed and approved by the JSC. The DT will
prepare final Development Plans and associated budgets for each subsequent
calendar year by [**] of the then-current calendar year. The JSC shall review
and, if appropriate, approve such Development Plans and budgets by [**] of the
then-current calendar year. In addition, a [**]-year long-range plan for
Development of the Products in the Field in the Territory (including the budget
for Development Costs) shall be established on a yearly basis under the
direction of the DT and submitted to the JSC by [**] of each calendar year
during any year that the Parties are operating under a Development Plan.

          3.1.3 DEVELOPMENT TEAM PROCEDURES. The Alkermes team leader shall
serve as the chairperson of the DT. The chairperson shall establish the timing
and agenda for all DT meetings and shall send notice of such meetings, including
the agenda therefor, to all DT members; provided, however, either Party may
request that specific items be included in the agenda and may request that
additional meetings be scheduled as needed. The DT will meet at least [**] each
calendar month, or as agreed by the DT, for the first [**] years following the
Effective Date, and at least [**] each calendar quarter, or as agreed by the DT,
thereafter. The location of regularly scheduled DT meetings shall alternate
between the offices of the Parties, unless

** CONFIDENTIAL TREATMENT REQUESTED

                                       20
<PAGE>
otherwise agreed. Meetings may be held telephonically or by videoconference. A
quorum of at least half the DT members appointed by each Party shall be present
at or shall otherwise participate in each DT meeting. The Party hosting any DT
meeting shall appoint one person (who need not be a member of the DT) to attend
the meeting and record the minutes of the meeting in writing. Such minutes shall
be circulated to the Parties promptly following the meeting for review, comment
and approval.

          3.1.4 DEVELOPMENT TEAM DECISION MAKING. As a general principle, the DT
will operate by consensus, with each Party collectively having one vote. In the
event that the DT members do not reach consensus with respect to a matter that
is within the purview of the DT within [**] days after they have met and
attempted to reach such consensus, such matter shall be presented to the JSC for
resolution; provided, however, that to the extent any matters are required by
Law or by safety concerns with respect to a Product to be resolved within a
shorter period of time, the periods set forth in this Section 3.1.4 shall be
shortened as appropriate to permit the resolution of such matters within the
required period.

     3.2 ACCOUNTING AND FINANCIAL REPORTING FOR DT AND CT. Each Party will
appoint a representative with expertise in the areas of accounting, cost
allocation, budgeting and financial reporting no later than [**] days after the
Effective Date. Such financial representatives shall work under the direction of
the JSC and provide services to and consult with the DT and CT in order to
address the financial, budgetary and accounting issues which arise in connection
with any Development Plan or Commercialization Plan. The financial
representatives from Cephalon and Alkermes shall develop systems to track their
respective Sales Representatives' Primary Position Details and Secondary
Position Details and any factors used to allocate less than full time Sales
Representative FTEs, Treatment System Specialist FTEs or other FTEs hereunder.
Within [**] days of the end of each calendar quarter the financial
representatives shall review the actual Development Costs or Commercialization
Costs, as applicable, incurred during the prior calendar quarter as charged by
Alkermes and Cephalon, respectively, and prepare a report to the DT or CT, as
applicable, comparing these costs to the comparable Development Plan budget or
Commercialization Plan budget, as applicable, specifically noting the extent, if
any, to which the Development Costs or Commercialization Costs exceed the
comparable budgeted amounts. Each financial representative may be replaced at
any time by the represented Party by providing notice thereof to the other
Party. The financial representatives will meet at least once each calendar
quarter, or as they or the DT or CT may agree. The financial representatives
shall agree upon the timing and agenda for all regular meetings. The location of
regularly scheduled meetings shall alternate between the offices of the Parties,
unless otherwise agreed. Meetings may be held telephonically or by
videoconference. One of the financial representatives shall record the minutes
of the meeting in writing. Such minutes shall be circulated to the other
financial representative promptly following the meeting for review, comment and
approval. Following their approval, the minutes shall be provided to each
Party's DT and CT team leaders.

** CONFIDENTIAL TREATMENT REQUESTED

                                       21
<PAGE>
     3.3 DEVELOPMENT EFFORTS. Each Party shall use its Commercially Reasonable
Efforts to perform its respective tasks and obligations in conducting all work
assigned to it in any Development Plan. The Parties agree that Alkermes shall be
primarily responsible for conducting Development hereunder; provided, however,
that in allocating responsibility for Development the DT shall also consider the
infrastructure and expertise of each Party and may elect to allocate specific
Development tasks and obligations to a Party to exploit such infrastructure and
expertise. Each Party shall also cooperate with and provide commercially
reasonable support to the other Party in connection with such other Party's
conduct of such work pursuant to any Development Plan. If any tasks, obligations
or support that a Party is required to perform or provide hereunder will be
performed or provided by any Affiliate or agent of such Party, such Party shall
not be relieved of its responsibilities hereunder.

     3.4 DEVELOPMENT RESPONSIBILITIES.

          3.4.1 FURTHER DEVELOPMENT OF PRODUCTS IN THE TERRITORY. If either
Party wishes to further Develop the Products for use in the Field in the
Territory, including any improvements to the Products or Development of the
Products for New Indications, such Party shall notify the DT, and the DT shall
determine whether it wishes to recommend such further Development of the
Products pursuant to a Development Plan, and accompanying budget, to the JSC for
approval. The Development Plan shall allocate responsibility for the conduct of
such activities between the Parties. If the DT makes such recommendation or, at
either Party's request, even if the DT does not make such recommendation, the
JSC shall consider such further Development of the Products. If such further
Development is approved by the JSC or pursuant to the dispute resolution
procedure set forth in Article 12, the Parties shall perform such Development.
Notwithstanding the foregoing, such further Development shall not be undertaken
if either Party notifies the JSC of its good faith determination [**].

          3.4.2 DATA TRANSFER AND COOPERATION.

               (I) REGULATORY SUBMISSIONS. Promptly after the Effective Date,
Alkermes shall provide Cephalon reasonable access at Alkermes' offices at
Cephalon's request to any portion of the NDA submission made by Alkermes on
March 31, 2005 for the Medisorb Product for the Initial Indication, including
any information referenced or otherwise incorporated therein. All such
information shall be deemed to be Confidential Information of Alkermes subject
to the terms and conditions set forth in Article 8.

               (II) ALKERMES DATA. Subject to Section 3.4.2(i), Alkermes shall
provide Cephalon at Cephalon's request with reasonable access to all relevant
materials, data and regulatory information in Alkermes' or its Affiliates'
possession related to any pre-clinical studies, Clinical Studies and Post
Marketing Clinical Trials of any Product in the Field conducted or sponsored by
Alkermes (including investigator sponsored trials) pursuant to a Development
Plan or a Commercialization Plan or

** CONFIDENTIAL TREATMENT REQUESTED

                                       22
<PAGE>
otherwise conducted by or on behalf of Alkermes (and, in electronic or other
form reasonably requested by Cephalon where practicable), including all clinical
safety and efficacy data and all regulatory data and information related to the
use and sale of the Products in the Field. Such materials, data and information
shall be delivered to Cephalon by Alkermes promptly after the relevant request
by Cephalon in an orderly fashion and in a manner such that the value of the
delivered information is preserved in all material respects. All such materials,
data and information shall be deemed to be Confidential Information of Alkermes
subject to the terms and conditions set forth in Article 8.

               (III) CEPHALON DATA. Cephalon shall provide Alkermes at Alkermes'
request with reasonable access to all relevant materials, data and regulatory
information in Cephalon's or its Affiliates' possession related to any
pre-clinical studies, Clinical Studies and Post Marketing Clinical Trials of a
Product in the Field conducted or sponsored by Cephalon (including investigator
sponsored trials and Post Marketing Clinical Trials) pursuant to a Development
Plan or a Commercialization Plan or otherwise conducted by or on behalf of
Cephalon (and, in electronic or other form reasonably requested by Alkermes
where practicable), including all clinical safety and efficacy data and all
regulatory data and information related to the use and sale of the Products in
the Field. Such materials, data and information shall be delivered to Alkermes
by Cephalon promptly after the relevant request by Alkermes in an orderly
fashion and in a manner such that the value of the delivered information is
preserved in all material respects. All such materials, data and information
shall be deemed to be Confidential Information of Cephalon subject to the terms
and conditions set forth in Article 8.

               (IV) ROW TERRITORY. Alkermes shall share with Cephalon relevant
materials, data and regulatory information in Alkermes' or its Affiliates'
possession and Control related to any pre-clinical studies, Clinical Studies and
post marketing clinical trials of a Product in the Field resulting from its
collaborations with respect to the Product for the ROW Territory to the extent
such materials, data or regulatory information are necessary or useful for
filing an IND or NDA or required to be disclosed by Law. In return Cephalon
agrees that Alkermes may share with its collaborators with respect to the
Product in the ROW Territory, subject to the provisions of Article 8, [**].

          3.4.3 REGULATORY FILINGS. Alkermes shall be responsible for applying
for and seeking Regulatory Approval for the Medisorb Product in the Territory
for the Initial Indication, which applications and approvals shall be held by
and in the name of Alkermes. Alkermes shall also be responsible for filing and
maintaining all INDs and NDAs, and for seeking Regulatory Approval for other
Products in the Territory, which applications and approvals shall be held by and
in the name of Alkermes (except to the extent that Cephalon is required to file
an IND in connection with Clinical Studies or Post Marketing Clinical Trials for
which Cephalon has responsibility in accordance with this Agreement). Prior to
submitting any IND or NDA within the Territory, the Parties,

** CONFIDENTIAL TREATMENT REQUESTED

                                       23
<PAGE>
through the DT, shall consult and cooperate in preparing and reviewing such IND
or NDA and its content and scope; provided, however, that in accordance with
Section 12.2 Alkermes shall have final decision making authority with respect to
any INDs, NDAs and Regulatory Approvals for a Product in the Territory.

          3.4.4 REGULATORY MEETINGS AND COMMUNICATIONS. Alkermes shall be
primarily responsible for conducting meetings and discussions related to the
Products with the FDA, provided, however, that Cephalon shall have the right to
participate in such meetings and discussions. Alkermes shall give Cephalon
reasonable advance notice of such activities to permit Cephalon to participate.
If Alkermes has substantive written or oral communication with the FDA relating
to the Products, Alkermes shall notify Cephalon and provide an advance copy to
Cephalon of any such written communication to the FDA at least [**] Business
Days, if reasonably possible to do so and otherwise as soon as practicable,
prior to such communication's intended occurrence and a copy to Cephalon of any
such written communication from the FDA within [**] Business Days of such
communication's occurrence. Alkermes shall consider in good faith any comments
provided by Cephalon regarding any planned communication to the FDA. In the
event Cephalon receives any written or oral communication from the FDA relating
to the Products, Cephalon shall notify Alkermes and provide a copy to Alkermes
of any such written communication within [**] Business Days of such
communication's occurrence. Cephalon shall not respond to any such communication
but shall permit Alkermes to respond on Cephalon's behalf; provided, however,
that Cephalon shall have the right to respond to FDA communication to the extent
reasonably required to comply with applicable Laws.

          3.4.5 DEBARMENT LIMITATIONS. In the course of Development of the
Products in the Territory, neither Party shall knowingly use any employee or
consultant who is or has been debarred by the FDA or any other regulatory
authority, or, to the best of such Party's knowledge, who is or has been the
subject of debarment proceedings by the FDA or any such regulatory authority.
Each Party shall promptly notify the other Party of and provide such other Party
with a copy of any correspondence or other reports that such Party receives from
any Third Party with respect to any use of a debarred employee or consultant in
connection with such Party's performance of its obligations under this
Agreement.

          3.4.6 COMPLIANCE WITH LAWS. Each Party shall conduct pre-clinical
studies and Clinical Studies hereunder, and other Development of the Products in
the Field in the Territory, in compliance with all applicable Laws.

     3.5 PHARMACOVIGILENCE AND ADVERSE EVENT REPORTING. Within [**] days of the
Effective Date, both Parties shall enter into a mutually acceptable safety data
exchange agreement, setting forth guidelines and procedures for the receipt,
investigation, recordation, review, communication, and exchange (as between the
Parties) of adverse event reports, pregnancy reports, technical complaints and
any

** CONFIDENTIAL TREATMENT REQUESTED

                                       24
<PAGE>
other information concerning the safety of the Products. Such guidelines and
procedures shall be in accordance with, and enable the Parties and their
Affiliates to fulfill, reporting obligations to the FDA or any other regulatory
authority. Furthermore, such guidelines and procedures shall be consistent with
relevant International Committee on Harmonization (ICH) guidelines, except where
said guidelines may conflict with reporting requirements of local regulatory
authorities, in which case local reporting requirements shall prevail. The
Parties shall maintain a common safety database for both clinical and
post-marketing adverse event data for the Products, which database shall be
managed by Alkermes. The Parties shall mutually agree within [**] days on the
actions necessary to address any safety concerns with respect to the Products
about which one Party provides notice to the other Party; provided, however,
that if the Parties cannot reach agreement within such [**]-day period, the
matter shall be referred to the JSC for immediate review. If the JSC cannot
reach agreement about such matter within [**] days after referral by the
Parties, then Alkermes shall have final say with respect to such matter.
Notwithstanding the foregoing provision, such [**]-day periods shall be
shortened if either Party provides notice to the other Party that more urgent
action is required. The Parties' costs incurred in connection with receiving,
investigating, recording, reviewing, communicating, and exchanging adverse
events and other reportable information as provided in such safety data exchange
agreement shall be included as an element of Development Costs (to the extent
relating to the Development of a Product) or Commercialization Costs (to the
extent relating to the Commercialization of a Product), as applicable. The
Parties' costs incurred in connection with receiving, investigating, recording,
reviewing, communicating, and exchanging adverse events and other reportable
information as provided in such safety data exchange agreement prior to the
receipt of Regulatory Approval for the Medisorb Product for the Initial
Indication shall be included as an element of Initial Indication Development
Costs.

     3.6 DEVELOPMENT COSTS. All Initial Indication Development Costs shall be
paid by Alkermes. All other Development Costs for activities conducted under a
Development Plan hereunder shall be Shared Expenses and shall be subject to
offset or credit against amounts due pursuant to Section 9.5 below

     3.7 DEVELOPMENT PLAN BUDGET. Responsibility for any Development Plan budget
shall rest with the DT, which shall develop budgets for Development, subject to
final approval by the JSC. Budgets will be prepared annually as set forth in
Section 3.1.2. Any dispute relating to the amount of a Development Plan budget
shall be considered a Reserved Dispute subject to resolution pursuant to Section
12.2. Such budgets shall include Development FTE Rates for FTEs conducting
Product Development activities. The financial representatives from Cephalon and
Alkermes appointed pursuant to Section 3.2 will be responsible for identifying,
analyzing and reporting to the DT all significant [**] between the budget and
the actual costs incurred and all [**] between the budget and such costs. If any
costs for a Development activity result in an increase [**] in the approved
budget of more than [**]percent ([**]%) for a given calendar quarter, the DT
shall forward to the JSC the report it received from the

** CONFIDENTIAL TREATMENT REQUESTED

                                       25
<PAGE>
financial representatives, and the JSC shall review such costs and shall
designate them as Development Costs if the JSC determines that incurring such
costs was [**]. [**]. A [**]-year long-range plan for Development of the
Products in the Field in the Territory (including the budget for Development
Costs) shall be established on a yearly basis under the direction of the DT as
set forth in Section 3.1.2 and shall be submitted to the JSC for final approval.

     3.8 LIMITATION ON DEVELOPMENT TEAM DECISION MAKING. Neither the DT nor the
JSC shall, without the consent of Cephalon, have any authority to modify or
reduce Alkermes' obligation under this Agreement to use Commercially Reasonable
Efforts to Develop the Product as provided herein. Notwithstanding anything to
the contrary herein, Alkermes shall not have any right to resolve any Reserved
Dispute in any manner that modifies or reduces Alkermes' obligations under this
Agreement or to amend any provision of this Agreement.

                                    ARTICLE 4
                                COMMERCIALIZATION

     4.1 COMMERCIALIZATION EFFORTS.

          4.1.1 COMMERCIALLY REASONABLE EFFORTS. Alkermes and Cephalon each
agree to collaborate in the Commercialization of the Products in the Field in
the Territory in accordance with the terms and conditions of this Agreement. The
Parties agree that Cephalon shall be primarily responsible for conducting
Commercialization hereunder; provided, however, that in allocating
responsibility for Commercialization the CT shall also consider the
infrastructure and expertise of each Party and may elect to allocate specific
Commercialization tasks and obligations to a Party to exploit such
infrastructure and expertise. Each Party shall use Commercially Reasonable
Efforts to Commercialize the Products in the Field in the Territory. Each Party
shall cooperate with and provide commercially reasonable support to the other
Party in connection with such other Party's performance of its tasks and
obligations. If any tasks, obligations or support that a Party is required to
perform or provide hereunder will be performed or provided by any Affiliate or
agent of such Party, such Party shall not be relieved of its responsibilities
hereunder.

          4.1.2 CEPHALON COMMERCIALIZATION COSTS. In addition to the foregoing
obligations, Cephalon shall be solely responsible for the payment, [**]. The
Cephalon Commercialization Costs shall not be Shared Expenses. [**].

     4.2 COMMERCIALIZATION TEAM.

          4.2.1 ESTABLISHMENT OF COMMERCIALIZATION TEAM. The JSC shall establish
the commercialization team (the "CT") no later than [**] days after the

** CONFIDENTIAL TREATMENT REQUESTED

                                       26
<PAGE>
Effective Date to coordinate and implement all activities for the marketing and
sale of the Products in the Field in the Territory. One representative from each
Party shall be designated as that Party's team leader to act as the primary CT
contact for that Party. The CT shall consist of an equal number of
representatives of each Party as are reasonably necessary to accomplish the
goals of the CT hereunder. The representatives of Cephalon and Alkermes to the
CT will be individuals with expertise and responsibilities in the areas of
medical affairs, strategic marketing and sales. Either Party may replace any or
all of its representatives at any time upon notice to the other Party.

          4.2.2 COMMERCIALIZATION TEAM RESPONSIBILITIES. The CT shall be
responsible for:

               (I) developing an overall strategy for the Commercialization of
the Products in the Field in the Territory for review and approval by the JSC;

               (II) formulating the Commercialization Plans (including the
allocation of Commercialization activities between the Parties) and associated
annual budgets and any substantive amendments thereto for review and approval by
the JSC;

               (III) formulating a multiyear long-range plan for
Commercialization of the Products in the Field in the Territory (including the
budget for Commercialization Costs) for review and approval by the JSC;

               (IV) implementing all activities pursuant to the
Commercialization Plans approved by the JSC;

               (V) in consultation with the DT, developing a communications and
publication strategy for the Products in the Field in the Territory;

               (VI) generating sales forecasts and measuring sales performance
for the Product in the Territory;

               (VII) in accordance with the terms and conditions set forth in
the Supply Agreement, by the end of each calendar quarter, generating an [**]
month rolling forecast for Product and Placebo requirements, incorporating any
forecast received from the DT, and delivering this forecast to the ST;

               (VIII) coordinating with the DT with respect to regulatory issues
and future Product Development activities to be undertaken pursuant to the
Development Plan and with respect to Post Marketing Clinical Trials;

               (IX) developing positioning and market strategies for the
Products in the Territory;

** CONFIDENTIAL TREATMENT REQUESTED

                                       27
<PAGE>
               (X) formulating a life cycle plan for the Products in the Field
in the Territory, including presentations, formulations, usage or dosage form;

               (XI) formulating an overall pricing strategy for the Products in
the Territory;

               (XII) exchanging information and facilitating cooperation and
coordination between the Parties as they exercise their respective rights and
meet their respective obligations under the Commercialization Plans and this
Agreement;

               (XIII) providing status updates to the JSC regarding marketing
and sales activities in the Territory; and

               (XIV) performing such other functions as appropriate to further
the purposes of this Agreement as determined by the Parties.

     In addition, the CT may designate subteams as appropriate to facilitate
coordination and cooperation in key areas. Within [**] days after the Effective
Date, the CT shall formulate a Commercialization Plan and associated budget for
the period from the Effective Date until the end of calendar year 2006 for
approval by the JSC. Thereafter by [**] of each calendar year during the Term,
the CT shall prepare a Commercialization Plan and associated annual budget for
the following calendar year and present such plan and budget to the JSC for
approval. The JSC shall review and, if appropriate, approve such
Commercialization Plans and budgets by [**] of the then-current calendar year.
In addition, by [**] of each calendar year during the Term, the CT shall prepare
a [**]-year long-range plan for Commercialization of the Products in the Field
in the Territory (including the budget for Commercialization Costs) and present
such plan to the JSC for approval. Prior to presenting this long-range plan to
the JSC for approval, the CT shall forward this long-range plan to the ST
pursuant to the Supply Agreement, and the CT team leader, and if applicable the
DT team leader, will discuss with the ST team leader this long-range plan as
provided in the Supply Agreement.

          4.2.3 COMMERCIALIZATION TEAM PROCEDURES. The Cephalon team leader
shall serve as the chairperson of the CT. The chairperson shall establish the
timing and agenda for all CT meetings and shall send notice of such meetings,
including the agenda therefor, to all CT members; provided, however, either
Party may request that specific items be included in the agenda and may request
that additional meetings be scheduled as needed. The CT will meet at least [**]
each calendar quarter or as agreed by the CT. The location of regularly
scheduled CT meetings shall alternate between the offices of the Parties, unless
otherwise agreed. Meetings may be held telephonically or by videoconference. The
Party hosting any CT meeting shall appoint one person (who need not be a member
of the CT) to attend the meeting and record the minutes of the meeting in
writing. Such minutes shall be circulated to the Parties promptly following the
meeting for review, comment and approval.

** CONFIDENTIAL TREATMENT REQUESTED

                                       28
<PAGE>
          4.2.4 COMMERCIALIZATION TEAM DECISION MAKING. As a general principle,
the CT will operate by consensus, with each Party collectively having one vote.
In the event that the CT members do not reach consensus with respect to a matter
that is within the purview of the CT within [**] days after they have met and
attempted to reach such consensus, such matter shall be presented to the JSC for
resolution; provided, however, that to the extent any matters are required by
Law or by safety concerns with respect to a Product to be resolved within a
shorter period of time, the periods set forth in this Section 4.2.4 shall be
shortened as appropriate to permit the resolution of such matters within the
required period.

     4.3 CONTENTS OF COMMERCIALIZATION PLAN. The Commercialization Plan shall
consist of a marketing plan (the "Marketing Plan") and a medical activity plan
(the "Medical Activity Plan").

          4.3.1 MARKETING PLAN. Each Marketing Plan shall contain at a minimum:

               (I) plans for branding and positioning the Products;

               (II) promotional campaigns for the Products and messaging by
audience;

               (III) competitive analysis of the Products;

               (IV) plans and strategies for presentations of the Products at
major meetings and conventions;

               (V) market research plans for the Products;

               (VI) distribution plans for the Products;

               (VII) strategies for the Products with respect to managed care
organizations, hospital systems, group purchasing organizations, physician
networks, pharmacies and any other private or government healthcare providers or
reimbursement entities;

               (VIII) pricing and reimbursement plans for the Products;

               (IX) high-level sales plans and activities for the Products;

               (X) concepts for development of appropriate sales training and
Promotional Materials; and

               (XI) sales forecasts for the Products by year for [**] years with
market sensitivities incorporated.

          4.3.2 MEDICAL ACTIVITY PLAN. Each Medical Activity Plan shall contain
at

** CONFIDENTIAL TREATMENT REQUESTED

                                       29
<PAGE>
a minimum:

               (I) Post Marketing Clinical Trial plans;

               (II) market and key opinion leader development plans for the
Products, including plans to support continuing medical education;

               (III) publication plans for the Products;

               (IV) plans to ensure appropriate medical information responses
with respect to the Products;

               (V) safety monitoring plans for the Products; and

               (VI) plans and expected activities for field based medical
affairs personnel for the Products.

     4.4 COMPLIANCE WITH LAW. Each Party shall Commercialize the Products in the
Field in the Territory in compliance with all applicable Laws, the Codes, the
terms of this Agreement, and the then-current Commercialization Plan. Each Party
shall promptly notify the other Party of and provide the other Party with a copy
of any correspondence or other reports with respect to the Commercialization of
the Products that such Party receives from the FDA or any other regulatory
authority, or from the Pharmaceutical Research and Manufacturers of America
(PhRMA) or the American Medical Association (AMA) relating to its compliance
with applicable Law or the Codes. Each Party shall Commercialize the Products,
including carrying out the Medical Activity Plan, in conformity with the
practices and procedures relating to the education of the medical community set
forth in the Standards. Each Party shall promptly notify the other Party of and
provide the other Party with a copy of any correspondence or other reports with
respect to the Commercialization of the Products that such Party receives from
the Accreditation Council for Continuing Medical Education (ACCME) relating to
its compliance with the Standards.

     4.5 CORPORATE NAME AND LOGO. To the extent not prohibited by Law and
subject to Regulatory Approval, the Products (including labels, packaging and
inserts) and all Promotional Materials for the same in the Territory will bear
the company names and logos of both Alkermes and Cephalon with equal prominence
(including equal sized type face), or if equal prominence is prohibited by Law,
with such relative prominence as may otherwise be permitted by Law.

     4.6 SALES AND DISTRIBUTION. [**]. Cephalon will book all sales of the
Products in the Field in the Territory.

     4.7 COMMERCIALIZATION COSTS. Except for the Cephalon Commercialization
Costs, all Commercialization Costs for activities conducted under a
Commercialization

** CONFIDENTIAL TREATMENT REQUESTED

                                       30
<PAGE>
Plan shall be Shared Expenses and shall be subject to offset or credit against
amounts due pursuant to Section 9.5 below.

     4.8 COMMERCIALIZATION PLAN BUDGET. Responsibility for any Commercialization
Plan budget shall rest with the CT, which shall develop budgets for
Commercialization in the Field in the Territory, subject to final approval by
the JSC. Budgets will be prepared annually as set forth in Section 4.2.2. Any
disputes relating to the amount of a Commercialization Plan budget shall be
considered a Reserved Dispute subject to resolution pursuant to Section 12.2.
The budgets shall be divided between the Marketing Plan and the Medical Activity
Plan. Such budgets shall include Sales Representative FTE Rates for the Sales
Representatives FTEs, Treatment System Specialist FTE Rates for the Treatment
System Specialists FTEs, and Commercialization FTE Rates for other FTEs
conducting Product Commercialization activities. The financial representatives
from Cephalon and Alkermes appointed pursuant to Section 3.2 will be responsible
for identifying, analyzing and reporting to the CT all significant [**] between
the budget and the applicable Commercialization Costs and all [**] between the
budget and the Commercialization Costs. If any costs for a Commercialization
activity result in an increase [**] in the approved budget for a calendar
quarter of more than [**] percent ([**]%), the CT shall forward to the JSC the
report it received from the financial representatives, and the JSC shall review
such costs and shall designate them as Commercialization Costs if the JSC
determines that incurring such costs was [**]. [**]. A [**]-year long-range plan
for Commercialization of the Products in the Field in the Territory (including
the budget for Commercialization Costs) shall be established on a yearly basis
under the direction of the CT as set forth in Section 4.2.2 and shall be
submitted to the JSC for final approval.

     4.9 PRODUCT LABEL AND PACKAGING. Pursuant to the terms and conditions of
the Supply Agreement, Alkermes shall be responsible for ensuring that labels,
inserts and packaging for the Products are in conformity with the applicable
Regulatory Approvals and applicable Laws.

     4.10 PROMOTIONAL MATERIALS.

          4.10.1 PROMOTIONAL MATERIALS PRODUCTION. Cephalon shall be responsible
for producing all Promotional Materials for the Territory. Cephalon shall own
all right, title and interest in and to the Promotional Materials, including all
copyrights thereto.

          4.10.2 APPROVAL OF PROMOTIONAL MATERIALS. Within [**] days of the
Effective Date, Cephalon shall establish a promotional review committee, or
designate an existing committee, that shall be responsible for reviewing and
approving Promotional Materials, training materials for the Product, materials
that will be distributed by medical science liaisons for the Product and
comparable materials (such committee, the "PRC"). Alkermes shall appoint a
representative to the PRC with expertise and responsibilities in the areas of
regulatory affairs. The PRC will meet at

** CONFIDENTIAL TREATMENT REQUESTED

                                       31
<PAGE>
least once each calendar quarter or as otherwise agreed by the PRC. Cephalon
shall establish the timing and agenda for all PRC meetings and shall send notice
of such meetings, including the agenda therefor, to all PRC members. In
addition, Cephalon will provide to the Alkermes representative drafts of all
materials to be considered at such meeting at the same time as they are provided
to the other PRC members, which shall be a reasonable time prior to the meeting
to allow review of such materials. As a general principle, the PRC will operate
by consensus, with each Party collectively having one vote. In the event that
the PRC members, including the Alkermes representative, do not reach consensus
with respect to a matter that is within the purview of the PRC within [**] days
after they have attempted to reach such consensus, such matter shall be
presented to the JSC for resolution. Cephalon and Alkermes shall maintain
Promotional Materials and any other materials reviewed by the PRC in confidence
pursuant to the terms of Article 8 and shall not publish, disseminate or use
them unless and until such materials are approved for publication, other general
dissemination or use by the PRC, the JSC or pursuant to the dispute resolution
procedure set forth in Article 12 (where any such matter shall be considered a
Reserved Dispute to be decided by Cephalon, subject to Alkermes' rights as the
holder of the Regulatory Approval for a Product to require that Cephalon not
implement certain decisions). Cephalon shall provide Alkermes with six (6) final
copies of all Promotional Materials concurrently with Cephalon's initial public
dissemination thereof, and such additional copies as may be reasonably requested
by Alkermes from time to time.

          4.10.3 COMPLAINTS REGARDING PROMOTIONAL MATERIALS. Each Party shall
promptly notify the other Party of and provide the other Party with a copy of
any correspondence or other reports or complaints received by such Party from
the FDA, any other regulatory authority or any Third Party claiming that any
Promotional Materials are inconsistent with the Product labeling or are
otherwise in violation of the Act.

          4.10.4 PROMOTIONAL MATERIALS. Each Party shall, and shall cause its
Sales Representatives and/or Treatment System Specialists, as applicable, to,
(i) use the Promotional Materials solely for the purposes of this Agreement and
(ii) immediately cease the use of any Promotional Materials when instructed to
do so by the CT.

     4.11 SALES FORCE.

          4.11.1 CEPHALON PERSONNEL. Cephalon shall use Commercially Reasonable
Efforts to provide sufficient marketing and sales support for the Products in
the Territory, which shall include, unless otherwise agreed by the Parties: (i)
an appropriate number of Sales Representatives, including a minimum number of
Sales Representatives as established pursuant to Section 4.11.3 (the "Minimum
Sales Representatives"); (ii) appropriate national account managers (including
public and private payers and management of distribution partners); (iii)
appropriate sales force management and training personnel; (iv) appropriate
field-based personnel to support reimbursement; and (v) appropriate field
medical affairs personnel. Performance of the

** CONFIDENTIAL TREATMENT REQUESTED

                                       32
<PAGE>
Sales Representative FTEs will be charged as Commercialization Costs at the
Sales Representative FTE Rate and Commercialization activities performed by all
other personnel described in this Section 4.11.1 will be charged as
Commercialization Costs at the Commercialization FTE Rate.

          4.11.2 ALKERMES PERSONNEL. As of the Effective Date, Alkermes shall
have the right to hire, in its sole discretion, such number of treatment system
specialists as both Parties agree is appropriate to provide information and
assistance to the Target Prescribers with respect to the Products (the
"Treatment System Specialists"); provided, however, that Alkermes shall be
entitled to hire at least thirty (30) Treatment System Specialists. Alkermes
shall also have the right to hire appropriate Treatment System Specialist
management and training personnel, in accordance with the Commercialization
Plan, provided, however, that the CT shall be obligated to provide for, and the
JSC to approve, reasonable management and training personnel for the Treatment
System Specialists in the Commercialization Plan. Commercialization activities
performed by the Treatment System Specialist FTEs will be charged as
Commercialization Costs at the Treatment System Specialist FTE Rate and
Commercialization activities performed by all other personnel described in this
Section 4.11.2 will be charged as Commercialization Costs at the
Commercialization FTE Rate.

          4.11.3 MINIMUM SALES REPRESENTATIVES. Cephalon shall provide at least
the following Minimum Sales Representatives: (i) by commercial launch of the
Medisorb Product for the Initial Indication and, subject to this Section 4.11.3,
thereafter during the Term, [**] Sales Representative FTEs engaged in Detailing
the Products to Target Prescribers, and (ii) by the first anniversary of such
commercial launch and, subject to this Section 4.11.3, thereafter during the
Term, an additional [**] Sales Representative FTEs, for a total of [**] Sales
Representative FTEs engaged in Detailing the Products to Target Prescribers.
During the first [**] months after commercial launch of the Medisorb Product for
the Initial Indication, the Minimum Sales Representatives shall be dedicated
solely to Detailing the Products. Thereafter at all times during the Term, at
least [**] Sales Representative FTEs shall spend at least [**] of their
allocated time performing Primary Position Details and no more than [**] of
their allocated time performing Secondary Position Details. [**].

          4.11.4 EXPANSION OF THE NUMBER OF SALES REPRESENTATIVES. If the CT
determines that it is desirable to increase the total number of Sales
Representative FTEs engaged in Detailing the Products to Target Prescribers, the
Commercialization Plan shall be amended accordingly. Alkermes shall have the
option to provide, using Alkermes Sales Representative FTEs, up to the first
[**] of such additional Sales Representative FTEs, which Alkermes Sales
Representatives FTEs shall Detail the Products to Target Prescribers as
specified in a Detailing plan to be included in the Commercialization Plan. In
addition if Alkermes exercises its option to provide any Alkermes Sales
Representative FTEs, the Parties shall promptly negotiate in good faith
appropriate revisions to the Commercialization Plans and this Agreement to
specify commercially reasonable terms and conditions for the coordination of the
Cephalon and

** CONFIDENTIAL TREATMENT REQUESTED

                                       33
<PAGE>
Alkermes Sales Representative FTEs, including terms and conditions regarding
training, sales meetings, and communication with the Sales Representative FTEs.

          4.11.5 RESPONSIBILITY FOR SALES FORCES. Subject to the
Commercialization Plan and Section 4.11.10, each Party shall have responsibility
for its Sales Representatives, Treatment System Specialists and other personnel
engaged in Commercializing the Products, including in carrying out the Medical
Activity Plan, and for performing its other obligations hereunder, including
recruiting, hiring, training, managing and compensating its personnel. Each
Party shall ensure that its personnel understand (as necessary) and comply with
this Agreement and applicable Laws. Each Party shall retain only personnel who
have sufficient technical training and experience to Commercialize the Products
and to carry out the Medical Activity Plan in a manner consistent with the
practice by leading pharmaceutical and biotechnology companies of comparable
activities.

          4.11.6 COMPENSATION. Each Party shall reasonably compensate its Sales
Representatives, Treatment System Specialists and other Commercialization
personnel with respect to the Products in a manner reasonably calculated to
incent such personnel to carry out their responsibilities in a manner consistent
with the objectives set forth in the Commercialization Plan. Notwithstanding the
foregoing, each of Cephalon and Alkermes may only charge Shared Expenses with
respect to the Commercialization activities performed by such personnel in
accordance with the Sales Representative FTE Rate, the Treatment System
Specialist FTE Rate or the Commercialization FTE Rate, as applicable.

          4.11.7 DEBARMENT LIMITATIONS. In the course of Commercialization of
the Products in the Territory, neither Party shall knowingly use any employee or
consultant who is or has been debarred by the FDA or any other regulatory
authority, or, to the best of such Party's knowledge, who is or has been the
subject of debarment proceedings by the FDA or any such regulatory authority.
Each Party shall promptly notify the other Party of and provide such other Party
with a copy of any correspondence or other reports that such Party receives from
any Third Party with respect to any use of a debarred employee or consultant in
connection with such Party's performance of its obligations under this
Agreement.

          4.11.8 CONDUCT OF SALES FORCES. In connection with the
Commercialization of the Products, including carrying out the Medical Activity
Plan, neither Party shall make, or permit any of its Sales Representatives,
Treatment System Specialists or other employees or agents to make, any
statement, representation or warranty, oral or written, to any Third Party
concerning the Products that is inconsistent with, or contrary to, the approved
Product labeling, the Promotional Materials, this Agreement and the
Commercialization Plan. In addition, each Party shall ensure that its Sales
Representatives Detail the Products in a fair and balanced manner consistent
with the requirements of the Act. Neither Party's Sales Representatives shall
engage in any pre-marketing activities for the Products that are prohibited by
Law.

** CONFIDENTIAL TREATMENT REQUESTED

                                       34
<PAGE>
          4.11.9 MEDICAL EDUCATION. The Parties shall support medical education
activities in accordance with the Medical Activity Plan and applicable Laws. In
connection with such medical education activities, the Parties may distribute
only those materials that have been approved pursuant to Section 4.10.2 for
distribution.

          4.11.10 PERSONNEL ISSUES. If either Party notifies the other Party
that it believes certain Sales Representatives, Treatment System Specialists or
other employees or agents of a Party, as applicable, may (i) have violated any
Laws, (ii) be damaging relationships with health care professionals or damaging
the Product brand or (iii) have failed to comply with this Agreement, the Party
giving notice shall have the right to request that the other Party immediately
address the performance of such individual, in addition to any other rights or
remedies available to the Party giving notice under this Agreement, at Law or in
equity. The Party employing or contracting with such individual shall promptly
evaluate such issue in accordance with applicable policies or as it may
otherwise deem appropriate. Such Party shall keep the other Party reasonably
informed of the progress of, and information learned during, its evaluation. If
determined by the Party employing or contracting with such individual, such
Sales Representative, Treatment System Specialist or other employee or agent
shall be replaced and removed from performance of Commercialization activities
for the Products pursuant to this Agreement.

     4.12 TRAINING MATERIALS.

          4.12.1 DEVELOPMENT. During the Term, the Parties shall be responsible
as set forth in the Commercialization Plan for developing and updating as
appropriate materials and programs to train the Sales Representatives, Treatment
System Specialists, medical science liaisons and other employees and agents to
Commercialize the Products and to carry out the Medical Activity Plan in the
Territory.

          4.12.2 APPROVAL. All Product-specific training materials developed
pursuant to Section 4.12.1 shall be prepared in compliance with all Laws, and
Cephalon shall send to Alkermes' PRC representative pursuant to Section 4.10.2 a
master copy of all such training materials that it develops, as well as all
other training materials relating to the Products that it intends to use in
connection with the training of its personnel to Commercialize the Products in
the Territory, including to carry out the Medical Activity Plan.
Product-specific training materials shall be approved pursuant to Section 4.10.2
prior to their use in training such personnel.

          4.12.3 RETURN; CONFIDENTIALITY. Each Party shall require any of its
Sales Representatives who ceases to be employed or to participate in the
promotion of the Products to return to such Party all Product training materials
and all other Confidential Information.

     4.13 SAMPLES. Each Party shall use samples of the Products strictly in
accordance with the Commercialization Plan, and shall store and distribute such
samples

** CONFIDENTIAL TREATMENT REQUESTED

                                       35
<PAGE>
in full compliance with all applicable Laws, including the requirements of the
Prescription Drug Marketing Act of 1987, as amended (the "PDMA"). Each Party
will maintain those records required by the PDMA and all other Laws with respect
to such Product samples. Each Party shall allow representatives of the other
Party to inspect such records and storage facilities for the Product samples
during regular business hours on request and with reasonable prior notice.
Subject to receipt of necessary information from Cephalon on a timely basis,
Alkermes shall be solely responsible for the filing of any necessary reports on
the Product samples to the FDA in connection with the PDMA, and Cephalon agrees
to provide Alkermes with any information in Cephalon's control that is required
by the PDMA to be included in such filings.

     4.14 MEDICAL INQUIRIES. Subject to terms and conditions of the safety data
exchange agreement for the Products executed by the Parties pursuant to Section
3.5, the CT shall develop a set of standard operating procedures for responding
promptly to medical questions or inquiries from members of the medical and
paramedical professions and consumers relating to the Products. Cephalon shall
be responsible for establishing such systems and maintaining such records as are
required to respond to such questions or inquiries in accordance with all
applicable Laws, including consulting with Alkermes and reporting such
information to Alkermes in a manner that allows Alkermes to fulfill its
obligations as the holder of the Regulatory Approvals for the Products, and
shall allow representatives of Alkermes to inspect such systems and records
during regular business hours on request with reasonable prior notice. In
response to unsolicited medical inquiries with respect to off-label use of the
Products the Parties may distribute to medical professionals, or otherwise, only
those materials that have been approved pursuant to Section 4.10.2 for
distribution.

     4.15 LIMITATION ON COMMERCIALIZATION TEAM DECISION MAKING. Neither the CT
nor the JSC shall, without the consent of Alkermes, have any authority to modify
or reduce Cephalon's obligation under this Agreement to use Commercially
Reasonable Efforts to Commercialize the Product as provided herein.
Notwithstanding anything to the contrary herein, Cephalon shall not have any
right to resolve any Reserved Dispute in any manner that modifies or reduces
Cephalon's obligations under this Agreement or to amend any provision of this
Agreement.

                                    ARTICLE 5
                             MANUFACTURE AND SUPPLY

     5.1 SUPPLY AGREEMENT. Concurrently with the execution of this Agreement,
the Parties are entering into a supply agreement (the "Supply Agreement")
pursuant to which Alkermes shall supply the Clinical Supplies and the Commercial
Supplies. The Parties shall negotiate within [**] days after the Effective Date
an associated Quality Agreement specifying certain quality assurance and quality
control requirements relating to the supply of Clinical Supplies and Commercial
Supplies by Alkermes.

** CONFIDENTIAL TREATMENT REQUESTED

                                       36
<PAGE>
     5.2 SUPPLY TEAM. The Parties shall establish a supply team, or ST, pursuant
to the provisions of the Supply Agreement.

     5.3 SUPPLY COSTS. The Fully Burdened Manufacturing Costs of Clinical
Supplies and Commercial Supplies (other the costs of Clinical Supplies included
within Initial Indication Development Costs) shall be Shared Expenses and shall
be subject to offset or credit against amounts due pursuant to Section 9.5
below.

                                    ARTICLE 6
                         LICENSE GRANTS AND ASSIGNMENTS

     6.1 PATENT AND KNOW-HOW LICENSE GRANT.

          6.1.1 BY ALKERMES. Alkermes hereby grants to Cephalon and its
Affiliates a semi-exclusive license (exclusive except as to the rights retained
by Alkermes and its Affiliates to perform their obligations and exercise their
rights under this Agreement and the Supply Agreement) under the Alkermes
Patents, the Alkermes Know-How, and Alkermes' right, title and interest in the
Joint Patents and the Joint Know-How to use, sell, offer for sale and import
(but not to make or have made) the Products in the Field in the Territory, with
the right to grant sublicenses to Third Party contractors if and only as
necessary to facilitate the performance of Cephalon's Development and
Commercialization responsibilities hereunder; provided that Cephalon shall not
sublicense the right to sell or offer for sale Products. [**]. Cephalon shall
notify Alkermes if it has granted a sublicense of the rights it has been
licensed pursuant to this Section 6.1.1.

          6.1.2 BY CEPHALON. Cephalon hereby grants to Alkermes a royalty-free
semi-exclusive license (exclusive except as to the rights retained by Cephalon
and its Affiliates to perform their obligations and exercise their rights under
this Agreement and the Supply Agreement), with the right to sublicense, under
the Cephalon Patents, the Cephalon Know-How and Cephalon's right, title and
interest in the Joint Patents and Joint Know-How to make, have made, use, offer
for sale and import (but not to sell) the Products in the Field in the
Territory. Alkermes shall notify Cephalon if it has granted a sublicense of the
rights it has been licensed pursuant to this Section 6.1.2.

          6.1.3 NO IMPLIED LICENSES. Except as expressly granted herein, there
are no implied licenses under the Alkermes Patents, the Alkermes Know-How, the
Cephalon Patents, the Cephalon Know-How, the Joint Patents, the Joint Know-How
or any other intellectual property rights Controlled by Alkermes, Cephalon or
their Affiliates, as applicable.

** CONFIDENTIAL TREATMENT REQUESTED

                                       37
<PAGE>
          6.1.4 RIGHTS UPON BANKRUPTCY. With respect to either Party, all rights
and licenses granted under this Agreement by one Party to the other Party are,
and shall otherwise be deemed to be, for purposes of Section 365 (n) of the
United States Bankruptcy Code, as amended from time to time (the "Bankruptcy
Code"), licenses of rights to "intellectual property" as defined under Section
101 (35A) of the Bankruptcy Code. The Parties agree that the licensee Party
shall retain and may fully exercise all of its rights and elections under the
Bankruptcy Code in the event of a bankruptcy of the licensor Party.

     6.2 ALKERMES PATENTS UPDATE. At the request of Cephalon, Alkermes shall
provide a list of patents and patent applications falling within the definition
of Alkermes Patents licensed to Cephalon hereunder.

     6.3 TRADEMARK ASSIGNMENT. Promptly after the Effective Date, Alkermes shall
transfer and assign to Cephalon, and Cephalon shall acquire and accept from
Alkermes, Alkermes' entire right, title, and interest in and to the Vivitrex
Trademark in the Territory, together with that portion of the good will of the
business of Alkermes associated with the use of and symbolized by such trademark
in the Territory and all common law rights in the Vivitrex Trademark in the
Territory. Alkermes hereby agrees that it will, upon Cephalon's request and at
Cephalon's cost and expense, execute all documents that may be necessary to
perfect Cephalon's title to the Vivitrex Trademark in the Territory.

     6.4 TRADEMARK LICENSE. Alkermes hereby grants to Cephalon and its
Affiliates a non-exclusive, royalty-free license to use the Medisorb Trademark
for the advertising, promotion, marketing, distribution and sale of the Products
in the Field in the Territory. Cephalon hereby acknowledges Alkermes' exclusive
right, title and interest in and to the Medisorb Trademark and agrees that
Cephalon and its Affiliates will not at any time do, or cause to be done, any
act or thing contesting or in any way intending to impair the validity of and/or
Alkermes' exclusive right, title and interest in and to the Medisorb Trademark.
In using the Medisorb Trademark, Cephalon and its Affiliates shall display the
registration symbol (R) to the right of and slightly above or below the last
letter of the Medisorb Trademark. Cephalon and its Affiliates will not in any
manner represent that they own the Medisorb Trademark and Cephalon hereby
acknowledges that use of the Medisorb Trademark as set forth in this Section 6.4
shall not create any right, title or interest in or to the Medisorb Trademark in
favor of Cephalon or its Affiliates, but that all use of the Medisorb Trademark
by Cephalon and its Affiliates shall inure to the benefit of Alkermes.

     6.5 CORPORATE NAME AND LOGO. During the Term, Alkermes grants Cephalon the
non-exclusive right to use the Alkermes name and corporate logo in the Territory
solely for the purpose of Cephalon's Commercialization of the Products in
accordance with the terms of this Agreement.

** CONFIDENTIAL TREATMENT REQUESTED

                                       38
<PAGE>
     6.6 ROW TERRITORY. Alkermes retains all of its rights to use, sell,
manufacture, offer for sale and import the Products in the ROW Territory. During
the period beginning on the Effective Date and ending one hundred eighty (180)
days thereafter (the "Option Period"), Alkermes shall not enter into any
agreement or negotiation with any Third Party regarding a license of the rights
to use, sell, offer for sale and import the Products in the ROW Territory. If
during the Option Period Cephalon notifies Alkermes in writing of its desire to
enter into an exclusive license to use, sell, offer for sale and import the
Products in the ROW Territory, then Alkermes shall exclusively negotiate with
Cephalon in good faith a definitive agreement for such an exclusive license
containing customary representations, warranties, covenants and agreements,
satisfactory in form and substance to the Parties and their legal advisors, as
are necessary or appropriate for transactions of this type. If Cephalon does not
notify Alkermes of its desire to enter into such an exclusive license within the
Option Period, or if at the end of the Option Period Alkermes and Cephalon are
unable to agree on terms for such a definitive license, then Alkermes shall be
free to use, sell, manufacture, offer for sale and import the Products in the
ROW Territory itself or to initiate discussions and execute a license with one
or more Third Parties to do so, with no further obligation to Cephalon under
this Agreement. [**].

     6.7 TERMINATION OF LICENSE TO CONTESTED PATENT RIGHTS. Either Alkermes, as
the licensor of the Alkermes Patents and the Alkermes Manufacturing Patents
under this Agreement, or Cephalon, as the licensor of the Cephalon Patents under
this Agreement, may at its option terminate its licenses to the other Party
under this Agreement of any of the licensor's Patent Rights as to which the
other Party commences any action or asserts any formal position in any forum
(including a court, a patent office or an arbitral tribunal, and whether in the
form of petitions for declaratory relief, claims, counterclaims, defenses,
interferences, petitions for reexamination or otherwise) that such Patent Right
is invalid or unenforceable.

                                    ARTICLE 7
                          INTELLECTUAL PROPERTY RIGHTS

     7.1 OWNERSHIP OF INTELLECTUAL PROPERTY.

          7.1.1 COLLABORATION TECHNOLOGY. Alkermes shall own all Collaboration
Technology, including all patents and patent applications thereon, that are
developed, made or conceived solely by or on behalf of Alkermes or its
Affiliates, subject to the rights and licenses granted herein. Cephalon shall
own all Collaboration Technology, including all patents and patent applications
thereon, that are developed, made or conceived solely by or on behalf of
Cephalon or its Affiliates, subject to the rights and licenses granted herein.
All Joint Patents shall be owned jointly by Alkermes and Cephalon, with full
ownership rights in any field and the right to license and sublicense, subject
to the rights and licenses granted herein. The Laws of the United States with

** CONFIDENTIAL TREATMENT REQUESTED

                                       39
<PAGE>
respect to determining inventorship shall govern determinations of ownership
pursuant to this Agreement. Alkermes and Cephalon shall jointly own all Joint
Know-How, subject to the rights and licenses granted herein.

          7.1.2 OTHER INVENTIONS.

               (I) During the Term, and pursuant to a Development Plan or
Commercialization Plan, inventions may be developed, made or conceived by
employees or agents of either Party or its Affiliates, solely or jointly, which
are not Collaboration Technology ("Other Inventions"). Alkermes shall own all
Other Inventions developed, made or conceived solely by or on behalf of Alkermes
or its Affiliates, and Cephalon shall own all Other Inventions developed, made
or conceived solely by or on behalf of Cephalon or its Affiliates. All Other
Inventions developed, made or conceived jointly by or on behalf of Alkermes or
its Affiliates and by or on behalf of Cephalon or its Affiliates shall be
jointly owned by Alkermes and Cephalon with full ownership rights in any field
and the right to license and sublicense.

               (II) Each Party, at its sole discretion and responsibility, may
prepare, file, prosecute and maintain patent applications and patents claiming
solely owned Other Inventions at its sole cost and expense. For Other Inventions
that are jointly owned by Alkermes and Cephalon, the Parties shall jointly
decide on a patent application preparation, filing, prosecution and maintenance
strategy, and shall equally share all costs and expenses associated therewith.
Unless otherwise agreed by the Parties, patent applications and patents claiming
Other Inventions that are jointly owned by Alkermes and Cephalon will be
prepared, filed, prosecuted and maintained by [**].

          7.1.3 ASSIGNMENT AND LICENSES. Each of Alkermes and Cephalon shall
require all of its and its Affiliates' employees, and each Party shall use
commercially reasonable efforts to require any Third Parties working on the
collaboration hereunder or who receive materials or know-how related to a
Product from a Party, including its sublicensees, to assign all intellectual
property developed, made or conceived by such employees or Third Parties
pursuant to a Development Plan or Commercialization Plan to Alkermes and/or
Cephalon according to the ownership principles described in Sections 7.1.1 and
7.1.2 above. In the event that a Party is unable to have a Third Party assign
such inventions, then that Party shall use commercially reasonable efforts to
require that Third Party to grant an exclusive, royalty-free, worldwide,
irrevocable license, including the right to sublicense, to all intellectual
property developed, made or conceived by that Third Party pursuant to a
Development Plan or Commercialization Plan to Alkermes and/or Cephalon according
to the ownership principles described in Sections 7.1.1 and 7.1.2 above.

          7.1.4 INVENTORSHIP AND OWNERSHIP PROCEDURE. The Parties shall within a
reasonable time after the Effective Date establish a mutually agreeable
procedure for determining inventorship of intellectual property that is
developed, made or conceived

** CONFIDENTIAL TREATMENT REQUESTED

                                       40
<PAGE>
pursuant to a Development Plan or Commercialization Plan, provided that such
determination shall be made in accordance with applicable United States Laws
relating to inventorship. All such determinations shall be documented to ensure
that any divisional or continuation patent applications reflect appropriate
inventorship and that inventions and patent rights are assigned to the
appropriate Party. To the extent possible, claims shall be separated into
divisional or equivalent patent applications to permit ownership of such
applications solely by one or the other of the Parties, rather than jointly by
the Parties, in accordance with the ownership principles set forth in Sections
7.1.1 and 7.1.2 above.

     7.2 DISCLOSURE OF PATENTABLE INVENTIONS. During any portion of the Term
during which the Parties are sharing Distributable Profit and Distributable
Losses pursuant to Section 9.5, each Party shall promptly provide to the other
Party any invention disclosure submitted in the normal course of its business
that disclose Collaboration Technology. Any such invention disclosure shall
constitute Confidential Information of the providing Party.

     7.3 PATENT COMMITTEE. Each Party will appoint a representative with patent
and intellectual property expertise no later than [**] days after the Effective
Date. Such representatives will meet (in person, by telephone or
videoconference) upon request by either Party during the Term, and the pendency
of any Joint Patents, to coordinate, discuss, and review strategies with respect
to preparing, filing, prosecuting, maintaining, enforcing and defending patent
applications and patents that disclose Collaboration Technology. The patent
representatives shall prepare an estimated budget for Patent Costs for patent
and patent application preparation, filing, prosecution and maintenance during
each subsequent calendar year by [**] of the then-current calendar year and
submit this budget to the JSC for review and approval.

     7.4 PATENT FILINGS.

          7.4.1 ALKERMES PATENTS. Alkermes, at its sole discretion and
responsibility, shall prepare, file, prosecute and maintain the Alkermes Patents
and the Alkermes Manufacturing Patents and shall be responsible for all material
actions relating to the prosecution and maintenance of the Alkermes Patents and
the Alkermes Manufacturing Patents worldwide, including patent interferences,
reexaminations, reissuances, appeals, oppositions and revocation proceedings.
The fees and expenses paid to outside legal counsel and experts, or the cost of
Alkermes' or its Affiliates' FTEs, incurred in connection with such preparation,
filing, prosecution and maintenance of the Alkermes Patents in the Territory
shall be Patent Costs. Any such fees and expenses paid to outside legal counsel
and experts, or the cost of Alkermes' or its Affiliates' FTEs, incurred in
connection with such preparation, filing, prosecution and maintenance of the
Alkermes Patents in the ROW Territory or of the Alkermes Manufacturing Patents
worldwide shall be paid by Alkermes.

** CONFIDENTIAL TREATMENT REQUESTED

                                       41
<PAGE>
          7.4.2 CEPHALON PATENTS. Cephalon, at its sole discretion and
responsibility, shall prepare, file, prosecute and maintain the Cephalon
Patents, and shall be responsible for all material actions relating to the
prosecution and maintenance of the Cephalon Patents worldwide, including patent
interferences, reexaminations, reissuances, appeals, oppositions and revocation
proceedings. The fees and expenses paid to outside legal counsel and experts, or
the cost of Cephalon's or its Affiliates' FTEs, incurred in connection with such
preparation, filing, prosecution and maintenance in the Territory shall be
Patent Costs. Any such fees and expenses paid to outside legal counsel and
experts, or the cost of Cephalon's or its Affiliates' FTEs, incurred in
connection with such preparation, filing, prosecution and maintenance in the ROW
Territory shall be paid by Cephalon.

          7.4.3 JOINT PATENTS. Alkermes, in consultation with Cephalon, shall
decide on a patent application preparation, filing and prosecution strategy and
a patent maintenance strategy with respect to Joint Patents. Unless otherwise
agreed by the Parties, all such Joint Patents will be prepared, filed,
prosecuted and maintained by [**]. The fees and expenses paid to outside legal
counsel and experts, or the cost of the Parties' and their Affiliates' FTEs,
incurred in connection with such preparation, filing, prosecution and
maintenance in the Territory shall be Patent Costs. The fees and expenses paid
to outside legal counsel and experts, or the cost of the Parties' and their
Affiliates' FTEs, incurred in connection with such preparation, filing,
prosecution and maintenance in the ROW Territory shall be paid by Alkermes.

          7.4.4 FILING, PROSECUTION AND MAINTENANCE. The Party that is
responsible for filing hereunder a patent application claiming Collaboration
Technology will be termed the "Filing Party." The Filing Party shall provide all
draft patent applications to the other Party sufficiently in advance of filing
for the other Party to have the opportunity to comment thereon and shall take
such comments into consideration in the application filed. The Filing Party
shall also promptly furnish the other Party with copies of all substantive
communications between the Filing Party and applicable patent offices relating
to such patent applications, and shall take the other Party's comments and
suggestions into consideration when framing responses and submissions to such
patent offices. The Filing Party shall timely inform the other Party of any
patent issuing or granted from such patent applications. The Filing Party shall
also provide an annual summary of the status of each patent application filed
hereunder and any patent issuing or granting therefrom.

          7.4.5 FAILURE TO PREPARE, FILE, PROSECUTE, MAINTAIN OR DEFEND PATENTS.

               (I) PREPARATION AND FILING.

                    (A) Alkermes shall inform Cephalon if it elects not to
prepare, file, prosecute, maintain or defend in the Territory a patent
application or patent that is an Alkermes Patent claiming Collaboration
Technology and that is the

** CONFIDENTIAL TREATMENT REQUESTED

                                       42
<PAGE>
subject of an unterminated license hereunder. Cephalon may then prepare, file,
prosecute, maintain and defend any such patent application or patent in the
Territory. The fees and expenses paid to outside legal counsel and experts, or
the cost of Cephalon's or its Affiliates' FTEs, incurred in connection with such
preparation, filing, prosecution, maintenance and defense in the Territory shall
be Patent Costs.

                    (B) Cephalon shall inform Alkermes if it elects not to
prepare, file, prosecute, maintain or defend in the Territory a patent
application or patent that is a Cephalon Patent claiming Collaboration
Technology and that is the subject of an unterminated license hereunder.
Alkermes may then prepare, file, prosecute, maintain and defend any such patent
application or patent in the Territory. The fees and expenses paid to outside
legal counsel and experts, or the cost of Alkermes' or its Affiliates' FTEs,
incurred in connection with such preparation, filing, prosecution, maintenance
and defense in the Territory shall be Patent Costs.

                    (C) If Alkermes elects not to have a patent application or
patent that is a Joint Patent prepared, filed, prosecuted, maintained or
defended, it shall so inform Cephalon. Cephalon may then have any such patent
application or patent prepared, filed, prosecuted, maintained or defended using
the counsel described in Section 7.4.3. The fees and expenses paid to outside
legal counsel and experts, or the cost of Cephalon's or its Affiliates' FTEs,
incurred in connection with such preparation, filing, prosecution, maintenance
and defense in the Territory shall be Patent Costs. Any such fees and expenses
paid to outside legal counsel and experts, or the cost of the Cephalon's or its
Affiliates' FTEs, incurred in connection with such preparation, filing,
prosecution, maintenance and defense in the ROW Territory shall be paid by
Cephalon.

               (II) ABANDONMENT. If the Filing Party intends to allow any patent
or patent application that is (A) a Joint Patent, (B) in the Territory, an
Alkermes Patent claiming Collaboration Technology that is the subject of an
unterminated license hereunder or (C) in the Territory, a Cephalon Patent
claiming Collaboration Technology that is the subject of an unterminated license
hereunder, to lapse or become abandoned without having first filed a
continuation or divisional application, the Filing Party shall notify the other
Party of such intention at least [**] days prior to the date upon which such
patent application or patent shall lapse or become abandoned, and the other
Party shall thereupon have the right, but not the obligation, to assume
responsibility for the prosecution and maintenance thereof. The fees and
expenses paid to outside legal counsel and experts, or the cost of the
prosecuting and maintaining Party's or its Affiliates' FTEs, incurred in
connection with such prosecution and maintenance in the Territory shall be
Patent Costs and in the ROW Territory shall be paid by the prosecuting and
maintaining Party.

     7.5 DEFENSE AND ENFORCEMENT RIGHTS.

** CONFIDENTIAL TREATMENT REQUESTED

                                       43
<PAGE>
          7.5.1 NOTIFICATION OF INFRINGEMENT. If either Party learns of any
actual or threatened infringement or any attack on the validity or
enforceability by a Third Party with respect to an Alkermes Patent, an Alkermes
Manufacturing Patent, a Cephalon Patent or a Joint Patent anywhere in the world,
such Party shall promptly notify the other Party and shall provide such other
Party with available evidence of such events.

          7.5.2 DEFENSE. Except as otherwise set forth in Section 7.5.3 below,
Alkermes shall be solely responsible for prosecuting an infringement or
defending any attack on the validity or enforceability of an Alkermes Patent or
Alkermes Manufacturing Patent worldwide and Cephalon shall be solely responsible
for prosecuting an infringement or defending any attack on the validity or
enforceability of a Cephalon Patent worldwide. Except as otherwise set forth in
Section 7.5.3 below, in the event of an infringement by a Third Party of a Joint
Patent or an attack by a Third Party on the validity or enforceability of a
Joint Patent, the Parties shall decide the best way to proceed.

          7.5.3 ENFORCEMENT OF ALKERMES PATENTS, ALKERMES MANUFACTURING PATENTS,
CEPHALON PATENTS AND JOINT PATENTS.

               (I) After the Effective Date, within a reasonable time prior to
(A) Alkermes bringing any legal action or proceeding or filing any counterclaim
(referred to in this Section 7.5.3 as an "Action") regarding an infringement of
any of the Alkermes Patents or Alkermes Manufacturing Patents in the Territory
by a product that is being developed or commercialized for the Initial
Indication or any New Indication for which a Product has received Regulatory
Approval or is under Development pursuant to a Development Plan in the
Territory, (B) Cephalon bringing any Action regarding an infringement of any of
the Cephalon Patents in the Territory by a product that is being developed or
commercialized for the Initial Indication or any New Indication for which a
Product has received Regulatory Approval or is under Development pursuant to a
Development Plan in the Territory or (C) Alkermes bringing any Action regarding
an infringement of any of the Joint Patents in the Territory, the Parties shall
consult with one another to determine the best way for the Parties to proceed.
If both Parties agree to institute an Action regarding such infringement, the
Parties shall jointly institute, prosecute and control such Action, using
mutually agreed counsel. In the event both Parties desire to institute an
Action, [**].

               (II) If both Parties do not agree to institute an Action pursuant
to Section 7.5.3(i) within [**] days of the date notice is received by a Party
pursuant to Section 7.5.1, then Alkermes shall have the right solely to
institute, prosecute and control such an Action with respect to the Alkermes
Patents, the Alkermes Manufacturing Patents and the Joint Patents, using counsel
of its own choice, at its own [**], and Cephalon shall have the right solely to
institute, prosecute and control such an Action with respect to the Cephalon
Patents, using counsel of its own choice, at its own cost and expense. In the
event either Party solely institutes such an Action, (A) the

** CONFIDENTIAL TREATMENT REQUESTED

                                       44
<PAGE>
other Party agrees to be joined as a party plaintiff if necessary to prosecute
such Action, to give the instituting Party authority to file and prosecute the
Action and to provide reasonable assistance in connection therewith and (B) any
recovery from any settlement or judgment from such Action [**].

               (III) If Alkermes does not institute an Action pursuant to
Section 7.5.3(ii) within [**] of the date notice is received by a Party pursuant
to Section 7.5.1, then Cephalon shall have the right solely to institute,
prosecute and control such an Action with respect to the Alkermes Patents, the
Alkermes Manufacturing Patents and the Joint Patents, using counsel of its own
choice, [**]. If Cephalon does not institute an Action pursuant to Section
7.5.3(ii) within [**] of the date notice is received by a Party pursuant to
Section 7.5.1, then Alkermes shall have the right solely to institute, prosecute
and control such an Action with respect to the Cephalon Patents, using counsel
of its own choice, [**]. In the event either Party solely institutes such an
Action, (A) the other Party agrees to be joined as a party plaintiff if
necessary to prosecute such Action, to give the instituting Party authority to
file and prosecute the Action and to provide reasonable assistance in connection
therewith and (B) any recovery from any settlement or judgment from such Action
[**].

               (IV) Either Party shall immediately notify the other Party of any
certification received by the Party giving notice under the U.S. Drug Price
Competition and Patent Term Restoration Act of 1984 (Public Law 98-417, the
"Hatch-Waxman Act"), as amended, with respect to a Product in the Field. If a
Party having the right to enforce an Alkermes Patent, Alkermes Manufacturing
Patent or Joint Patent decides not to bring infringement proceedings against the
Third Party making such a certification, such Party shall give notice to the
other Party of its decision not to bring suit within [**] after receipt of
notice of such certification. The other Party may then, but is not required to,
bring suit against the Third Party that filed the certification. Any suit by
Alkermes or Cephalon shall either be in the name of Alkermes or in the name of
Cephalon, or jointly by Alkermes and Cephalon, as may be required by Law. For
this purpose, the Party not bringing suit shall execute such legal papers
necessary for the prosecution of such suit as may be reasonably requested by the
Party bringing suit and shall provide the Party bringing suit reasonable
assistance in connection therewith.

          7.5.4 SETTLEMENT WITH A THIRD PARTY INFRINGER. If both Parties bring
suit to enforce or defend a given Alkermes Patent, Alkermes Manufacturing
Patent, Cephalon Patent or Joint Patent [**].

     7.6 INFRINGEMENT DEFENSE. After the Effective Date, if a Third Party
asserts, or if either Party otherwise becomes aware, that a patent or other
right owned by a Third Party may be infringed by the manufacture, use, sale,
offer for sale or import of a Product in the Field in the Territory or the
manufacture of a Product outside the Territory for use, sale, offer for sale or
import in the Territory, then such Party shall promptly notify the other Party
and the Parties shall [**].

** CONFIDENTIAL TREATMENT REQUESTED

                                       45
<PAGE>
     7.7 THIRD-PARTY PATENT LICENSES. If the Parties agree pursuant to Section
7.6 or pursuant to this Section 7.7 to obtain a license from a Third Party with
respect to a patent that may be infringed by the manufacture, use, sale, offer
for sale or import of a Product in the Field in the Territory or the manufacture
of a Product outside the Territory for use, sale, offer for sale or import in
the Territory, then [**].

     7.8 PATENT MARKING. Each Party agrees to comply with the patent marking
statutes in the United States with respect to the Products.

     7.9 TRADEMARK MAINTENANCE. After the Effective Date, Cephalon shall
prosecute, maintain and defend in the Territory the Vivitrex Trademark and any
other trademark (other than the Medisorb Trademark) used for the advertising,
promotion, marketing, distribution or sale of a Product anywhere in the
Territory (each an "Additional Product Trademark") and prosecute and maintain
any applications for registration or registrations for any such mark. After the
Effective Date, Alkermes may, in its sole discretion, prosecute, maintain and
defend in the Territory the Medisorb Trademark and prosecute and maintain any
applications for registration or registrations for such mark. After the
Effective Date, Alkermes may, in its sole discretion, prosecute, maintain and
defend in the Territory the Medisorb Trademark and prosecute and maintain any
applications for registration or registrations for such mark. If Alkermes elects
to abandon any registration for the Medisorb Trademark in the Territory that is
relevant to the Products, Alkermes shall provide Cephalon with reasonable
advance notice and, subject to Alkermes' obligations to Third Parties existing
as of the Effective Date, Cephalon shall have the right to assume responsibility
for the maintenance of such trademark registrations.

     7.10 TRADEMARK INFRINGEMENT.

          7.10.1 NOTIFICATION OF INFRINGEMENT. If either Party learns that a
Third Party is infringing the Vivitrex Trademark, any Additional Product
Trademark or the Medisorb Trademark, such Party shall promptly notify the other
Party.

          7.10.2 INFRINGEMENT ACTION WITH RESPECT TO THE VIVITREX TRADEMARK OR
ANY ADDITIONAL PRODUCT TRADEMARK. After the Effective Date, Cephalon shall have
the sole right to take the appropriate steps to stop the infringement of the
Vivitrex Trademark or any Additional Product Trademark in the Territory,
including instituting an action with respect to such infringement, with counsel
of its own choice. Such enforcement costs shall be Commercialization Costs.
Alkermes agrees to provide reasonable assistance to Cephalon, with any costs of
providing such assistance constituting Commercialization Costs, in taking any
such steps. Any recovery from any settlement or judgment from any such action to
stop infringement of the Vivitrex Trademark or any Additional Product Trademarks
in the Territory shall be [**].

                                    ARTICLE 8

** CONFIDENTIAL TREATMENT REQUESTED

                                       46
<PAGE>
                                 CONFIDENTIALITY

     8.1 CONFIDENTIALITY. Except to the extent authorized by this Agreement or
otherwise agreed in writing, the Parties agree that the receiving Party shall
keep confidential and shall not publish or otherwise disclose or use for any
purpose any proprietary and confidential information and materials furnished to
it by the disclosing Party pursuant to this Agreement and the Supply Agreement
(collectively, "Confidential Information"), except to the extent that it can be
established by the receiving Party that such Confidential Information:

          (I) was already known to the receiving Party or its Affiliates, other
than under an obligation of confidentiality, at the time of disclosure by the
disclosing Party;

          (II) was generally available to the public or otherwise part of the
public domain at the time of its disclosure by the disclosing Party;

          (III) became generally available to the public or otherwise part of
the public domain after its disclosure and other than through any act or
omission of the receiving Party in breach of this Agreement;

          (IV) was disclosed to the receiving Party or its Affiliates, other
than under an obligation of confidentiality, by a Third Party who had no
obligation to the disclosing Party not to disclose such information to others;
or

          (V) was subsequently developed by the receiving Party or its
Affiliates without use of the Confidential Information of the disclosing Party
as demonstrated by competent written records.

Alkermes Know-How, Alkermes Manufacturing Know-How, Alkermes Patents and
Alkermes Manufacturing Patents shall be considered Confidential Information of
Alkermes. Cephalon Know-How and Cephalon Patents shall be considered
Confidential Information of Cephalon. Joint Know-How and Joint Patents shall be
considered Confidential Information of both Parties.

     8.2 AUTHORIZED USE AND DISCLOSURE. Each Party shall maintain the
Confidential Information of the other Party in confidence and may use
Confidential Information of the other Party only in performance of its
obligations under this Agreement and the Supply Agreement. Each Party may
disclose such Confidential Information to its employees, Affiliates,
sublicensees, agents, consultants or other Third Parties who need to know such
Confidential Information in connection with the performance of such Party's
obligations under this Agreement and the Supply Agreement and who are under a
written obligation of confidentiality and non-use at least substantially
equivalent to the obligations of this Article 8. Each Party shall be liable for
any unauthorized use or disclosure of Confidential Information by its

** CONFIDENTIAL TREATMENT REQUESTED

                                       47
<PAGE>
employees, Affiliates, sublicensees, agents, consultants or other Third Parties
to which it has disclosed or transferred such Confidential Information.

     Without limiting the generality of the foregoing paragraph, a Party may
disclose information to the extent that such disclosure is reasonably necessary
in connection with:

          (I) filing or prosecuting patent applications, subject to the terms of
Section 8.4;

          (II) prosecuting or defending litigation;

          (III) conducting pre-clinical studies or Clinical Studies according to
a Development Plan or Post Marketing Clinical Trials according to a
Commercialization Plan;

          (IV) seeking Regulatory Approval of a Product, including Regulatory
Approval of a manufacturing facility for a Product;

          (V) seeking pricing approvals from private or governmental payors;

          (VI) complying with Laws, including securities Laws and the rules of
any securities exchange or market on which a Party's securities are listed or
traded;

          (VII) providing information to Alkermes' collaborators in the ROW
Territory pursuant to Section 3.4.2(iv) or

          (VIII) complying with subpoenas or governmental requests for
information.

In making any disclosures set forth in clauses (i) through (viii) above, the
disclosing Party shall, except where impracticable for necessary disclosures (as
in the event of medical emergency), give such advance notice to the other Party
of such disclosure requirement as is reasonable under the circumstances and,
except to the extent inappropriate (as in the case of patent applications), will
use its reasonable efforts to cooperate with the other Party in order to secure
confidential treatment of such Confidential Information required to be
disclosed.

     8.3 SURVIVAL. This Article 8 shall survive the termination or expiration of
this Agreement for a period of [**] years; provided, however, that following any
termination or expiration of this Agreement either Party shall have the right
use and disclose any Joint Know-How and Joint Patents solely to the extent
necessary to Develop, Manufacture or Commercialize the Products in the Field.

** CONFIDENTIAL TREATMENT REQUESTED

                                       48
<PAGE>
     8.4 PUBLICATIONS.

          8.4.1 GENERAL. Each Party agrees that the Parties' personnel involved
in the collaboration, together or with other authors, shall be permitted to
present at symposia, national or regional professional meetings and to publish
in journals the research and development conducted pursuant to the collaboration
in accordance with the publication strategy developed from time to time by the
DT and CT and in accordance with the review process of this Section 8.4.

          8.4.2 PUBLICATIONS STRATEGY. For the Medisorb Product, within [**]
days following the Effective Date, the DT, in consultation with the CT, shall
approve a strategy for the publication or presentation of the results of
pre-clinical studies or Clinical Studies of the Medisorb Product for the Initial
Indication; provided, however, that any submissions made by Alkermes prior to
the Effective Date shall not be subject to withdrawal or other modification.
Once Regulatory Approval for the Medisorb Product has been received, the DT and
CT shall jointly approve a strategy for publication or presentation with respect
to the Medisorb Product for the Initial Indication for the Territory, and
thereafter the DT and CT shall jointly approve a general strategy for
publication or presentation with respect to the Products in the Field for the
Territory.

          8.4.3 PRIOR REVIEW. Except as required by Law, each Party agrees that
it shall publish or present the results of any pre-clinical studies, Clinical
Studies or Post Marketing Clinical Trials identified in Section 8.4.2 pursuant
to the strategy approved by the DT and CT, following prior review and approval
by the other Party, in accordance with the following provisions of this Section
8.4.3. Notwithstanding the foregoing, any proposed abstracts, manuscripts or
presentation of the results of the Phase III clinical trial (or extensions
thereof) of the Medisorb Product for which submissions have been made by
Alkermes prior to the Effective Date as described in Section 8.4.2 shall only be
provided to Cephalon for review, but not for prior approval. Each Party, as
applicable, shall provide to the other Party the opportunity to review proposed
abstracts, manuscripts or presentations (including information to be presented
verbally) at least [**] days prior to their presentation or intended submission
for publication. During such [**] day period, such other Party shall have the
right to (i) require the deletion from such proposed abstract, manuscript or
presentation, prior to its publication or presentation, of any of such other
Party's Confidential Information or any information prohibited from publication
by applicable Laws, including the Act, and (ii) seek appropriate patent
protection for any material in such abstract, manuscript or presentation which
it believes is patentable. If Section 8.4.3(ii) above applies, the
non-publishing Party may request a delay, and the publishing Party shall delay
such publication or presentation, for a period not exceeding [**] days, to
permit the timely preparation and filing of a patent application or an
application for a certificate of invention on the information at issue.

          8.4.4 SUBSEQUENT DISCLOSURES. Notwithstanding the foregoing, the
provisions of Section 8.4.3 shall not apply to subsequent publications or
presentations

** CONFIDENTIAL TREATMENT REQUESTED

                                       49
<PAGE>
of substantially the same subject matter that was previously reviewed under
Section 8.4.3, provided that the disclosing Party's patent counsel provides
prior written notice of any such subsequent publication or presentation to the
other Party's patent counsel, and such publications or presentations are in
accordance with the strategy approved by the DT and CT for such publications or
presentations.

          8.4.5 THIRD PARTIES. Each of the Parties will require its Affiliates
and agents to comply with publication and presentation restrictions compatible
with those set forth herein. Each of the Parties will also use commercially
reasonable efforts to require any other Third-Party agents who are participating
in the collaboration to comply with such publication and presentation
restrictions.

                                    ARTICLE 9
              UP-FRONT PAYMENT, MILESTONE PAYMENTS AND PROFIT SPLIT

     9.1 UP-FRONT PAYMENT. On the Effective Date, Cephalon shall pay, or cause
to be paid, to Alkermes a one-time nonrefundable payment in the amount of One
Hundred and Sixty Million Dollars ($160,000,000).

** CONFIDENTIAL TREATMENT REQUESTED

                                       50
<PAGE>
     9.2 MILESTONE PAYMENTS. After the Effective Date, within [**] Business Days
following the occurrence of each event set forth below, Cephalon shall pay, or
cause to be paid, to Alkermes the following nonrefundable milestone payments:

<TABLE>
<CAPTION>
                  EVENT                    MILESTONE PAYMENT
                  -----                    -----------------
<S>                                        <C>
Receipt of the first Regulatory Approval
for a Product in the Territory             $110,000,000

Net Sales in any calendar year period
reach or exceed $[**]                      [**], if any

Net Sales in any calendar year period
reach or exceed $[**]                      $ [**]

Net Sales in any calendar year period
reach or exceed $[**]                      $[**]
</TABLE>

Each Party shall promptly notify the other of the occurrence of any milestone
event of which it becomes aware. Each milestone payment shall be made only once
and total milestone payments shall not exceed Two Hundred and Eighty-Five
Million Dollars ($285,000,000) plus the [**], if any.

     9.3 PROFIT SHARING. Subject to Sections 9.3.1 and 9.3.2 below, Cephalon
shall receive or pay, as applicable, [**] of the Distributable Profit (Loss) for
the Products with respect to sales in the Territory, and Alkermes shall receive
or pay, as applicable, [**] of the Distributable Profit (Loss) for the Products
with respect to sales in the Territory, to be calculated and paid in accordance
with the reconciliation and payment provisions of Section 9.5.

          9.3.1 ALKERMES OBLIGATIONS. Notwithstanding the foregoing, for the
period from the Effective Date until the later of (a) December 31, 2007 or (b)
the date eighteen (18) months after the first Regulatory Approval of a Product
in the Territory, Alkermes shall be responsible for the payment of monthly
Distributable Losses up to an aggregate of One Hundred and Twenty Million
Dollars ($120,000,000).

          9.3.2 CEPHALON OBLIGATIONS. Notwithstanding the foregoing, for the
period from the Effective Date until the later of (a) December 31, 2007 or (b)
the date eighteen (18) months after the first Regulatory Approval of a Product
in the Territory, Cephalon shall be responsible for the payment of monthly
Distributable Losses exceeding an aggregate of One Hundred and Twenty Million
Dollars ($120,000,000).

     9.4 REPORTING NET SALES AND SHARED EXPENSES. Within [**] Business Days
after the end of each calendar month, Cephalon shall submit to Alkermes a true
and

** CONFIDENTIAL TREATMENT REQUESTED

                                       51
<PAGE>
accurate report providing in reasonable detail (i) an accounting of all Net
Sales made in the Territory during such calendar month, including the total
gross sales and the allowable deductions therefrom (the "Net Sales Report"); and
(ii) within [**] Business Days after the end of each calendar month, Cephalon
shall submit to Alkermes a true and accurate report providing in reasonable
detail all Shared Expenses incurred by Cephalon (the "Cephalon Incurred Shared
Expenses" and such report the "Cephalon Incurred Shared Expenses Report"),
including a calculation showing as separate line items each component of Shared
Expenses. Within [**] Business Days after the end of each calendar month,
Alkermes shall submit to Cephalon a true and accurate report providing in
reasonable detail all Shared Expenses incurred by Alkermes (the "Alkermes
Incurred Shared Expenses" and such report the "Alkermes Incurred Shared Expenses
Report"), including a calculation showing as separate line items each component
of Shared Expenses. Each such report shall be considered Confidential
Information of the submitting Party, subject to the terms and conditions of
Article 8 hereof.

     9.5 FINANCIAL RECONCILIATION. Within [**] Business Days after the end of
each calendar month, Cephalon shall, using the Net Sales Report, the Cephalon
Incurred Shared Expenses Report and the Alkermes Incurred Shared Expenses
Report, prepare a reconciliation report for the Products for such calendar month
(the "Reconciliation Report"). The Reconciliation Report shall set forth, in
reasonable detail:

          (I) a statement of the Cephalon Incurred Shared Expenses, the Alkermes
Incurred Shared Expenses and the total Shared Expenses;

          (II) a calculation of Distributable Profit or Distributable Loss, as
applicable;

          (III) a statement of any amount ("Reconciliation Payment") owed by one
Party to the other Party in accordance with the following:

               (A) If there is a Distributable Profit, Cephalon shall pay to
Alkermes an amount equal to Alkermes' Incurred Shared Expenses plus forty-nine
percent (49%) of the Distributable Profit.

               (B) Subject to adjustment as set forth in Section 9.5(iii)(C)
below, if there is a Distributable Loss during any month in the period from the
Effective Date until the later of (a) December 31, 2007 or (b) the date eighteen
(18) months after the first Regulatory Approval of a Product in the Territory,
then neither Party individually shall have a profit during such month and
Alkermes shall bear the Distributable Loss as follows:

                    (X) If the net amount that Cephalon has received is negative
or a loss (that is, Net Sales minus Cephalon's Incurred Shared Expenses is less
than zero (0)), then Alkermes shall pay the amount of such difference to
Cephalon; and

** CONFIDENTIAL TREATMENT REQUESTED

                                       52
<PAGE>
                    (Y) If the net amount that Cephalon has received is positive
or a profit (that is, Net Sales minus Cephalon's Incurred Shared Expenses is
greater than zero (0)), then Cephalon shall pay the amount of such difference to
Alkermes.

               (C) If the cumulative Distributable Loss from all months in which
there is a Distributable Loss, during the period from the Effective Date until
the later of (a) December 31, 2007 or (b) the date eighteen (18) months after
the first Regulatory Approval of a Product in the Territory, exceeds One Hundred
and Twenty Million Dollars ($120,000,000), then the amounts payable to Cephalon
under Section 9.5(iii)(B) above shall be reduced and/or the amounts payable by
Cephalon under Section 9.5(iii)(B) above shall be increased, as applicable, so
that Cephalon bears the amount of such cumulative Distributable Loss in excess
of One Hundred and Twenty Million Dollars ($120,000,000).

               (D) If there is a Distributable Loss during the period after the
later of (a) December 31, 2007 or (b) the date eighteen (18) months after the
first Regulatory Approval of a Product in the Territory, then neither Party
individually shall have a profit and each Party shall share such Distributable
Loss as follows:

                    (X) If Alkermes has paid more than [**] of the Distributable
Loss (that is, the amount of Alkermes' Incurred Shared Expenses exceeds [**] of
the Distributable Loss), then Cephalon shall pay such difference to Alkermes;
and

                    (Y) If Alkermes has paid less than [**] of the Distributable
Loss (that is, the amount of Alkermes' Incurred Shared Expenses is less than
[**] of the Distributable Loss), then Alkermes shall pay such difference to
Cephalon.

Within [**] Business Days after delivery by Cephalon of a Reconciliation Report
to Alkermes, Cephalon or Alkermes, as the case may be, shall pay the
Reconciliation Payment to the other Party; provided, however, that if within
[**] days of receipt of the Reconciliation Report by Alkermes, the Alkermes
financial representative informs the Cephalon financial representative that it
disputes the amount of all or a portion of the Reconciliation Payment, the
financial representatives of the Parties shall meet and attempt in good faith to
resolve such dispute. To the extent the dispute is not resolved by such
financial representatives, such matter shall be presented to the JSC for
resolution.

     9.6 GENERIC PRODUCT.

          9.6.1 [**]. [**].

          9.6.2 ROYALTY REPORT. Within [**] Business Days after the end of each
calendar month for which royalties are payable by Cephalon to Alkermes, or by
Alkermes to Cephalon, with respect to Net Sales in the Territory pursuant to
Sections

** CONFIDENTIAL TREATMENT REQUESTED

                                       53
<PAGE>
9.6.1, 13.4 or 13.5, Cephalon shall deliver to Alkermes, or Alkermes shall
deliver to Cephalon, as applicable, in addition to a Net Sales Report as
provided herein, a true and accurate calculation of the applicable royalties due
under Section 9.6.1, 13.4 and 13.5. Simultaneous with the submission of such
report, Cephalon shall pay to Alkermes or Alkermes shall pay to Cephalon, as
applicable, all royalties payable by it under Sections 9.6.1, 13.4 or 13.5, as
applicable, as indicated in such calculation.

     9.7 RECORDS AND REPORTING; AUDITS.

          9.7.1 RECORDS AND REPORTING. Each Party shall keep, and shall cause
its Affiliates to keep, such accurate and complete records of Net Sales and its
Commercialization Costs, Development Costs and Fully Burdened Manufacturing
Costs as are necessary to determine the amounts due to Cephalon and Alkermes
under this Agreement, including time records. In determining Commercialization
Costs and Development Costs chargeable under this Agreement, each Party will use
its project accounting systems and will review and approve its project
accounting systems and methodologies with the other Party within [**] days of
the Effective Date. Each Party shall report its Commercialization Costs and
Development Costs in a manner consistent with such project accounting system.
Records of Net Sales, Commercialization Costs, Development Costs and Fully
Burdened Manufacturing Costs shall be retained by each Party or any of its
Affiliates (in such capacity, the "Recording Party") for three (3) years
following the end of the calendar year to which they pertain.

          9.7.2 AUDITS. During normal business hours and with reasonable advance
notice to the Recording Party, such records shall be made available for
inspection, review and audit, at the request and expense of the other Party (the
"Auditing Party"), by an independent certified public accountant, appointed by
such Auditing Party and reasonably acceptable to the Recording Party, for the
sole purpose of verifying the accuracy of the Recording Party's accounting
reports and payments made or to be made pursuant to this Agreement; provided,
however, that such audits may not be performed by the Auditing Party more than
once per calendar year and that such Auditing Party shall not be permitted to
audit the same period of time more than once. Such accountants, prior to any
review hereunder, shall have entered into an appropriate confidentiality
agreement with the Recording Party on mutually acceptable terms and shall have
been instructed not to reveal to the Auditing Party the details of its review,
except for (i) such information as is required to be disclosed under this
Agreement and (ii) such information presented in a summary fashion as is
necessary to report the accountants' conclusions to the Auditing Party. The
report prepared by such accountants shall be sent or otherwise provided to the
Recording Party by such accountants at the same time it is sent or otherwise
provided to the Auditing Party. All costs and expenses incurred in connection
with performing any such audit shall be paid by the Auditing Party unless the
audit uncovers a net underpayment or overreporting of expenses by a Recording
Party of [**] percent ([**]%) of total amounts owed or expenses reported by such
Recording Party for any calendar year period covered by the audit, in which case
the Recording Party will bear the full cost of such audit. The

** CONFIDENTIAL TREATMENT REQUESTED

                                       54
<PAGE>
Auditing Party will be entitled to recover any underpayment or will be paid the
amount of any overreported expenses, plus interest calculated in accordance with
Section 9.9 within [**] days after receipt of such audit report, or
alternatively shall have the right to offset any such amounts against payments
the Auditing Party is otherwise required to make to the Reporting Party under
this Agreement.

          9.7.3 BINDING EFFECT. If a Party fails to invoke its audit rights
pursuant to this Section 9.7 with respect to a calendar year within [**] years
following the end of such year, the calculation of royalties, Net Sales,
Development Costs, Commercialization Costs, Fully Burdened Manufacturing Costs
and Distributable Profits (Losses) with respect to such year shall be binding
and conclusive upon the other Party, and each Party and its Affiliates and
sublicensees shall be released from any liability or accountability with respect
to royalties, Net Sales and Distributable Profits (Losses), as the case may be.

     9.8 MANNER OF PAYMENTS. All sums due to Alkermes or Cephalon under this
Article 9 shall be payable by bank wire transfer in immediately available funds
to such bank account(s) as Alkermes and Cephalon, respectively, shall designate
from time to time. Each Party shall endeavor to notify the other Party as to the
date and amount of any such wire transfer to the other Party at least [**]
Business Days prior to such transfer, but in no event later than the Business
Day of such transfer.

     9.9 INTEREST ON LATE PAYMENTS. Without limitation on other available rights
or remedies, all amounts payable under this Agreement will bear interest at the
rate of [**] per calendar month from the date due until paid.

     9.10 TAXES.

          9.10.1 WITHHOLDING. Cephalon will make all payments to Alkermes under
this Agreement, and Alkermes will make all payments to Cephalon, as applicable,
without deduction or withholding except to the extent that any such deduction or
withholding is required by Law to be made on account of Taxes (as that term is
defined in Section 9.10.4 below).

          9.10.2 PAYMENT OF TAXES. Any Tax required to be withheld by Law on
amounts payable under this Agreement will promptly be paid by Cephalon on behalf
of Alkermes or Alkermes on behalf of Cephalon, as applicable, to the appropriate
governmental authority, and the Party making such payment will furnish the other
Party with proof of payment of such Tax within [**] calendar month of such
payment. With the exception of Tax on any royalty payments made by Alkermes to
Cephalon hereunder, any such Tax required to be withheld will be an expense of
and borne by Alkermes. The Party making Tax payments hereunder will give notice
of its intention to begin withholding any such Tax in advance of such
withholding and will use reasonable and legal efforts to cooperate with the
other Party to reduce such Tax on payments made to the other Party hereunder.

** CONFIDENTIAL TREATMENT REQUESTED

                                       55
<PAGE>
          9.10.3 DOCUMENTATION. Cephalon and Alkermes will cooperate with
respect to producing all documentation required by any government taxing
authority or reasonably requested by Cephalon or Alkermes, as applicable, to
secure a reduction in the rate of applicable withholding Taxes.

          9.10.4 TAX. Solely for purposes of this Section 9.10, "Tax" or "Taxes"
means any present or future taxes, levies, imposts, duties, charges, assessments
or fees of any nature (other than incomes taxes and excluding interest,
penalties and additions thereto) that are imposed by a taxing authority with
respect to amounts payable under this Agreement.

     9.11 [**].

          9.11.1 DECISION TO DEVELOP. For [**] from the date of the First
Commercial Sale of a Finished Product in the Territory if either Party or its
Affiliates (such Party, the "Developing Party") wishes, directly or indirectly,
to develop for sale, or sell, in the Territory [**] the Developing Party shall
provide written notice and a detailed information package concerning such [**]
to the other Party. Within [**] days of receipt of such notice and information
package the other Party shall notify the Developing Party in writing if it
wishes to participate in the development or acquisition of such [**] pursuant to
the terms and conditions of this Agreement (the "Initial Notice"). If the other
Party provides an Initial Notice, then such [**]. If the other Party does not
provide an Initial Notice within [**] days of receipt of the notice and
information package from the Developing Party, then [**].

          9.11.2 [**] OPTION. Promptly following the completion of [**], the
Developing Party shall provide to the other Party a detailed information package
concerning such [**] (the "[**] Data Package"). Upon receipt of such [**] Data
Package, the other Party shall have a period of [**] days in which to notify the
Developing Party in writing that it wishes to have the [**] become [**] under
this Agreement, subject to Section 9.11.5 (the "[**] Notice"). If the other
Party provides an [**] Notice to the Developing Party, it shall pay the
Developing Party within [**] days of the date of such [**] Notice an amount
equal to [**] percent ([**]%) [**]. If the other Party does not provide an [**]
Notice within [**] days of receipt of the [**] Data Package from the Developing
Party, then the other Party shall [**], and the Developing Party shall be free
to develop for sale or sell such [**] in the Territory subject to the
obligations set forth in Sections 9.11.3 and 9.11.4. [**].

          9.11.3 [**] OPTION. No later than [**] days after the [**], the
Developing Party shall provide to the other Party a detailed information package
concerning the [**] (the "[**] Data Package"). Upon receipt of such [**] Data
Package, the other Party shall have a period of [**] days in which to notify the
Developing Party in writing that it wishes to have the [**] become a [**] under
this Agreement, subject to Section 9.11.5 (the "[**]

** CONFIDENTIAL TREATMENT REQUESTED

                                       56
<PAGE>
Notice"). If the other Party provides a [**] Notice to the Developing Party, it
shall pay the Developing Party within [**] of the date of such [**] Notice an
amount equal to [**]. If the other Party does not provide a [**] Notice within
[**] days of receipt of the [**] Data Package from the Developing Party, then
the other Party shall be [**], and the Developing Party shall be free to develop
for sale or sell such [**] in the Territory subject to the obligations set forth
in Section 9.11.4. [**].

          9.11.4 [**] OPTION. No later than [**] days after the date [**], the
Developing Party shall notify the other Party of such filing and provide the
other Party with an estimation of the total [**] (as defined below) incurred in
[**]. Upon receipt of such notice, the other Party shall have until the date
[**] days after such filing in which to notify the Developing Party in writing
that it wishes to have [**] become a [**] under this Agreement, subject to
Section 9.11.5 (the "[**] Notice"). If the other Party provides an [**] Notice
to the Developing Party, it shall pay the Developing Party within [**] days of
the date of such [**] Notice an amount equal to [**] percent ([**]%) of the
[**]. If the other Party does not provide an [**] Notice within [**] days after
such [**], then the other Party shall be [**], and the Developing Party shall be
free to develop for sale or sell such [**] in the Territory. [**].

          9.11.5 TERMS APPLICABLE TO A [**]. If the [**] becomes a [**] under
this Agreement pursuant to Sections 9.11.1, 9.11.2, 9.11.3 or 9.11.4 hereof,
then such [**] shall be subject to the applicable terms of this Agreement,
including payments pursuant to Section 9.5 hereof, but excluding Section 9.6
hereof. In addition the Term shall be extended until [**]. The Parties shall
also negotiate the terms and conditions for the manufacture and supply of such
[**]. For the avoidance of doubt, any [**] for which payments have been made by
one Party to the other Party pursuant to Sections 9.11.2, 9.11.3, or 9.11.4 may
not be included as part of the cost of goods for any [**].

                                   ARTICLE 10
                         REPRESENTATIONS AND WARRANTIES

     10.1 DISCLAIMER. EXCEPT AS EXPRESSLY PROVIDED HEREIN, EACH PARTY DISCLAIMS
ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF
COMMERCIAL UTILITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY
OR SCOPE OF PATENT RIGHTS OR NON-INFRINGEMENT OF THIRD PARTY INTELLECTUAL
PROPERTY RIGHTS.

     10.2 MUTUAL REPRESENTATIONS AND WARRANTIES. Each Party represents, warrants
and covenants to the other that as of the Effective Date:

          (I) This Agreement and the Supply Agreement have been duly executed
and delivered by such Party and constitute the valid and binding obligation of

** CONFIDENTIAL TREATMENT REQUESTED

                                       57
<PAGE>
such Party, enforceable against that Party in accordance with each of their
terms, except as enforceability may be limited by bankruptcy, fraudulent
conveyance, insolvency, reorganization, moratorium and other Laws relating to or
affecting creditors' rights generally and by general equitable principles. Such
Party has the right, power and authority to execute, deliver and perform this
Agreement and the Supply Agreement, including making the grant of rights
described in Article 6. The execution, delivery and performance of this
Agreement and the Supply Agreement have been duly authorized by all necessary
action on the part of such Party and its officers and directors. The execution,
delivery and performance of this Agreement and the Supply Agreement do not
breach, violate, contravene or constitute a default under any contracts,
arrangements or commitments to which such Party is a party or by which it is
bound nor do the execution, delivery and performance of this Agreement or the
Supply Agreement by such Party violate any order, Law or regulation of any
court, governmental body or administrative or other agency having authority over
it; and

          (II) Such Party will not enter into any contract, arrangement or
commitment in the future which conflicts with or violates any term or provision
of this Agreement or the Supply Agreement.

     10.3 ALKERMES REPRESENTATIONS AND WARRANTIES. Alkermes further represents,
warrants and covenants to Cephalon that as of the Effective Date:

          (I) the Alkermes Patents [**] and the Alkermes Manufacturing Patents
[**] are all patent applications and patents Controlled by Alkermes or its
Affiliates as of the Effective Date that are necessary or directly relate to the
manufacture, use, sale or offer for sale of the Medisorb Product in the Field in
the Territory;

          (II) Alkermes has given Cephalon access to all clinical and
pre-clinical data and information for the Medisorb Product that is in Alkermes'
or its Affiliates' possession;

          (III) none of the issued Alkermes Patents listed on Exhibit A has been
found invalid and unenforceable by a court of competent jurisdiction, and
Alkermes is not aware of any facts that would render such Alkermes Patents
invalid or unenforceable;

          (IV) Alkermes is not required to obtain the consent of any Third Party
to make the grant of rights to Cephalon described in Article 6;

          (V) Alkermes has not received written notice from a Third Party
claiming that a patent owned by such Third Party would be infringed by the
manufacture, use, sale, offer for sale or import of the Medisorb Product in the
Field in the Territory, no Third Party has threatened in writing to make any
such claim and Alkermes is not aware of any Third Party issued patents or
published patent

** CONFIDENTIAL TREATMENT REQUESTED

                                       58
<PAGE>
applications that if issued would be infringed by the making, using, selling, or
importing of the Medisorb Product in the Field in the Territory;

          (VI) Alkermes or its Affiliates Control the Alkermes Patents and the
Alkermes Know How existing as of the Effective Date;

          (VII) except as previously disclosed by Alkermes to Cephalon in
writing, Alkermes is not aware of any claim made against it asserting the
invalidity, misuse, unregisterability, unenforceability or non-infringement of
any Alkermes Patents listed on Exhibit A or Alkermes Manufacturing Patents
listed on Exhibit B in the Territory and is not aware of any claim made against
it challenging its right to use or ownership of any Alkermes Patents, Alkermes
Manufacturing Patents, Alkermes Know How or Alkermes Manufacturing Know-How or
making any adverse claim of ownership thereof;

          (VIII) except as previously disclosed by Alkermes to Cephalon in
writing, Alkermes is not aware of the use or sale by any Third Party in the
Territory of a product that is being developed or commercialized for the Initial
Indication that would infringe the Alkermes Patents listed on Exhibit A or the
Alkermes Manufacturing Patents listed on Exhibit B in the Territory;

          (IX) Alkermes has given Cephalon access to the INDs, the NDA and
related filings with the FDA for the Medisorb Product and all material
correspondence to and from the FDA relating to the foregoing matters; and

          (X) the Development of the Medisorb Product for the Initial
Indication, including the Clinical Studies, has been conducted by Alkermes in
material compliance with all applicable Laws, including the Act.

     10.4 NO GUARANTY OF DEVELOPMENT OR COMMERCIALIZATION SUCCESS. The Parties
each specifically acknowledge and agree that the Development to be performed by
the Parties hereunder, including the Clinical Studies, is research based and as
such there is no guaranty that such Development will be successful, in whole or
in part. The Parties each further specifically acknowledge and agree that the
Commercialization to be performed by the Parties hereunder may be affected by
various market, regulatory and other factors and as such there is no guaranty
that such Commercialization will be successful, in whole or in part.

                                   ARTICLE 11
                                    LIABILITY

     11.1 LIMITATION OF LIABILITY. Except pursuant to Sections 11.2 and 11.3
below, neither Party shall be liable to the other for indirect, incidental,
special, punitive, exemplary, or consequential damages arising out of or
resulting from this Agreement

** CONFIDENTIAL TREATMENT REQUESTED

                                       59
<PAGE>
and the Supply Agreement.

     11.2 CEPHALON INDEMNIFICATION.

          11.2.1 OBLIGATION. Cephalon shall indemnify, defend and hold harmless
Alkermes and its Affiliates and their respective directors, officers, employees
and agents (each an "Alkermes Indemnified Party") from and against all costs,
losses, liabilities, expenses (including reasonable attorneys' fees, experts'
fees and other costs of investigation or defense at any stage of the
proceedings) and damages to the extent relating to a claim, action or demand by
a Third Party or Governmental Authority arising out of or resulting from:

               (I) any breach of this Agreement or the Supply Agreement by
Cephalon, including the breach of any of Cephalon's representations or
warranties in Section 10.2;

               (II) the violation of any Law by or on behalf of Cephalon or its
Affiliates;

               (III) negligence or willful misconduct by or on behalf of
Cephalon or its Affiliates relating to the Development, Manufacture,
Commercialization or use of a Product for sale in the Territory by or on behalf
of Cephalon or its Affiliates; or

               (IV) without limiting the generality of clause (iii) above,
Product Liability Claims arising out of or resulting from the negligence or
willful misconduct by or on behalf of Cephalon or its Affiliates relating to the
Development, Manufacture, Commercialization or use of a Product for sale in the
Territory by or on behalf of Cephalon or its Affiliates;

except to the extent such claim, action or demand arose or resulted from the
negligence or willful misconduct of any Alkermes Indemnified Party.

          11.2.2 PROCESS. In the event that an Alkermes Indemnified Party seeks
indemnification under this Section 11.2, Alkermes shall: (i) give prompt notice
to Cephalon of any such claim, action or demand; (ii) permit Cephalon to assume
direction and control of the defense of such claim, action or demand (including
decisions regarding its settlement or other disposition, which may be made in
Cephalon's sole discretion except as otherwise provided herein); (iii) assist
Cephalon at Cephalon's expense in defending such claim, action or demand; and
(iv) not compromise or settle such claim, action or demand without Cephalon's
prior written consent, which shall not be unreasonably withheld or delayed.
Alkermes may participate in the defense of such claim, action or demand through
counsel of its choice, but the cost of such counsel shall be borne solely by
Alkermes. Except with the approval of Alkermes, which approval shall not be
unreasonably withheld or delayed, Cephalon shall not consent to

** CONFIDENTIAL TREATMENT REQUESTED

                                       60
<PAGE>
entry of any judgment or enter into any settlement which (i) would result in
injunctive or other relief being imposed against an Alkermes Indemnified Party;
or (ii) does not include as an unconditional term thereof the giving by the
claimant or plaintiff to all applicable Alkermes Indemnified Parties of a
release from all liability in respect to such claim or litigation. If an
Alkermes Indemnified Party in good faith determines that such party may have
available to it one or more defenses or counterclaims that are inconsistent with
one or more of those defenses or counterclaims that may be available to Cephalon
in respect of any claim, action or demand, then the Alkermes Indemnified Party
shall have the right at all times to assume control over the defense or
settlement of any such claim, action or demand at Cephalon's cost and expense;
provided, however, that if the Alkermes Indemnified Party does so assume
control, the Alkermes Indemnified Party shall not consent to entry of any
judgment or enter into any settlement without the consent of Cephalon, which
consent shall not to be unreasonably withheld or delayed. Third-Party claims,
actions or demands subject to the indemnification, defense and hold harmless
obligations hereunder shall not include any claims, actions or demands asserted
by any agent of Alkermes.

     11.3 ALKERMES INDEMNIFICATION.

          11.3.1 OBLIGATION. Alkermes shall indemnify, defend and hold harmless
Cephalon and its Affiliates and their respective directors, officers, employees
and agents (each a "Cephalon Indemnified Party") from and against all costs,
losses, liabilities, expenses (including reasonable attorney's fees, experts'
fees and other costs of investigation or defense at any stage of the
proceedings) and damages relating to a claim, action or demand by a Third Party
or Governmental Authority to the extent arising out of or resulting from:

               (I) any breach of this Agreement or the Supply Agreement by
Alkermes, including the breach of any of Alkermes' representations or warranties
in Section 10.2 and 10.3;

** CONFIDENTIAL TREATMENT REQUESTED

                                       61
<PAGE>
               (II) the violation of any Law by or on behalf of Alkermes or its
Affiliates;

               (III) negligence or willful misconduct by or on behalf of
Alkermes or its Affiliates relating to the Development, Manufacture,
Commercialization or use of a Product for sale in the Territory by or on behalf
of Alkermes or its Affiliates;

               (IV) without limiting the generality of clause (iii) above,
Product Liability Claims arising out of or resulting from (A) the negligence or
willful misconduct by or on behalf of Alkermes or its Affiliates relating to the
Development, Manufacture, Commercialization or use of a Product for sale in the
Territory by or on behalf of Alkermes or its Affiliates or (B) any breach of
Alkermes' obligations under the Supply Agreement; or

               (V) the Development, Manufacture, Commercialization or use of a
Product for sale outside the Territory by or on behalf of Alkermes or its
Affiliates;

except to the extent such claim, action or demand arose or resulted from the
negligence or willful misconduct of any Cephalon Indemnified Party.

          11.3.2 PROCESS. In the event that an Cephalon Indemnified Party seeks
indemnification under this Section 11.3, Cephalon shall: (i) give prompt notice
to Alkermes of any such claim, action or demand; (ii) permit Alkermes to assume
direction and control of the defense of such claim, action or demand (including
decisions regarding its settlement or other disposition, which may be made in
Alkermes' sole discretion except as otherwise provided herein); (iii) assist
Alkermes at Alkermes' expense in defending such claim, action or demand; and
(iv) not compromise or settle such claim, action or demand without Alkermes'
prior written consent, which shall not be unreasonably withheld or delayed.
Cephalon may participate in the defense of such claim, action or demand through
counsel of its choice, but the cost of such counsel shall be borne solely by
Cephalon. Except with the approval of Cephalon which approval shall not be
unreasonably withheld or delayed, Alkermes shall not consent to entry of any
judgment or enter into any settlement which (i) would result in injunctive or
other relief being imposed against a Cephalon Indemnified Party; or (ii) does
not include as an unconditional term thereof the giving by the claimant or
plaintiff to all applicable Cephalon Indemnified Parties of a release from all
liability in respect to such claim or litigation. If a Cephalon Indemnified
Party in good faith determines that such party may have available to it one or
more defenses or counterclaims that are inconsistent with one or more of those
defenses or counterclaims that may be available to Alkermes in respect of any
claim, action or demand, then the Cephalon Indemnified Party shall have the
right at all times to assume control over the defense or settlement of any such
claim, action or demand at Alkermes' cost and expense; provided, however, that
if the Cephalon Indemnified Party does so assume control, the Cephalon

** CONFIDENTIAL TREATMENT REQUESTED

                                       62
<PAGE>
Indemnified Party shall not consent to entry of any judgment or enter into any
settlement without the consent of Alkermes, which consent shall not to be
unreasonably withheld or delayed. Third-Party claims, actions or demands subject
to indemnification, defense and hold harmless obligations hereunder shall not
include any claims, actions or demands asserted by any agent of Cephalon.

          11.3.3 INDEMNIFICATION FOR PATENT LIABILITY. If the Parties agree
pursuant to Section 7.7 to obtain a license from a Third Party pursuant to
Section 7.7 with respect to any Indemnification Patent, then the payment
obligations to the Third Party incurred in connection with such license shall be
borne solely by Alkermes. If Alkermes otherwise determines pursuant to Section
7.7 to obtain a license from a Third Party pursuant to Section 7.7 with respect
to any Indemnification Patent, then the payment obligations to the Third Party
incurred in connection with such license shall be borne solely by Alkermes. If
neither Cephalon or Alkermes takes a license with respect to an Indemnification
Patent, and a Third Party with right, title or interest in an Indemnification
Patent makes a claim, action or demand against a Cephalon Indemnified Party
arising out of or resulting from the alleged infringement of such
Indemnification Patent by the use, sale, offer for sale or import of a Product
in the Field in the Territory, then Alkermes shall indemnify, defend and hold
harmless such Cephalon Indemnified Party from and against all costs, losses,
liabilities, expenses (including reasonable attorneys' fees, experts' fees and
other costs of investigation or defense at any stage of the proceedings) and
damages to the extent relating to such claim, action or demand pursuant to the
terms and conditions of Section 11.3.2.

     11.4 INSURANCE

          11.4.1 CEPHALON COVERAGE. Cephalon agrees to carry and maintain in
full force and effect during the Term Commercial General Liability Insurance and
Product Liability/Completed Operations Insurance, including contractual
liability coverage, in an amount not less than [**] Dollars ($[**]) per
occurrence bodily injury/property damage combined and [**]Dollars ($[**])
aggregate annually. Such insurance shall be primary to any insurance owned,
secured or put in place by Alkermes. The policies shall provide for [**] days
written notice to Alkermes of cancellation, suspension, non-renewal, or
reduction in scope or limits. All such policies shall be written by insurance
companies with an A.M. Best's rating (or its equivalent) of A- or higher. Upon
written request, Cephalon shall provide Alkermes with a certificate of insurance
attesting to such coverage. It is understood and agreed that this insurance
shall not be construed to limit Cephalon's liability with respect to its
indemnification obligations hereunder.

          11.4.2 ALKERMES COVERAGE. Alkermes agrees to carry and maintain in
full force and effect during the Term Commercial General Liability Insurance and
Product Liability/Completed Operations Insurance, including contractual
liability coverage, in an amount not less than [**]Dollars ($[**]) per
occurrence bodily

** CONFIDENTIAL TREATMENT REQUESTED

                                       63
<PAGE>
injury/property damage combined and [**]Dollars ($[**]) aggregate annually. Such
insurance shall be primary to any insurance owned, secured or put in place by
Cephalon. The policies shall provide for [**] days written notice to Cephalon of
cancellation, suspension, non-renewal, or reduction in scope or limits. All such
policies shall be written by insurance companies with an A.M. Best's rating (or
its equivalent) of A- or higher. Upon written request, Alkermes shall provide
Cephalon with a certificate of insurance attesting to such coverage. It is
understood and agreed that this insurance shall not be construed to limit
Alkermes' liability with respect to its indemnification obligations hereunder.

                                   ARTICLE 12
                               DISPUTE RESOLUTION

     12.1 DISPUTES.

          12.1.1 OBJECTIVE. The Parties recognize that disputes, controversies
or claims arising out of or relating to this Agreement or the Supply Agreement
(the "Agreements"), or the interpretation, breach, termination or invalidity
thereof (each a "Dispute"), may from time to time occur during the Term. It is
the objective of the Parties to establish procedures to facilitate the
resolution of Disputes occurring with respect to any of the Agreements, in an
expedient manner by mutual cooperation and without resort to litigation. To
accomplish this objective, the Parties agree to follow the procedures set forth
in this Article 12 if and when a Dispute occurs with respect to an Agreement.

          12.1.2 RESOLUTION BY THE JSC AND CEOS. Unless otherwise specifically
recited in the relevant Agreement, any Disputes relating to the Agreements shall
be first referred to the JSC by either Party at any time after such Dispute has
arisen; provided, however, that any Dispute relating to the scope, validity or
enforceability of an Alkermes Patent, Alkermes Manufacturing Patent, Cephalon
Patent or Joint Patent may only be determined in accordance with Section 12.5
hereof. If the JSC is unable to resolve such a Dispute within [**] days of being
requested by a Party to do so, unless otherwise agreed by the Parties, or the
JSC is unable to resolve a Dispute among its members, either Party may present
the Dispute to the Chief Executive Officer ("CEO")) of each of Alkermes and
Cephalon for resolution by providing a dispute notice (the "Dispute Notice") to
the CEOs and the other Party. The Dispute Notice shall set concisely forth the
Dispute, the Parties' respective positions, and the specific relief requested.
If the Party providing the Dispute Notice (the "Complaining Party") contends
that the dispute is a Reserved Dispute as defined in Section 12.2 below, the
Dispute Notice shall so state. Within [**] days after receipt of the Dispute
Notice, the other Party (the "Responding Party") shall provide a concise written
response (the "Response") to the Dispute Notice to the CEOs and the Complaining
Party. If the Responding Party does not agree with the Complaining

** CONFIDENTIAL TREATMENT REQUESTED

                                       64
<PAGE>
Party's contention regarding whether the Dispute is a Reserved Dispute, the
Response shall so state. The CEOs shall attempt to resolve the Dispute within
[**] days after their receipt of the Response. If the Dispute Notice and
Response indicate that the Parties are in disagreement about whether a Dispute
is a Reserved Dispute, the CEOs shall also attempt to resolve that disagreement.
In the event that the CEO's cannot resolve a Dispute within this period, unless
otherwise agreed by the Parties, [**] and any other Dispute may be referred by
either Party to arbitration in accordance with Section 12.3 upon written notice
to the other Party. [**].

     12.2 RESERVED DISPUTES. [**].

          (I) [**];

          (II) [**];

          (III) [**]:

               (A) [**]; and

               (B) [**].

          (IV) [**]

          (V) [**].

     12.3 ARBITRATION. The Parties agree that any Dispute referred for
arbitration by a Party pursuant to Section 12.1 shall be resolved through
binding arbitration in accordance with the CPR Institute for Dispute Resolution
Rules for Non-Administered Arbitration. Any Dispute in which either Party seeks
in excess of [**] Dollars ($[**]) in damages, or in which any equitable relief
is sought by either Party, shall be resolved by an arbitral tribunal consisting
of three (3) arbitrators, one of whom shall be designated by each Party in
accordance with the screened appointment procedure provided in CPR Rule 5.4, and
a third arbitrator who shall chair the tribunal and who shall be selected as
provided in CPR Rule 5.2. Any other Dispute shall be submitted to a sole
arbitrator, appointed by CPR pursuant to CPR Rule 6. The arbitrator(s) shall
render a written opinion setting forth findings of fact and conclusions of Law
with the reasons therefor stated. Arbitration pursuant to this Section 12.3
shall be governed by the Federal Arbitration Act, 9 U.S.C. Sections 1-16, and
judgment upon the award rendered by the arbitrators may be entered by any court
having jurisdiction thereof. If Alkermes has tendered the Dispute for
resolution, the arbitration proceedings shall be conducted in the Commonwealth
of Pennsylvania. If Cephalon has tendered the Dispute for resolution,
arbitration proceedings shall be conducted in the Commonwealth of Massachusetts.
Each Party shall continue to perform its obligations under the Agreements
pending final resolution of any Dispute unless to do so would be

** CONFIDENTIAL TREATMENT REQUESTED

                                       65
<PAGE>
impossible or impracticable under the circumstances. The Parties agree that they
shall share equally the cost of arbitration filing and hearing fees, and the
cost of the arbitrators. Each Party must bear its own attorney's fees and
associated costs and expenses. Unless otherwise specifically provided herein,
the arbitrator(s) shall base his/her decision on the stated goal of the Parties
in entering into this Agreement which is to maximize, subject to budget
constraints set forth herein, the overall profits for the Products, rather than
the value of the Products, or associated profits, for either individual Party.

     12.4 JURISDICTION. For the purposes of this Article 12, the Parties agree
to accept the jurisdiction of the federal courts located in the State of
Delaware for the purposes of enforcing awards entered pursuant to this Article
and for enforcing the agreements reflected in this Article 12.

     12.5 DETERMINATION OF DISPUTES RELATING TO PATENTS AND OTHER INTELLECTUAL
PROPERTY. Notwithstanding the foregoing, any dispute relating to the
determination of scope, validity or enforceability of an Alkermes Patent,
Alkermes Manufacturing Patent, Cephalon Patent or Joint Patent shall be
submitted exclusively to the federal court having jurisdiction over the disputed
patent.

** CONFIDENTIAL TREATMENT REQUESTED

                                       66
<PAGE>
                                   ARTICLE 13
                              TERM AND TERMINATION

     13.1 TERM. This Agreement shall commence as of the Effective Date and,
unless sooner terminated as provided in this Article 13, shall continue in
effect until the later of (i) the expiration of the last to expire Valid Claim
of an Alkermes Patent or Joint Patent or (ii) fifteen (15) years from the date
of the First Commercial Sale of a Finished Product in the Territory (such
period, the "Term").

     13.2 RIGHT TO TERMINATE FOR BREACH. Except as otherwise provided herein, if
either Party shall commit a material breach with respect to any material
provision of this Agreement and the other Party shall have given the breaching
Party written notice of such breach, the breaching Party shall have [**] days to
cure such breach. If such breach is not cured in all material respects within
such [**] day period, the non-breaching Party shall have the right, upon notice
to the breaching Party and without prejudice to any other rights the
non-breaching Party may have, to terminate this Agreement, unless the breaching
Party is in the process of attempting in good faith to cure such breach, in
which case the [**] day cure period shall be extended by an additional [**]
days.

     13.3 CEPHALON'S RIGHT TO TERMINATE.

          13.3.1 TERMINATION. Cephalon shall have the right to terminate this
Agreement at any time by providing one hundred eighty (180) days prior written
notice to Alkermes.

          13.3.2 CEPHALON'S OBLIGATIONS UPON TERMINATION. In addition to
Cephalon's other obligations upon termination set forth elsewhere in this
Agreement, if Cephalon terminates this Agreement pursuant to Section 13.3.1:

               (I) The Parties shall, subject to the provisions of this
Agreement providing for the sharing of Shared Expenses, complete, or facilitate
the completion (including the completion of final reports for such studies) of,
all ongoing Clinical Studies and Post Marketing Clinical Trials being conducted
by the Parties for the Territory (without the obligation to enroll any
additional patients after the notice of termination hereunder); provided,
however, Cephalon may complete, or facilitate the completion of, a Clinical
Study or Post Marketing Clinical Trial by ending a Clinical Study or Post
Marketing Clinical Trial if it is medically reasonable to do so, but only after
giving Alkermes prior notice of Cephalon's intention to end such Clinical Study
or Post Marketing Clinical Trial and providing Alkermes the opportunity to
continue the Clinical Study or Post Marketing Clinical Trial; and

               (II) in connection with any termination after the commercial
launch of the Products in the Territory, Cephalon shall continue to market and
sell the

** CONFIDENTIAL TREATMENT REQUESTED

                                       67
<PAGE>
Products in the Territory in accordance with the terms of this Agreement for a
period of [**] calendar months after the effective date of termination.

     13.4 ALKERMES' RIGHTS ON TERMINATION.

          13.4.1 LICENSE GRANT. If Alkermes terminates this Agreement pursuant
to Section 13.2 hereof, or Cephalon terminates this Agreement pursuant to
Section 13.3 hereof, (i) Alkermes shall be automatically granted a
non-exclusive, worldwide, sublicensable, perpetual license under the Cephalon
Patents and Cephalon Know-How to make, have made, use, sell, offer for sale and
import the Products in the Field; and (ii) all licenses and rights granted to
Cephalon under this Agreement shall terminate subject only to a non-exclusive
license to the extent and for the term necessary to permit the performance of
Cephalon's obligations pursuant to Sections 13.3 and 13.4.

          13.4.2 DOCUMENTS; CONTRACTS, INTELLECTUAL PROPERTY. Following the
effective date of termination of this Agreement by Alkermes pursuant to Section
13.2 hereof, or termination of this Agreement by Cephalon pursuant to Section
13.3 hereof, Cephalon shall have the following obligations:

               (I) Cephalon shall promptly provide Alkermes with copies of all
relevant documentation regarding Cephalon Patents and Cephalon Know-How, whether
written or electronic, and materials composing Cephalon Know-How, in the form
existing as of the effective date of such termination, reasonably necessary for
Alkermes to exercise its license rights under Section 13.4.1 above. Such
transfer shall be made in a timely and orderly fashion and in a manner such that
the value of what is being transferred is preserved in all material respects. In
the exercise of its license rights under Section 13.4.1 above, Alkermes may use
and disclose any Confidential Information of Cephalon contained in such
documentation or otherwise furnished to Alkermes by Cephalon pursuant to this
Agreement;

               (II) Cephalon shall promptly transfer and assign to Alkermes its
and its Affiliates' entire right, title and interest in and to any copyrights
for Promotional Materials and training materials for the Products in the
Territory. Cephalon will execute all documents that may be necessary to transfer
the title to such copyrights to Alkermes. Cephalon shall also promptly, at
Alkermes request, transfer copies of such materials to Alkermes;

               (III) Cephalon shall promptly transfer and assign to Alkermes its
and its Affiliates' entire right, title, and interest in and to the Vivitrex
Trademark and any Additional Product Trademarks in the Territory, together with
that portion of the good will of the business of Cephalon and its Affiliates
associated with the use of and symbolized by such trademarks in the Territory
and all common law rights in such trademarks in the Territory. Cephalon will
execute all documents that may be necessary to perfect the title to such
trademarks by Alkermes;

** CONFIDENTIAL TREATMENT REQUESTED

                                       68
<PAGE>
               (IV) at Alkermes' written request, Cephalon or its Affiliates
shall promptly assign to Alkermes or its nominee such agreements as Alkermes
designates between Cephalon or its Affiliates and Third Parties that are freely
assignable and relate solely to Development and Commercialization; and

               (V) at Alkermes' written request, Cephalon shall promptly
transfer to Alkermes Cephalon's system for responding to medical questions or
inquiries from members of the medical and paramedical professions and consumers
regarding the Products.

[**].

          13.4.3 CEPHALON'S RIGHT TO SELL INVENTORY. Following the effective
date of termination of this Agreement by Alkermes pursuant to Section 13.2
hereof, Cephalon and its Affiliates shall have the right to sell their inventory
of the Products for a period of [**] calendar months from the date of
termination; provided, however, that Cephalon shall within [**] Business Days of
the end of each such calendar month pay Alkermes a royalty of [**] percent
([**]%) of Net Sales of such Products during the prior calendar month, and
Cephalon shall comply with the provisions of Sections 9.6.2 and 9.7 through 9.10
hereof.

     13.5 CEPHALON'S RIGHTS ON TERMINATION. If Cephalon terminates this
Agreement pursuant to Section 13.2 hereof, then:

          (I) all licenses and rights granted to Cephalon under this Agreement
shall survive;

          (II) Alkermes shall provide to Cephalon copies of all relevant
documentation regarding Alkermes Patents and Alkermes Know-How, whether written
or electronic, and materials composing Alkermes Know-How, in the form existing
as of the effective date of such termination, as reasonably necessary for
Cephalon to continue to exercise its license rights under Section 13.5(i) and
meet its obligations as the holder of the NDA pursuant to Section 13.5(iv), and
not previously provided to Cephalon. Such transfer shall be made in a timely and
orderly fashion and in a manner such that the value of what is being transferred
is preserved in all material respects. In the exercise of its license rights
under Section 13.5(i) above, Cephalon may use and disclose any Confidential
Information of Alkermes contained in such documentation or otherwise furnished
to Cephalon by Alkermes pursuant to this Agreement;

          (III) Alkermes shall take all appropriate and necessary actions,
including action before the FDA, to transfer to Cephalon or its designee any
Regulatory Approvals, NDAs and INDs held by or on behalf of Alkermes for the
Products, along with all supporting data and information necessary for Cephalon
to continue to prosecute any such NDAs;

** CONFIDENTIAL TREATMENT REQUESTED

                                       69
<PAGE>
          (IV) at Cephalon's written request, Alkermes shall assign to Cephalon
or its nominee such agreements between Alkermes or its Affiliates and Third
Parties that Cephalon designates and that are freely assignable and relate
solely to Development and Commercialization;

          (V) Alkermes shall promptly transfer to Cephalon or its designee the
common safety database for both clinical and post-marketing adverse event data
for the Products described in Section 3.5;

          (VI) if Cephalon at the time of such termination does not have the
ability to Manufacture the Products, Alkermes shall continue to Manufacture the
Products for Cephalon pursuant to the provisions of the Supply Agreement until
manufacturing operations for the Products have been transferred to Cephalon
pursuant to the terms set forth in Section 6.3 of the Supply Agreement; and

          (VII) [**].

     13.6 CEPHALON'S RIGHTS ON EXPIRATION. Upon the expiration of this
Agreement, Cephalon shall have a non-exclusive, perpetual, fully paid-up
license, without the right to sublicense, under the Alkermes Patents and the
Alkermes Know-How to use, sell, offer for sale and import the Products in the
Field in the Territory. If either Party wishes to negotiate terms and conditions
upon which the Parties will continue to collaborate in the Development,
Commercialization or Manufacture of the Products in the Field in the Territory
following the expiration of this Agreement, then such Party shall notify the
other Party and following the other Party's receipt of such notice, the Parties
shall negotiate in good faith the terms and conditions for such continued
collaboration.

     13.7 RIGHT TO TERMINATE UPON BANKRUPTCY. Either Party may, in addition to
any other remedies available to it by Law or in equity, terminate this
Agreement, in whole or in part as the terminating Party may determine, by notice
to the other Party in the event (i) the other Party shall have become bankrupt
or shall have made an assignment for the benefit of its creditors; (ii) there
shall have been appointed a trustee or receiver for the other Party or for all
or a substantial part of its property; or (iii) any case or proceeding shall
have been commenced or other action taken by or against the other Party in
bankruptcy or seeking reorganization, liquidation, dissolution, winding-up,
arrangement, composition or readjustment of its debts or any other relief under
any bankruptcy, insolvency, reorganization or other similar act or Law of any
jurisdiction now or hereafter in effect, and any such event shall have continued
for [**] days undismissed, unbonded and/or undischarged.

     13.8 SURVIVAL OF CERTAIN PROVISIONS. Termination of this Agreement for any
reason or expiration of this Agreement shall not release either Party from any
obligation arising prior to the date of termination. The rights and obligations
under Sections 3.5,

** CONFIDENTIAL TREATMENT REQUESTED

                                       70
<PAGE>
7.1.2, 7.4.3, 7.4.5 and 7.5 (with respect to the Joint Patents), 9.6.2, 9.7 -
9.10, 13.3.2, 13.4, 13.5, 13.6, and this Section 13.8 and Articles 8, 11, 12 and
14, in each case only in the event and to the extent applicable and subject to
the terms and conditions stated therein, shall survive any termination or
expiration of this Agreement. In addition, any other provision required to
interpret and enforce the Parties' rights and obligations under this Agreement
shall also survive, but only to the extent required for the full performance of
this Agreement. Any right to terminate this Agreement, and any rights a Party
has under Sections 13.3, 13.4 and 13.5, as applicable, shall be in addition to
and not in lieu of all other rights or remedies that the Party giving notice of
termination may have at Law or in equity or otherwise.

                                   ARTICLE 14
                               GENERAL PROVISIONS

     14.1 NOTICES. All notices, reports, requests or demands required or
permitted under this Agreement shall be sent by air courier or by facsimile,
with confirmed transmission, properly addressed to the respective Parties as
follows:

          If to Alkermes:
             Alkermes, Inc.
             88 Sidney Street
             Cambridge, Massachusetts 02139
             Attention: Chief Executive Officer
             Facsimile No.: [**]

          with a copy to:

             Alkermes, Inc.
             88 Sidney Street
             Cambridge, Massachusetts 02139
             Attention: General Counsel
             Facsimile No.: [**]

          If to Cephalon:
             Cephalon, Inc.
             41 Moores Road
             Frazer, Pennsylvania 19355
             Attn: Chief Executive Officer
             Facsimile No.: [**]

** CONFIDENTIAL TREATMENT REQUESTED

                                       71
<PAGE>
          with a copy to:

             Cephalon, Inc.
             41 Moores Road
             Frazer, Pennsylvania 19355
             Attn: General Counsel
             Facsimile No.: [**]

or to such addresses or addresses as the Parties hereto may designate for such
purposes during the Term. Notices shall be deemed to have been sufficiently
given or made: (i) if by facsimile with confirmed transmission, when performed,
and (ii) if by air courier upon receipt by the Party.

     14.2 GOVERNING LAW. This Agreement shall be governed by and construed in
accordance with the Laws of the State of Delaware (other than its choice of law
principles).

     14.3 ENTIRE AGREEMENT; AMENDMENT. This Agreement, together with the
Exhibits hereto and the Supply Agreement, including all consideration and the
rights and obligations of the Parties under such agreements, represents the
entire agreement between the Parties regarding the subject matter hereof and
thereof, and there are no prior or contemporaneous written or oral promises or
representations relating to this subject not incorporated herein. No amendment
or modification of the terms and conditions of this Agreement shall be binding
on either Party unless reduced to writing referencing this Agreement and signed
by an authorized officer of the Party to be bound. In the event of a conflict
between the provisions of this Agreement and those of the Supply Agreement, the
provisions of the Supply Agreement shall control.

     14.4 BINDING EFFECT AND ASSIGNMENT. This Agreement shall be binding upon
and inure to the benefit of the Parties hereto and their respective permitted
successors and assigns. This Agreement shall not be assignable by either Party
without the other's prior written consent; provided, however, that either Party
may assign this Agreement, without the other Party's written consent but after
providing [**] days prior notice to the other Party, to an Affiliate or to any
successor pursuant to a sale, license, lease or other transfer or disposition to
such successor of more than fifty percent (50%) of the assets of such Party; or
an acquisition, reorganization, merger, consolidation, business combination,
share exchange or similar transaction or series of related transactions with
such successor that results in an acquisition by such successor of fifty percent
(50%) or more of the voting control or other ownership interest in such Party.

     14.5 WAIVER. A waiver by either Party of any of the terms and conditions of
this Agreement in any instance shall not be deemed or construed to be a waiver
of such term or condition for the future, or of any other term or condition
hereof. All rights, remedies, undertakings, obligations and agreements contained
in this Agreement shall

** CONFIDENTIAL TREATMENT REQUESTED

                                       72
<PAGE>
be cumulative and none of them shall be in limitation of any other remedy,
right, undertaking, obligation or agreement of either Party.

     14.6 SEVERABILITY. If any part of this Agreement shall be found to be
invalid or unenforceable under applicable Law in any jurisdiction, such part
shall be ineffective only to the extent of such invalidity or unenforceability
in such jurisdiction, without in any way affecting the remaining parts of this
Agreement in that jurisdiction or the validity or enforceability of the
Agreement as a whole in any other jurisdiction. In addition, the part that is
ineffective shall be reformed in a mutually agreeable manner so as to as nearly
approximate the intent of the Parties as possible.

     14.7 PUBLICITY. Subject to the further provisions of this Section 14.7,
neither Party shall originate any written publicity, news release or public
announcement, whether to the public or press, concerning this Agreement or the
Supply Agreement other than such announcements that are required to be made by
Law (or the applicable rules of any securities exchange or market on which a
Party's securities are listed or traded) or that are otherwise agreed by the
Parties or expressly permitted under this Agreement or the Supply Agreement. An
approved press release announcing this Agreement is attached hereto as Exhibit
F. Routine references to this Agreement, the Supply Agreement and the
arrangements hereunder and thereunder shall be allowed in the usual course of a
Party's business. Once information has been approved for disclosure or
publication under this Section 14.7, either Party may use such approved
information in written publicity, news releases, public announcements and other
future communications with Third Parties. If a Party decides to make an
announcement or any filing with a governmental agency or securities exchange or
market as required by Law or the applicable rules of any securities exchange or
market on which a Party's securities are listed or traded, it will give the
other Party at least [**] days advance notice, where possible, of the text of
the announcement or content of the filing so that the other Party will have an
opportunity to comment upon the announcement or filing. To the extent that the
non-disclosing Party reasonably requests that any information in the materials
proposed to be disclosed be maintained as confidential, the disclosing Party
shall use commercially reasonable efforts to request confidential treatment of
such information, except to the extent that the disclosing Party receives advice
from its legal counsel that such information is required to be disclosed under
applicable Laws.

     14.8 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original for all purposes, but
all of which together shall constitute one and the same instrument.

     14.9 FORCE MAJEURE. Neither Party shall be held liable or responsible to
the other Party or be deemed to have breached or defaulted under this Agreement
for failure or delay in performing its obligations hereunder (except for payment
of money) to the extent, and as long as, such failure or delay is caused by or
results from causes beyond the reasonable control of the affected Party (a
"Force Majeure Delay"), including fire, floods, embargoes, war, insurrections,
riots, civil commotions, terrorism,

** CONFIDENTIAL TREATMENT REQUESTED

                                       73
<PAGE>
strikes, lockouts or other labor disturbances, sabotage, acts of God, failure or
delay of transportation, prevention from or hindrance in obtaining energy or
other utilities, omissions or delays in acting by any governmental authority,
acts of a government or agency thereof or judicial orders or decrees. In the
event of a Force Majeure Delay, the affected Party shall give prompt notice
thereof to the other Party, shall use commercially reasonable efforts to
mitigate the adverse consequences thereof and shall resume performance hereunder
with dispatch whenever the consequences of the Force Majeure Delay have been
mitigated; provided, however, in no event shall a Party be required to settle
any labor dispute or disturbance.

     14.10 AMBIGUITIES. Ambiguities, if any, in this Agreement shall not be
construed against any Party, irrespective of which Party may be deemed to have
authorized the ambiguous provision.

     14.11 HEADINGS. Headings are for the convenience of reference only and
shall not control the construction or interpretation of any of the provisions of
this Agreement.

     14.12 NO PARTNERSHIP. Nothing in this Agreement is intended or shall be
deemed to constitute a partnership, agency, or joint venture relationship
between the Parties. Notwithstanding any of the provisions of this Agreement,
neither Party shall at any time enter into, incur, or hold itself out to Third
Parties as having authority to enter into or incur, on behalf of the other
Party, any commitment, expense, or liability whatsoever.

     14.13 USE OF NAMES, TRADE NAMES AND TRADEMARKS. Except as expressly
provided in this Agreement or the Supply Agreement neither Party shall have the
right to use in advertising, publicity, other promotional activities or
otherwise any name, trade name, trademark, corporate logo or other designation
of the other Party hereto or its Affiliates or sublicensees, including any
contraction or abbreviation of any of the foregoing, unless the express written
permission of such other Party has been obtained.

     14.14 PERFORMANCE BY AN AFFILIATE. Each of Cephalon and Alkermes
acknowledge that obligations under this Agreement may be performed by Affiliates
of Cephalon and Alkermes. Each of Cephalon and Alkermes guarantee performance of
this Agreement by its Affiliates, notwithstanding any assignment to Affiliates
in accordance with Section 14.4 of this Agreement.

     14.15 NON-SOLICITATION OF EMPLOYEES. During the [**] year period following
the Effective Date, neither Party shall, directly or indirectly, recruit or
solicit any employee of the other Party or any of such other Party's Affiliates
if such employee has been materially involved in the performance of this
Agreement or the Supply Agreement, except pursuant to general solicitations not
targeted at such employees.

** CONFIDENTIAL TREATMENT REQUESTED

                                       74
<PAGE>
                            [SIGNATURE PAGE FOLLOWS]

** CONFIDENTIAL TREATMENT REQUESTED

                                       75
<PAGE>
     IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be
executed and delivered by its duly authorized representatives to be effective as
of the date set forth above.

ALKERMES, INC.                          CEPHALON, INC.

By: /s/ Michael J. Landine              By: /s/ J. Kevin Buchi
    ---------------------------------       ------------------------------------
Name: Michael J. Landine                Name: J. Kevin Buchi
Title: Vice President, Corporate        Title: Senior Vice President and Chief
       Development                             Financial Officer

** CONFIDENTIAL TREATMENT REQUESTED

                                       76
<PAGE>
                                    EXHIBIT A

                                ALKERMES PATENTS

                                 [**] [2 Pages]

** CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
                                    EXHIBIT B

                         ALKERMES MANUFACTURING PATENTS

                                      [**]

** CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
                                    EXHIBIT C

                    VIVITREX TRADEMARK AND MEDISORB TRADEMARK

<TABLE>
<S>                   <C>          <C>
VIVITREX              REGISTERED   US REGISTRATION NO. 2,660,659

VIVITREX AND DESIGN   PENDING      US APPLICATION NO. 76544129

MEDISORB              REGISTERED   US REGISTRATION NO. 2,217,667
</TABLE>

** CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
                                    EXHIBIT D

                DEVELOPMENT PLAN FOR CALENDAR YEARS 2005 AND 2006

                                 [**] [5 Pages]

** CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
                                    EXHIBIT E

                                      [**]

** CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
                                    EXHIBIT F

                                  PRESS RELEASE

Filed as Exhibit 99.1 to the Company's Current Report on Form 8-K dated June 29,
2005

** CONFIDENTIAL TREATMENT REQUESTED<PAGE>
                                                                 EXHIBIT 10.2

       WHENEVER CONFIDENTIAL INFORMATION IS OMITTED HEREIN (SUCH OMISSIONS
      ARE DENOTED BY AN ASTERISK *), SUCH CONFIDENTIAL INFORMATION HAS BEEN
         SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION
                PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT.

                                SUPPLY AGREEMENT

                                     BETWEEN

                                 ALKERMES, INC.

                                       AND

                                 CEPHALON, INC.
<PAGE>
       WHENEVER CONFIDENTIAL INFORMATION IS OMITTED HEREIN (SUCH OMISSIONS
      ARE DENOTED BY AN ASTERISK *), SUCH CONFIDENTIAL INFORMATION HAS BEEN
         SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION
                PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT.

                                SUPPLY AGREEMENT

     THIS SUPPLY AGREEMENT ("Agreement") is made and entered into, effective as
of June 23, 2005 (the "Effective Date"), by and between Alkermes, Inc., a
Pennsylvania corporation, having a principal place of business at 88 Sidney
Street, Cambridge, MA 02139 ("Alkermes"), and Cephalon, Inc., a Delaware
corporation having a principal place of business at 41 Moores Road, Frazer,
Pennsylvania 19355 ("Cephalon") (collectively, the "Parties" or individually, a
"Party").

                                    RECITALS:

     WHEREAS, concurrently with the execution of this Agreement, Alkermes and
Cephalon have entered into the License and Collaboration Agreement (as defined
below), pursuant to which Alkermes granted Cephalon a semi-exclusive license to
commercialize and sell the Product (as defined below) in the Territory (as
defined below);

     WHEREAS, under the terms of the License and Collaboration Agreement,
Alkermes has an obligation to manufacture and supply the Product to Cephalon for
development and commercial sale; and

     WHEREAS, Alkermes hereby agrees to manufacture and supply, and Cephalon
hereby agrees to purchase, the Product on the terms and conditions set forth
herein.

     NOW, THEREFORE, in consideration of the premises and the mutual covenants
and agreements set forth herein, and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties agree as
follows:

                                    ARTICLE 1
                                   DEFINITIONS

     Capitalized terms used in this Agreement, whether used in the singular or
plural, shall have the meanings set forth below, unless otherwise specifically
indicated herein. Capitalized terms used in this Agreement and not defined in
this Agreement shall have the meanings ascribed to them in the License and
Collaboration Agreement. In the event of a conflict between the definition of a
term contained herein and the definition of such term in the License and
Collaboration Agreement, this Agreement shall control.

     1.1 "ACT" shall mean the United States Food, Drug and Cosmetic Act, as
amended from time to time, and the regulations promulgated thereunder including
the guidelines and guidance issued by the FDA.

* CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
     1.2 "ADDITIONAL COMPONENTS" shall mean all components supplied together
with the Product and the Diluent that are necessary to reconstitute or
administer the Product, or that are necessary for final packaging.

     1.3 "AFFILIATES" shall mean with respect to any Party, shall mean any
entity that controls, is controlled by, or is under common control with such
Party, but only for so long as such control shall continue. For these purposes,
"control" shall refer to: (i) the possession, directly or indirectly, of the
power to direct the management or policies of an entity, whether through
ownership of voting securities, by contract or otherwise, or (ii) the ownership,
directly or indirectly, of at least fifty percent (50%) of the voting securities
or other ownership interest of an entity.

     1.4 "ALKERMES MANUFACTURING FACILITY" shall mean the facility owned and
operated by Alkermes or an Affiliate located in Wilmington, Ohio, or any other
manufacturing facility owned and operated by Alkermes or an Affiliate where the
Manufacture of the Product is performed for supply to Cephalon pursuant to this
Agreement; provided, however, an Alkermes Manufacturing Facility shall not
include a manufacturing facility owned and operated by Alkermes or an Affiliate
that is constructed for the Manufacture of the Product for supply outside the
Territory.

     1.5 "ALKERMES VIVITREX MANUFACTURING KNOW-HOW" shall mean the Alkermes
Manufacturing Know-How defined in the License and Collaboration Agreement that
is necessary or directly related to the Manufacture of the Product.

     1.6 "BUSINESS DAY" shall mean a day on which banking institutions in New
York, New York are open for business

     1.7 "CERTIFICATE OF ANALYSIS AND CONFORMITY" shall mean the certificate for
each batch or lot of Product delivered hereunder in the form contemplated by
Section 3.11 of this Agreement.

     1.8 "CGMPS" shall mean the then current good manufacturing practices
promulgated by the FDA under the U.S. Food, Drug and Cosmetic Act, 21 C.F.R.
Section 210-211, as amended from time to time.

     1.9 "CLINICAL REQUIREMENTS" shall mean the quantities of the Product,
Placebo and Diluent required for the conduct of pre-clinical studies and/or
Clinical Studies of Product in the Field pursuant to a Development Plan.

     1.10 "CLINICAL STUDIES" shall have the meaning set forth in the License and
Collaboration Agreement.

* CONFIDENTIAL TREATMENT REQUESTED

                                       2
<PAGE>
     1.11 "COMMERCIAL REQUIREMENTS" shall mean the quantities of the Product
required for (i) for commercial sale by Cephalon and its Affiliates in the Field
in the Territory pursuant to the License and Collaboration Agreement or (ii) for
compassionate use, use in investigator-sponsored Clinical Studies or post
marketing clinical studies in the Field in the Territory pursuant to the License
and Collaboration Agreement.

     1.12 "COMMERCIALIZATION" (including variations such as "Commercialize" and
the like) shall mean the performance by a Party or its Affiliates of any and all
activities directed to promoting, marketing, importing, exporting, distributing,
selling or offering to sell (including pre-marketing), sampling, post-marketing
clinical trials and post-marketing drug surveillance of the Product in the Field
in the Territory.

     1.13 "COMMERCIALIZATION PLAN" shall have the meaning set forth in the
License and Collaboration Agreement.

     1.14 "COMMERCIALLY REASONABLE MANUFACTURING EFFORTS" shall mean [**].

     1.15 "CONFIDENTIAL INFORMATION" shall have the meaning set forth in the
License and Collaboration Agreement with respect to information and materials
furnished by a Party to the other Party pursuant to this Agreement.

     1.16 "CT" shall mean a commercialization team established pursuant to the
License and Collaboration Agreement.

     1.17 "DEVELOPMENT FTE RATE" shall have the meaning set forth in the License
and Collaboration Agreement.

     1.18 "DEVELOPMENT PLAN" shall have the meaning set forth in the License and
Collaboration Agreement.

     1.19 "DILUENT" shall mean any injectable liquid pharmaceutical formulation
required to reconstitute the Product prior to injection, filled in a primary
container.

     1.20 "DOSAGE UNIT" shall mean a unit of the Product or the Finished Product
determined by the amount of the single dose of Naltrexone contained therein.

     1.21 "DT" shall mean a development team established pursuant to the License
and Collaboration Agreement.

     1.22 "FDA" shall mean the United States Food and Drug Administration or any
successor agency.

* CONFIDENTIAL TREATMENT REQUESTED

                                       3
<PAGE>
     1.23 "FIELD" shall mean the treatment, prevention or diagnosis of any human
disease, disorder or condition, including the treatment and/or prevention of
alcohol abuse/dependence.

     1.24 "FINISHED PRODUCT" shall mean a finished, packaged, labeled final
Dosage Unit of the Product plus Diluent and syringes.

     1.25 "FIRM PO" shall have the meaning set forth in Section 3.8(a).

     1.26 "FIRM ZONE" shall have the meaning set forth in Section 3.7(d).

     1.27 "[**] -YEAR FORECAST" shall mean a [**] year annual forecast of the
Product Requirements and Placebo Requirements in each year of such forecast,
starting with the next calendar year (i.e., the calendar year following the due
date of such forecast), provided that the forecast for the first [**] months
shall be broken down by month.

     1.28 "FULLY BURDENED MANUFACTURING COST" shall mean the costs incurred
(i.e., paid or accrued) by a Party, its Affiliates or agents in the Manufacture
of a Product, Placebo or Diluent, as applicable, which shall be [**]. Fully
Burdened Manufacturing Cost shall exclude [**] that are required to obtain
Regulatory Approval for the Medisorb Product for the Initial Indication (which
costs shall be borne solely by Alkermes). In addition, for the avoidance of
doubt, any Manufacturing development costs that are included in Shared Expenses
as Development Costs shall not be included as part of the Fully Burdened
Manufacturing Cost.

     1.29 "FTE" shall have the meaning set forth in the License and
Collaboration Agreement.

     1.30 "GOVERNMENT AUTHORITY" shall mean any court, tribunal, agency,
department, legislative body, commission or other instrumentality of any
federal, state, county, city or other political subdivision in the Territory.

     1.31 "JSC" shall mean the joint steering committee established pursuant to
the License and Collaboration Agreement.

     1.32 "LAWS" or "LAW" shall mean all applicable laws, statutes, rules,
regulations, ordinances and other pronouncements having the binding effect of
law of any applicable Government Authority, including the Act.

* CONFIDENTIAL TREATMENT REQUESTED

                                       4
<PAGE>
     1.33 "LICENSE AND COLLABORATION AGREEMENT" shall mean that certain License
and Collaboration Agreement by and between the Parties entered into as of June
23, 2005, as such agreement may be amended from time to time.

     1.34 "MANUFACTURING" (including variations such as "Manufacture") shall
mean the performance of any and all activities directed to producing,
manufacturing, processing, filling, finishing, packaging, labeling, quality
control, quality assurance, testing and release, shipping and storage of the
Product, Finished Product, Placebo, or Diluent as applicable.

     1.35 "NALTREXONE" shall mean [**].

     1.36 "NDA" shall mean the New Drug Application number 21-897 filed with the
FDA by Alkermes on March 31, 2005 with respect to the Product.

     1.37 "OUTBOUND COSTS" shall mean any outbound costs associated with the
delivery of Product or Placebo including costs related to transport, cold
storage shipping containers and external storage (if required) of Product or
Placebo, such costs including freight, duty, insurance and warehousing.

     1.38 "PLACEBO" shall mean an inactive substitute for the Product that does
not contain measurable quantities of Naltrexone.

     1.39 "PLACEBO REQUIREMENTS" shall means the quantities of Placebo required
for the conduct of pre-clinical studies and/or Clinical Studies of the Product
in the Field pursuant to a Development Plan.

     1.40 "PROCEDURES" shall mean the procedures for manufacturing, control and
testing the Product as set forth in the NDA, as such procedures may be amended
by amendment to such applications from time to time.

     1.41 "PRODUCT" shall mean the injectable pharmaceutical product containing
Naltrexone utilizing Alkermes' Medisorb(R) sustained-release technology as
described in the NDA.

     1.42 "PRODUCT REQUIREMENTS" shall mean Clinical Requirements plus
Commercial Requirements.

     1.43 "QUALITY AGREEMENT" shall have the meaning set forth in Section 3.12.

* CONFIDENTIAL TREATMENT REQUESTED

                                       5
<PAGE>
     1.44 "RECALL" shall mean any action by Alkermes or Cephalon to recover
title to or possession of or to prevent the distribution, prescription,
consumption or release of a Finished Product or Product sold or shipped to Third
Parties. The term "Recall" also includes the failure by Alkermes or Cephalon to
sell or ship a Finished Product or Product to Third Parties that would have been
subject to recall if it had been sold or shipped.

     1.45 "REGULATORY APPROVAL" shall mean any approvals of the FDA necessary
for the manufacture, marketing or sale of the Product in the Territory.

     1.46 "ROLLING MONTHLY FORECAST" shall mean a rolling [**] month forecast
specifying Product Requirements and Placebo Requirements for each month of such
forecast, starting with the calendar month following the due date of such
forecast.

     1.47 "SEIZURE" shall mean any action by the FDA to detain or destroy a
Finished Product or Product or prevent the distribution, prescription,
consumption or release of a Finished Product or Product.

     1.48 "SHARED EXPENSES" shall have the meaning set forth in the License and
Collaboration Agreement.

     1.49 "SPECIFICATIONS" shall mean the specifications for the manufacture,
release, storage, handling and packaging of the Product as set forth in the NDA,
as such specifications may be amended from time to time as provided herein.

     1.50 "STRATEGIC FORECAST" shall mean a reasonable estimate of the
long-range (at least [**] years) manufacturing capacity forecast for the
Alkermes Manufacturing Facility for supply to Cephalon pursuant to this
Agreement, the current version of which is attached as Exhibit A.

     1.51 "SUPPLY TEAM" shall have the meaning set forth in Section 2.1.

     1.52 "TECHNOLOGY TRANSFER AGREEMENT" shall have the meaning set forth in
Section 6.3.

     1.53 "TERM" shall have the meaning set forth in Section 6.1.

     1.54 "TERRITORY" shall mean the United States of America, its territories
and possessions, including the Commonwealth of Puerto Rico.

     1.55 "THIRD PARTY" shall mean any entity other than the Parties or their

* CONFIDENTIAL TREATMENT REQUESTED

                                       6
<PAGE>
respective Affiliates.

     Where words and phrases are used herein in the singular, such usage is
intended to include the plural forms where appropriate to the context, and vice
versa. The words "including", "includes" and "such as" are used in their
non-limiting sense and have the same meaning as "including without limitation"
and "including but not limited to". References to Articles, Sections,
subsections, and clauses are to the same with all their subparts as they appear
in this Agreement. "Herein" means anywhere in this Agreement. "Hereunder" and
"hereto" means under or pursuant to any provision of this Agreement.

                                    ARTICLE 2
                                   SUPPLY TEAM

     2.1 ESTABLISHMENT OF SUPPLY TEAM. The JSC shall establish a supply team
(the "ST") no later than [**] days after the Effective Date to coordinate and
implement all activities for the Manufacture of the Product for sale to
Cephalon. One representative from each Party shall be designated as that Party's
team leader to act as the primary ST contact for that Party. The ST shall
consist of an equal number of representatives of each Party as are reasonably
necessary to accomplish the goals of the ST hereunder. Such representatives may
include individuals with expertise and responsibilities in the areas of quality
control, quality assurance, operational planning, supply chain management and
regulatory affairs. Either Party may replace any or all of its representatives
at any time upon notice to the other Party.

     2.2 SUPPLY TEAM RESPONSIBILITIES. The ST shall be responsible for:

          (i) implementing the provisions set forth in this Agreement in a
manner consistent with Alkermes' Manufacture and supply obligations hereunder;

          (ii) pursuant to Section 3.5, reviewing the Strategic Forecast and the
long range plan for Commercialization of the Product in the Territory;

          (iiii) developing a Manufacturing strategy for the Product, including
an annual Strategic Forecast, for review and approval by the JSC;

          (iv) formulating a plan for Manufacturing development to reduce
Manufacturing cost and enhance Manufacturing output and associated annual
budgets and any substantive amendments thereto for incorporation into the
Development Plans;

          (v) reviewing quality issues and ongoing quality control/quality
assurance programs;

* CONFIDENTIAL TREATMENT REQUESTED

                                       7
<PAGE>
          (vi) implementing all Manufacturing activities pursuant to the
Development Plans approved by the JSC;

          (vii) exchanging information and facilitating cooperation and
coordination between the Parties as they exercise their respective rights and
meet their respective obligations under the Development Plans, the
Commercialization Plans and this Agreement;

          (viii) providing status updates and identifying critical issues to the
JSC regarding Manufacturing activities; and

          (ix) performing such other functions as appropriate to further the
purposes of this Agreement and the License and Collaboration Agreement as
determined by the Parties.

     2.3 SUPPLY TEAM PROCEDURES. The Alkermes team leader shall serve as the
chairperson of the ST. The chairperson shall establish the timing and agenda for
all ST meetings and shall send notice of such meetings, including the agenda
therefor, to all ST members; provided, however, either Party may request that
specific items be included in the agenda and may request that additional
meetings be scheduled as needed. The ST will meet at least once each calendar
month, or as agreed by the ST, for the first [**] years following the Effective
Date, and at least once each calendar quarter, or as agreed by the ST,
thereafter. The location of regularly scheduled ST meetings shall alternate
between the offices of the Parties, unless otherwise agreed. Meetings may be
held telephonically or by videoconference. A quorum of at least half the ST
members appointed by each Party shall be present at or shall otherwise
participate in each ST meeting. Alkermes shall appoint one person (who need not
be a member of the ST) to attend the meeting and record the minutes of the
meeting in writing. Such minutes shall be circulated to the Parties promptly
following the meeting for review, comment and approval.

     2.4 SUPPLY TEAM DECISION MAKING. As a general principle, the ST will
operate by consensus with each Party collectively having one vote. In the event
that the ST members do not reach consensus with respect to a matter that is
within the purview of the ST within [**] days after they have met and attempted
to reach such consensus, such matter shall be presented to the JSC for
resolution; provided, however, that to the extent any matters are required by
Law or by safety concerns with respect to a Product to be resolved within a
shorter period of time, the periods set forth in this Section 2.4 and in Section
2.1.4 and Article 12 of the License and Collaboration Agreement shall be
shortened as appropriate to permit the resolution of such matters within the
required period.

* CONFIDENTIAL TREATMENT REQUESTED

                                       8
<PAGE>
     2.5 LIMITATION ON SUPPLY TEAM DECISION MAKING. Neither the ST nor the JSC
shall, without the consent of Cephalon, have any authority to modify or reduce
Alkermes' obligation under this Agreement to use Commercially Reasonable
Manufacturing Efforts as set forth in Section 3.15 or to amend any provision of
this Agreement. Notwithstanding anything to the contrary in the License and
Collaboration Agreement, Alkermes shall not have any right to resolve any
Reserved Dispute in any manner that modifies or reduces Alkermes' obligation
under this Agreement to use Commercially Reasonable Manufacturing Efforts as set
forth in Section 3.15 or to amend any provision of this Agreement.

                                    ARTICLE 3
                               SUPPLY OF PRODUCTS

     3.1 PURCHASE AND SALE OF PRODUCT. During the Term, and subject to the terms
and conditions hereof, Alkermes agrees to supply to Cephalon, and Cephalon
agrees to purchase exclusively from Alkermes, Cephalon's Product Requirements.
During the Term and subject to applicable Law, Alkermes agrees to use
commercially reasonable efforts to limit the ability of Third Parties to which
Alkermes supplies Product for sale and distribution in the ROW Territory [**].
Alkermes agrees that, if at any time during the Term Alkermes is unable to fully
satisfy worldwide demand for the Product, [**].

     3.2 MANUFACTURE OF THE PRODUCT. Alkermes shall Manufacture the Product for
supply to Cephalon. Alkermes shall Manufacture, or have Manufactured by a
designated Third Party, the Diluent, the Additional Components, and the Finished
Product (packaging and labeling of the Product) for supply to Cephalon.

     3.3 MANUFACTURING DEVELOPMENT. Alkermes shall conduct Manufacturing
development for the Product to reduce Manufacturing cost and enhance
Manufacturing output. The ST shall submit a plan and budget for such
Manufacturing development to the DT, which in turn shall incorporate this plan
into the Development Plan submitted to the JSC for review and approval. Such
plan and budget shall be consistent with, and reasonably calculated to enable
Alkermes to perform, its obligations pursuant to Section 3.15. Alkermes shall
then conduct Manufacturing development in accordance with the Development Plan
and budget approved by the JSC.

     3.4 MANUFACTURING FACILITY. Alkermes shall Manufacture the Product at the
Alkermes Manufacturing Facility. In accordance with the terms and conditions set
forth in the Quality Agreement, Cephalon shall have the right from time to time,
upon reasonable advance notice to Alkermes, to inspect the Alkermes
Manufacturing Facility, to review all records kept by Alkermes relating to the
Manufacture of Product hereunder and to observe Alkermes' conduct of
Manufacturing operations with respect to the

* CONFIDENTIAL TREATMENT REQUESTED

                                       9
<PAGE>
Product.

     3.5 STRATEGIC FORECAST. The ST will formulate the initial Strategic
Forecast within [**] days of the Effective Date. Promptly after the formulation
of the long-range Commercialization plan for the Product pursuant to the License
and Collaboration Agreement, the CT shall forward the long-range
Commercialization plan to the ST. The ST will review the Strategic Forecast in
light of such long-range Commercialization plan and promptly notify the CT if
the ST believes that the Commercialization Plan does not reflect good faith
projections of demand for the Product or requires Manufacturing efforts or
resources beyond Alkermes' obligations pursuant to Section 3.15 or the
manufacturing capacity as described in the Strategic Forecast. In such case the
ST team leaders, the DT team leaders and the CT team leaders will promptly
discuss appropriate revisions to the long-range Commercialization plan and/or
the Strategic Forecast, including the development of additional capacity for
Manufacture of the Product in accordance with Section 5.3.

     3.6 LABELING AND PACKAGING. At the time of Cephalon's submission of its
forecast pursuant to Section 3.7, Cephalon also shall provide Alkermes with the
images and text developed by Cephalon that are to be used by Alkermes in
producing labeling, inserts and packaging for the Product. Dimensions and other
physical attributes of such labeling, inserts and packaging shall be subject to
the approval of Alkermes, which approval shall not be unreasonably withheld or
delayed. In addition as holder of the Regulatory Approval for the Product,
Alkermes shall have the right to confirm that labels, inserts and packaging for
the Product are in conformity with the Regulatory Approval and applicable Laws.

     3.7 FORECASTS.

          (A) INITIAL FORECASTS. Within [**] days of the Effective Date, the CT
shall provide to the ST both a Rolling Monthly Forecast and a [**]-Year Forecast
of expected Product Requirements and Placebo Requirements.

          (B) FORECASTS DUE PERIODICALLY. Thereafter during the Term, the CT
shall provide to the ST:

               (i) a Rolling Monthly Forecast by the end of each calendar
quarter; and

               (ii) a [**]-Year Forecast, on or before August 15th of each year.

          (C) FORECAST BREAKDOWNS. All of the forecasts provided under this
Agreement shall specify Placebo Requirements by the number of units and shall
break down Product Requirements covered by such forecast by Clinical
Requirements and

* CONFIDENTIAL TREATMENT REQUESTED

                                       10
<PAGE>
Commercial Requirements, and by the number of units and Dosage Units of the
Product.

          (D) FIRM ZONE; VOLUME LIMITATIONS. [**]. Notwithstanding the
foregoing, Alkermes will not be obligated to Manufacture volumes of Product or
Placebo that are in excess of Alkermes' manufacturing capacity as established by
the Strategic Forecast from time to time.

     3.8 FIRM PURCHASE ORDERS FOR PRODUCT.

          (A) DELIVERY OF POS. Cephalon shall deliver firm purchase orders
(each, a "Firm PO") for Product Requirements and Placebo Requirements to
Alkermes at least [**] prior to the requested delivery date for Product and
Placebo. Cephalon shall submit on a monthly basis separate Firm POs for
Commercial Requirements, Clinical Requirements and Placebo Requirements. The
details of a Firm PO shall be consistent with the volume requirements for
Product and Placebo established by the Firm Zone. Cephalon agrees that in the
event that a Firm PO for Product or Placebo differs significantly from the
volume requirements established by the Firm Zone, either by specifying a larger
amount of Product or Placebo or an earlier delivery date, Alkermes may not be
able to deliver such Product or Placebo in accordance with the terms of such
Firm PO, but shall use its Commercially Reasonable Manufacturing Efforts to
deliver such Product or Placebo as soon as possible and shall confer with
Cephalon regarding such delivery.

          (B) BATCH QUANTITIES. The Parties agree that notwithstanding the
quantities specified in the Firm POs for Product Requirements and Placebo
Requirements, Alkermes shall be obligated to Manufacture and supply Product only
in full batch quantities and may Manufacture and supply Product in an amount
that is greater or less than the amount specified in a Firm PO as a result of
the Manufacture and supply of such full batch quantities.

          (C) TERMS. Each Firm PO shall, subject to the limitations set forth in
Section 3.8(a), specify the (i) quantity of Product, in number of units of each
Dosage Unit, and the number of units of Placebo; (ii) month of delivery; (iii)
carrier; and (iv) destination or destinations in the Territory. The only terms
of a Firm PO that shall be binding on the Parties shall be those identified in
this Section 3.8(c) that are set forth on the face of such Firm PO. No
modification or amendment to this Agreement shall be effected by or result from
the receipt, acceptance, signing or acknowledgment of any Party's purchase
orders, quotations, invoices, shipping documents or other business forms
containing terms or conditions in addition to or different from the terms and
conditions set forth in this Agreement, and the terms of this Agreement shall
supersede any provision in any purchase order, specification or other document
that is in addition to or inconsistent with the terms of this Agreement.

* CONFIDENTIAL TREATMENT REQUESTED

                                       11
<PAGE>
          (D) ACKNOWLEDGEMENT. If Alkermes has not notified Cephalon within [**]
Business Days of receiving a Firm PO that the terms of such Firm PO are not in
accordance with the provisions of this Agreement and that Alkermes therefore
rejects such Firm PO, such Firm PO shall be deemed accepted. In the event that
Alkermes rejects a Firm PO, the Parties will promptly consult with each other to
resolve the underlying issues as promptly as feasible, and such Firm PO will be
modified accordingly. Once accepted, Firm POs may neither be canceled nor
modified by either Party, except as expressly provided in this Agreement.

     3.9 DELIVERY DATES. Alkermes shall deliver the Product and Placebo in
accordance with Firm POs, as such Firm POs may have been modified with the
agreement of the Parties, solely in accordance with the provisions of this
Agreement. If Alkermes reasonably expects any delay in shipment to Cephalon, it
shall promptly inform Cephalon of such expected delay, shall immediately update
the delivery schedule and shall use its Commercially Reasonable Manufacturing
Efforts to minimize the delay. [**].

     3.10 SHIPMENT.

          (A) TERMS. Alkermes shall ship the Product to the destinations
specified by Cephalon in the Territory. Products shall be delivered FCA
(Incoterms 2000) Alkermes' (or its contract manufacturer's, if applicable)
manufacturing facility in the applicable month of delivery specified in the Firm
PO. Alkermes shall arrange for the delivery of the Product to the carrier
specified in the applicable Firm PO. Title and risk of loss shall pass to
Cephalon upon delivery of each order of Product to such carrier. Notwithstanding
anything to the contrary, Cephalon shall be responsible, and pay Third Parties
directly, for all Outbound Costs from Alkermes' (or its contract manufacturer's,
if applicable) manufacturing facility to any destination or destinations
specified by Cephalon. Alkermes shall pack and address the Product in accordance
with the Firm POs.

          (B) SHIPPING DOCUMENTS. Alkermes will send with each shipment of the
Product a packing list containing the purchase order number, batch or lot
number, manufacturing date, expiry date, Dosage Unit and total quantity
delivered.

          (C) SHELF LIFE OF PRODUCT AT TIME OF SHIPMENT. Unless otherwise agreed
by the Parties, once Alkermes is able to establish a shelf life for the Product
of greater than [**] from the date of Manufacture in accordance with applicable
Laws, Alkermes shall ensure that the Product shall have a minimum of [**] of
shelf life remaining at the time that it is shipped to Cephalon; [**].

     3.11 COMPLIANCE. Alkermes shall be responsible for the Manufacture of the

* CONFIDENTIAL TREATMENT REQUESTED

                                       12
<PAGE>
Product in accordance with the Procedures, cGMPs and the Quality Agreement.
Alkermes shall cause the Finished Product to be Manufactured in accordance with
the Procedures, cGMPs and the Quality Agreement, and shall cause the Diluent and
Additional Components to be Manufactured in accordance with the cGMPs and the
Quality Agreement. Alkermes shall obtain representative samples from each batch
of the Product produced by Alkermes. Alkermes shall assay and analyze such
samples in accordance with the Specifications and shall prepare a Certificate of
Analysis and Conformity that shall be delivered to Cephalon. The Product
supplied hereunder shall be handled and stored by Cephalon in accordance with
the Specifications prior to any sale or distribution.

     3.12 QUALITY CONTROL AND QUALITY ASSURANCE.

          (A) QUALITY AGREEMENT. As soon as possible, but in no case later than
sixty (60) days following the Effective Date, the Parties agree to negotiate in
good faith and use diligent efforts to enter into a Quality Agreement ("Quality
Agreement") setting forth the individual responsibilities of Alkermes and
Cephalon with respect to the Manufacture of the Product. The Quality Agreement
shall be reviewed annually by the Parties and, upon mutual agreement, revised
and updated as necessary. In the event of a conflict between the Quality
Agreement and this Agreement, this Agreement shall govern and control, unless
otherwise expressly provided in the Quality Agreement but in any case consistent
with the standards set forth in Section 3.11.

          (B) ALKERMES PROCEDURES. Alkermes shall number or cause to be numbered
each shipment with a manufacturer lot number that is traceable to all raw
materials and/or Additional Components used to Manufacture such Product.

          (C) CEPHALON PROCEDURES. Cephalon shall identify such Product with a
vendor lot number that is traceable to the shipment purchased from Alkermes.

     3.13 RECALLS OR SEIZURES. Alkermes shall be responsible for undertaking any
Recall of any Product or Finished Product and the Parties shall consult with one
another with respect to any proposed Recall; provided, however, that a Recall
shall be undertaken in the event that either Party believes a Recall is
necessary or prudent. Each Party shall also immediately notify the other Party
of any Seizure of any Product or Finished Product. Alkermes shall meet all
regulatory requirements related to any such Recall or Seizure. Alkermes shall
use Commercially Reasonable Manufacturing Efforts to supply a quantity of
Finished Products sufficient to enable Cephalon to replace all Finished Products
subject to the Recall or Seizure. Such replacement Finished Products shall be
delivered as soon as reasonably possible. If the Product or Finished Product
defect causing the Recall or Seizure results primarily from a breach of
Alkermes' Manufacture and supply obligations hereunder, including the storage or
distribution of the Product or Finished Product by Alkermes prior to shipment,
then the

* CONFIDENTIAL TREATMENT REQUESTED

                                       13
<PAGE>
cost and expenses of such Recall or Seizure, including the cost of replacement
Finished Products, shall be paid by Alkermes. If the Product or Finished Product
defect causing the Recall or Seizure results primarily from Cephalon's acts or
omissions, including the storage or distribution of the Product or Finished
Product after shipment, then the costs and expenses of such Recall or Seizure,
including the cost of replacement Finished Products, shall be paid by Cephalon.
If the Product or Finished Product defect causing the Recall or Seizure does not
result primarily from the acts or omissions of either Party or such cause cannot
be determined with reasonable certainty, then the costs and expenses of such
Recall or Seizure, including the cost of replacement Finished Products, shall be
Shared Expenses. Recalls or Seizures shall otherwise be conducted in accordance
with the provisions of the Quality Agreement.

     3.14 PRODUCT COMPLAINTS AND ADVERSE EVENT REPORTING. The procedures for
handling Product complaints and reporting adverse events shall be set forth in
the Quality Agreement and the safety data exchange agreement executed pursuant
to the License and Collaboration Agreement.

     3.15 COMMERCIALLY REASONABLE MANUFACTURING EFFORTS. Alkermes shall use
Commercially Reasonable Manufacturing Efforts to Manufacture and supply Product
in a timely and cost-effective manner and in sufficient quantities to enable the
Parties to carry out the Development Plans and the Commercialization Plans, in
each case to the extent that such plans reflect good faith projections of the
demand for the Product consistent with the long-range Commercialization Plan.

     3.16 REPRESENTATIONS AND WARRANTIES OF ALKERMES. Alkermes hereby represents
and warrants that:

          (A) Alkermes shall perform its obligations under this Agreement in a
competent, professional and workmanlike manner;

          (B) all Product and Finished Product shall have been Manufactured in
accordance with the Procedures, cGMPs, the Quality Agreement, and shall, as of
the date delivered to the common carrier, meet the Specifications; and

          (C) no Product or Finished Product shall, as of the date delivered to
the common carrier, be adulterated or misbranded, within the meanings ascribed
to such terms under the Act.

In addition, (i) the representation and warranty of Alkermes made in Section
10.3(v) of the License and Collaboration Agreement to the extent applicable to
the manufacture of the Product is incorporated herein by reference, and (ii) the
provisions of Section 7.7 of the License and Collaboration Agreement shall apply
in the event that either Party

* CONFIDENTIAL TREATMENT REQUESTED

                                       14
<PAGE>
believes that it is necessary or desirable to obtain a patent license from a
Third Party [**].

     3.17 NO IMPLIED REPRESENTATIONS, WARRANTIES OR CONDITIONS. EXCEPT AS
OTHERWISE EXPRESSLY HEREIN PROVIDED, ALKERMES MAKES NO REPRESENTATIONS OR
WARRANTIES AND THERE ARE NO CONDITIONS, EXPRESS OR IMPLIED, STATUTORY OR
OTHERWISE, WITH RESPECT TO THE PRODUCTS SUPPLIED HEREUNDER, INCLUDING ANY SUCH
REPRESENTATIONS, WARRANTIES OR CONDITIONS WITH RESPECT TO THE NON-INFRINGEMENT
OF THIRD PARTY RIGHTS, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF
SUCH PRODUCT.

                                    ARTICLE 4
                                    PAYMENTS

     4.1 PAYMENT FOR PRODUCT REQUIREMENTS AND PLACEBO REQUIREMENTS. For each
Dosage Unit of Product and each unit of Placebo produced by Alkermes pursuant to
a Firm Order and shipped to Cephalon hereunder, Cephalon shall pay Alkermes the
Fully Burdened Manufacturing Cost of such Dosage Unit of Product or unit of
Placebo.

     4.2 INVOICES AND METHOD OF PAYMENT OF AMOUNTS DUE TO ALKERMES. Alkermes
shall invoice Cephalon in U.S. Dollars for each shipment of Product and Placebo,
and Cephalon shall pay all such invoices within [**] days of the invoice date,
such date not to precede the shipment date as stated on the bill of lading or
the air waybill. Cephalon shall make such payments in U.S. Dollars. Cephalon
shall make all payments hereunder by bank wire transfer in immediately available
funds to such bank account as Alkermes shall designate from time to time.
Alkermes shall endeavor to notify Cephalon as to the date and amount of any such
wire transfer to Alkermes at least [**] Business Days prior to such transfer,
but in no event later than the Business Day of such transfer. Without limitation
on other available rights or remedies, all amounts payable under this Agreement
will bear interest at the rate of [**] per calendar month from the date due
until paid.

     4.3 RECORDS AND REPORTING; AUDITS. Section 9.7 of the License and
Collaboration Agreement shall apply to all Fully Burdened Manufacturing Costs
charged for Product or Placebo delivered hereunder, including all underlying
costs included by Alkermes in such Fully Burdened Manufacturing Costs.

     4.4 MANUFACTURING DEVELOPMENT ACTIVITIES. Subject to Section 5.1 below, all
Manufacturing development activities performed hereunder shall be charged by
Alkermes as Development Costs pursuant to the License and Collaboration
Agreement with the activities performed by the Alkermes FTEs billed at the
Development FTE Rate.

* CONFIDENTIAL TREATMENT REQUESTED

                                       15
<PAGE>
                                   ARTICLE 5
                  SCALE UP, BACK-UP SUPPLY AND CAPITAL EXPENSES

     5.1 SCALE-UP TO [**]SCALE. [**]. All expenses incurred by Alkermes in
performing such activities that are required to obtain Regulatory Approval for
the Product for the alcohol abuse/dependence indication shall be borne solely by
Alkermes. Any other costs incurred by Alkermes in performing Manufacturing
development activities pursuant to a Development Plan shall be charged as
Development Costs pursuant to the License and Collaboration Agreement with the
activities performed by the Alkermes FTEs billed at [**].

     5.2 [**]. A dedicated joint taskforce to be appointed by the ST and the ST
itself will oversee a timely execution of the agreed plan. [**]. The cost of all
such activities to scale-up Product Manufacture or to otherwise reduce cost and
enhance production output for the Product for the Territory will be deemed to be
Development Costs.

     5.3 BACK-UP OR SECOND SOURCE SUPPLY. If Cephalon believes that it is
desirable or necessary to qualify and/or engage a back-up or second source
supplier of the Product for the Territory, Cephalon shall notify Alkermes. The
Parties shall discuss such matter in good faith. If the Parties do not agree on
a course of action with respect to qualifying and/or engaging a back-up or
second source supplier, the Parties shall resolve such dispute through agreement
of the Parties' Chief Executive Officers pursuant to the terms of Section 12.1.2
of the License and Collaboration Agreement. Such dispute shall not be considered
a Reserved Dispute subject to Section 12.2 of the License and Collaboration
Agreement.

     5.4 CAPITAL EXPENSES. If Alkermes is required to expand the Alkermes
Manufacturing Facility or build an additional facility for the Manufacture and
supply of Product for Cephalon pursuant to this Agreement, [**].

                                    ARTICLE 6
                                TERM; TERMINATION

     6.1 TERM. This Agreement shall commence as of the Effective Date and,
unless sooner terminated as provided in this Article 6, shall continue in effect
until the expiration or termination of the License and Collaboration Agreement
and thereafter for any period after expiration or termination specified in the
License and Collaboration Agreement during which Alkermes has agreed to continue
supplying Product to Cephalon for the Territory (such period, the "Term").

* CONFIDENTIAL TREATMENT REQUESTED

                                       16
<PAGE>
     6.2 TERMINATION UPON MATERIAL BREACH. If either Party shall commit a
material breach with respect to any material provision of this Agreement and the
other Party shall have given the breaching Party written notice of such breach,
the breaching Party shall have [**] days to cure such breach. If such breach is
not cured in all material respects within such [**] day period, the
non-breaching Party shall have the right, upon notice to the breaching Party and
without prejudice to any other rights the non-breaching Party may have, to
terminate this Agreement, unless the breaching Party is in the process of
attempting in good faith to cure such breach, in which case the [**] day cure
period shall be extended by an additional [**] days.

     6.3 ALKERMES FAILURE TO SUPPLY

          (A) FAILURE TO SUPPLY. In the event that Alkermes fails to supply the
market for the Finished Product in the Territory for a consecutive [**] day
period, in lieu of terminating this Agreement pursuant to Section 6.2, Cephalon
may exercise the license grant made by Alkermes of Alkermes Manufacturing
Patents and Alkermes Manufacturing Know-How pursuant to the License and
Collaboration Agreement, and Alkermes shall transfer to Cephalon the Alkermes
Vivitrex Manufacturing Know-How to enable Cephalon or its designated contract
manufacturer to Manufacture the Product. The Parties shall enter into a
Technology Transfer Agreement ("Technology Transfer Agreement") to address
logistical issues relating to the transfer by Alkermes of the Alkermes Vivitrex
Manufacturing Know-How. Alkermes shall have no obligation to transfer or
otherwise provide any equipment to Cephalon under the Technology Transfer
Agreement.

          (B) TECHNOLOGY TRANSFER AGREEMENT. The Technology Transfer Agreement
shall include the following terms and conditions, together with such other
customary representations, warranties, covenants and conditions satisfactory in
form and substance to the Parties and their legal advisors as are necessary or
appropriate for transactions of this type:

               (I) Alkermes shall [**]; and

               (II) Cephalon shall pay Alkermes the Development FTE Rate for all
work performed by Alkermes FTEs in [**].

Cephalon acknowledges and agrees that the Alkermes Vivitrex Manufacturing
Know-How is the Confidential Information of Alkermes. Accordingly the Technology
Transfer Agreement shall also provide appropriate protections to ensure the
nondisclosure of the Alkermes Vivitrex Manufacturing Know-How and to restrict
its use by Cephalon or its designated contract manufacturer solely to the
Manufacture of the Product for the Territory.

* CONFIDENTIAL TREATMENT REQUESTED

                                       17
<PAGE>
     6.4 EFFECTS OF TERMINATION OR EXPIRATION.

          (A) PRODUCT. Upon expiration or termination of this Agreement,
Alkermes shall Manufacture and ship to Cephalon and Cephalon shall purchase in
accordance with the provisions hereof all Product ordered pursuant to Firm POs
issued hereunder prior to the date on which notice of such termination was
given, or prior to the expiration date of the Agreement, as applicable.

          (B) ACCRUED RIGHTS AND OBLIGATIONS; SURVIVAL. Termination of this
Agreement for any reason or expiration of this Agreement shall not release
either Party from any obligation arising prior to the date of termination. The
rights and obligations under Sections 3.13, 3.16(b), 3.16(c), 3.17, 6.3 and this
6.4 and Articles 7 and 8, in each case only in the event and to the extent
applicable and subject to the terms and conditions stated therein, shall survive
any termination or expiration of this Agreement. In addition, any other
provision required to interpret and enforce the Parties' rights and obligations
under this Agreement shall also survive, but only to the extent required for the
full performance of this Agreement. Except as otherwise set forth herein, any
right to terminate this Agreement shall be in addition to and not in lieu of all
other rights or remedies that the Party giving notice of termination may have at
Law or in equity or otherwise.

* CONFIDENTIAL TREATMENT REQUESTED

                                       18
<PAGE>
                                   ARTICLE 7
           MATTERS GOVERNED BY THE LICENSE AND COLLABORATION AGREMENT

     7.1 DISPUTES. Except as otherwise specified herein, in the event that a
dispute arises under this Agreement, the dispute resolution provisions of
Article 12 of the License and Collaboration Agreement shall apply to such
dispute mutatis mutandis.

     7.2 LIMITATIONS ON LIABILITY; INDEMNIFICATION; INSURANCE. Except as
otherwise specified herein, the limitations on liability, indemnification and
insurance provisions of Article 11 of the License and Collaboration Agreement
shall apply to this Agreement mutatis mutandis.

     7.3 CONFIDENTIALITY. Except as otherwise specified herein, the
confidentiality provisions of Article 8 of the License and Collaboration
Agreement shall apply to any Confidential Information obtained by a Party under
this Agreement mutatis mutandis.

     7.4 PUBLICITY. Except as otherwise specified herein, the publicity
provisions of Section 14.7 of the License and Collaboration Agreement shall
apply to this Agreement mutatis mutandis.

                                    ARTICLE 8
                               GENERAL PROVISIONS

     8.1 NOTICES. All notices, reports, requests or demands required or
permitted under this Agreement shall be sent by air courier or by facsimile,
with confirmed transmission, properly addressed to the respective Parties as
follows:

               If to Alkermes:
               Alkermes, Inc.
               88 Sidney Street
               Cambridge, Massachusetts 02139
               Attn: Chief Executive Officer
               Facsimile: [**]

               If to Alkermes:
               Alkermes, Inc.
               88 Sidney Street
               Cambridge, Massachusetts 02139
               Attn: General Counsel

* CONFIDENTIAL TREATMENT REQUESTED

                                       19
<PAGE>
               Facsimile: [**]

* CONFIDENTIAL TREATMENT REQUESTED

                                       20
<PAGE>
               If to Cephalon:
               Cephalon, Inc.
               41 Moores Road
               Frazer, Pennsylvania 19355
               Attention: Chief Executive Officer
               Facsimile: [**]

               If to Cephalon:
               Cephalon, Inc.
               41 Moores Road
               Frazer, Pennsylvania 19355
               Attention: General Counsel
               Facsimile: [**]

or to such addresses or addresses as the Parties hereto may designate for such
purposes during the Term. Notices shall be deemed to have been sufficiently
given or made: (i) if by facsimile with confirmed transmission, when performed,
and (ii) if by air courier upon receipt by the Party.

     8.2 GOVERNING LAW. This Agreement shall be governed by and construed in
accordance with the Laws of the State of Delaware (other than its choice of law
principles).

     8.3 ENTIRE AGREEMENT; AMENDMENT. This Agreement and the License and
Collaboration Agreement, including all consideration and the rights and
obligations of the Parties under such agreements, represents the entire
agreement between the Parties regarding the subject matter hereof and thereof,
and there are no prior or contemporaneous written or oral promises or
representations relating to this subject not incorporated herein. No amendment
or modification of the terms and conditions of this Agreement shall be binding
on either Party unless reduced to writing referencing this Agreement and signed
by an authorized officer of the Party to be bound. In the event of a conflict
between the provisions of this Agreement and those of the License and
Collaboration Agreement, the provisions of this Agreement shall control.

     8.4 BINDING EFFECT AND ASSIGNMENT. This Agreement shall be binding upon and
inure to the benefit of the Parties hereto and their respective permitted
successors and assigns. This Agreement shall not be assignable by either Party
without the other's prior written consent; provided, however, that either Party
may assign this Agreement, without the other Party's written consent but after
providing thirty (30) days prior notice to the other Party, to an Affiliate or
to any successor to which the License and

* CONFIDENTIAL TREATMENT REQUESTED

                                       21
<PAGE>
Collaboration Agreement is assigned pursuant to the terms and conditions of that
Agreement.

     8.5 WAIVER. A waiver by either Party of any of the terms and conditions of
this Agreement in any instance shall not be deemed or construed to be a waiver
of such term or condition for the future, or of any other term or condition
hereof. All rights, remedies, undertakings, obligations and agreements contained
in this Agreement shall be cumulative and none of them shall be in limitation of
any other remedy, right, undertaking, obligation or agreement of either Party.

     8.6 SEVERABILITY. If any part of this Agreement shall be found to be
invalid or unenforceable under applicable Law in any jurisdiction, such part
shall be ineffective only to the extent of such invalidity or unenforceability
in such jurisdiction, without in any way affecting the remaining parts of this
Agreement in that jurisdiction or the validity or enforceability of the
Agreement as a whole in any other jurisdiction. In addition, the part that is
ineffective shall be reformed in a mutually agreeable manner so as to as nearly
approximate the intent of the Parties as possible.

     8.7 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original for all purposes, but
all of which together shall constitute one and the same instrument.

     8.8 FORCE MAJEURE. Neither Party shall be held liable or responsible to the
other Party or be deemed to have breached or defaulted under this Agreement for
failure or delay in performing its obligations hereunder (except for payment of
money) to the extent, and as long as, such failure or delay is caused by or
results from causes beyond the reasonable control of the affected Party (a
"Force Majeure Delay"), including fire, floods, embargoes, war, insurrections,
riots, civil commotions, terrorism, strikes, lockouts or other labor
disturbances, sabotage, acts of God, failure or delay of transportation,
prevention from or hindrance in obtaining energy or other utilities, omissions
or delays in acting by any governmental authority, acts of a government or
agency thereof or judicial orders or decrees. In the event of a Force Majeure
Delay, the affected Party shall give prompt notice thereof to the other Party,
shall use commercially reasonable efforts to mitigate the adverse consequences
thereof and shall resume performance hereunder with dispatch whenever the
consequences of the Force Majeure Delay have been mitigated provided, however,
in no event shall a Party be required to settle any labor dispute or
disturbance.

     8.9 AMBIGUITIES. Ambiguities, if any, in this Agreement shall not be
construed against any Party, irrespective of which Party may be deemed to have
authorized the ambiguous provision.

* CONFIDENTIAL TREATMENT REQUESTED

                                       22
<PAGE>
     8.10 HEADINGS. Headings are for the convenience of reference only and shall
not control the construction or interpretation of any of the provisions of this
Agreement.

     8.11 NO PARTNERSHIP. Nothing in this Agreement is intended or shall be
deemed to constitute a partnership, agency, or joint venture relationship
between the Parties. Notwithstanding any of the provisions of this Agreement,
neither Party shall at any time enter into, incur, or hold itself out to Third
Parties as having authority to enter into or incur, on behalf of the other
Party, any commitment, expense, or liability whatsoever.

     8.12 USE OF NAMES, TRADE NAMES AND TRADEMARKS. Except as expressly provided
in this Agreement or the License and Collaboration Agreement neither Party shall
have the right to use in advertising, publicity or other promotional activities
any name, trade name, trademark or other designation of the other Party hereto
or its Affiliates or sublicensees, including any contraction or abbreviation of
any of the foregoing, unless the express written permission of such other Party
has been obtained.

     8.13 PERFORMANCE BY AN AFFILIATE. Each of Cephalon and Alkermes acknowledge
that obligations under this Agreement may be performed by Affiliates of Cephalon
and Alkermes. Each of Cephalon and Alkermes guarantee performance of this
Agreement by its Affiliates, notwithstanding any assignment to Affiliates in
accordance with Section 8.4 of this Agreement.

     8.14 NON-SOLICITATION OF EMPLOYEES. During the [**] period following the
Effective Date, neither Party shall, directly or indirectly, recruit or solicit
any employee of the other Party or any of such other Party's Affiliates if such
employee has been materially involved in the performance of this Agreement or
the License and Collaboration Agreement, except pursuant to general
solicitations not targeted at such employees.

                            [SIGNATURE PAGE FOLLOWS]

* CONFIDENTIAL TREATMENT REQUESTED

                                       23
<PAGE>
     IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be
executed and delivered by its duly authorized representatives to be effective as
of the date set forth above.

ALKERMES, INC.                          CEPHALON, INC.

By: /s/ Michael J. Landine              By: /s/ J. Kevin Buchi
    ---------------------------------       ------------------------------------
Name: Michael J. Landine                Name: J. Kevin Buchi
Title: Vice President, Corporate        Title: Senior Vice President and Chief
       Development                             Financial Officer

* CONFIDENTIAL TREATMENT REQUESTED

                                       24
<PAGE>
                                    EXHIBIT A

                           INITIAL STRATEGIC FORECAST

[**]

       [**]

       [**]

       [**]

[**]

              [**]   [**]   [**]   [**]   [**]   [**]

              [**]   [**]   [**]   [**]   [**]   [**]

* CONFIDENTIAL TREATMENT REQUESTED

                                       25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}]]